WorldWideScience

Sample records for behandling med infliximab

  1. Pneumocystepneumoni ved behandling med infliximab

    DEFF Research Database (Denmark)

    Josephson, Maria Eklund; Kristensen, Lena Hagelskjaer; Andersen, Vibeke

    2008-01-01

    The treatment of ulcerative colitis has improved since the appearance of Tumor Necrosis Factor (TNF)-alpha inhibitors. However, the use of TNF-alpha inhibitors increases the risk of opportunistic infections. We describe two cases of Pneumocystis jiroveci pneumonia during infliximab therapy...... for active ulcerative colitis. They were successfully treated with sulfametoxazole/trimetroprim. High awareness of P. jiroveci pneumonia in patients who develop pulmonary symptoms with hypoxia during TNF-alpha modulator therapy is recommended....

  2. Legionella pneumoni hos patienter, der er i behandling med infliximab

    DEFF Research Database (Denmark)

    Vinter, Hanne; Nielsen, Henrik Ib

    2009-01-01

    Therapy with tumour necrosis factor-alfa inhibitors is widely used in various inflammatory disorders, but adverse events from severe infections with intracellular pathogens may occur. We describe two cases of severe pulmonary legionellosis in patients treated with infliximab for Crohn's disease a...... and psoriasis, respectively. We conclude that legionella infections are probably more frequent in patients receiving immunosuppressive therapy with tumour necrosis factor-alfa inhibitors than in the background population. Udgivelsesdato: 2009-Jan-19...

  3. Fysisk rehabilitering i forbindelse med behandling af hæmatologiske sygdomme

    DEFF Research Database (Denmark)

    Høgdal, Nina; Bartels, Frederik Reith; Smith, Nicholas Simon

    2015-01-01

    I denne statusartikel vurderes det, hvorvidt det eksisterende fysioterapeutiske træningstilbud under behandling af maligne sygdomme med højdosis kemoterapi og perifer stamcellestøtte (HD-ASCT) lever op til anbefalingerne i Kræftplan III. Alle seks hospitaler i Danmark, som behandler patienter med...

  4. GIM-behandling af en traumatiseret flygtning med PTSD – med fokus på traumebearbejdning

    Directory of Open Access Journals (Sweden)

    Torben Moe

    2016-12-01

    Full Text Available Artiklen omhandler en case med fokus på direkte traumebehandling i traumefokuseret Guided Imagery and Music (GIM. Patienten deltog i et mixed methods feasibility-pilotprojekt vedrørende behandling af traumatiserede flygtninge, som er beskrevet i artiklen Feasibility of trauma-focused Guided Imagery and Music with adult refugees diagnosed with PTSD – a pilot study. Patienten modtog 16 sessioner over en periode på ca. 6 måneder. I artiklen gives eksempler på traumefokuserede interventioner og eksempler på patientens kommentarer, oplevelser, refleksioner og udbytte af behandlingen. Behandlingstilgangen i konteksten med traumatiserede flygtninge er en ny variation inden for spektret af GIM-terapi, og beskrivelsen af behandlingsforløbet understøttes af teoretisk forståelse af processen. Resultater for pilotstudiet viser, at patienten fik signifikant udbytte af terapien. Dette bliver understøttet af patientens egne udtalelser i evalueringen af forløbet samt ud fra data fra de spørgeskemaer, der blev anvendt i undersøgelsen. Patienten har efter GIM-forløbet en score på Harwards Trauma Questionaire (HTQ, som ligger under cut-off for diagnosen PTSD og scorer markant højere på WHO-5 livsstil-skemaet.

  5. Frakturerede fortænder – behandling med direkte plast

    DEFF Research Database (Denmark)

    Pallesen, Ulla; van Dijken, Jan WV

    2017-01-01

    . Klasse IV fyldninger har kortere holdbarhed end fuldkeramiske - og metalkeramikkroner. Holdbarheden er blevet forbedret med nyere materialer og adhæsiver. En plastopbygning af en fraktureret tand er mere konservativ for både tandsubstans, pulpa og det omgivende blødtvæv end en krone. Taget i betragtning...

  6. Dilemmaer i musikterapeutisk behandling af en traumatiseret flygtning med musikerbaggrund

    Directory of Open Access Journals (Sweden)

    Bolette Daniels Beck

    2016-12-01

    Full Text Available Denne artikel præsenterer et single case-studie af et receptivt musikterapiforløb med en 55-årig syrisk flygtning, som har været udsat for fængsling og tortur på grund af sine aktiviteter som protestsanger og musiker. Der beskrives problemstillinger og dilemmaer relateret til at anvende musik, der både kan trigge traumer, men også vække indre ressourcer. Kortlægning af patientens forskellige personlighedsdele og musikkens evne til integration af dem vil blive belyst gennem teorien om strukturel dissociation.

  7. Revmatoid artritt i Norge – demografi, sykdomskarakteristika og behandling. En sammenligning med andre europeiske land og USA

    Directory of Open Access Journals (Sweden)

    Glenn Haugeberg

    2012-11-01

    Full Text Available Bakgrunn: Revmatoid artritt (RA er en kronisk inflammatorisk leddsykdom som gir økt sykelighet og dødelighet. Nye biologiske legemidler har de siste 10 årene bedret prognosen betydelig. I 2005 ble QUEST-RA (Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis prosjektet etablert for å sammenligne sykdomsstatus og behandling hos RA-pasienter i forskjellige land. I denne artikkelen presenteres status for RA-pasienter i Norge sammenlignet med andre europeiske land og USA.Materiale og metode: Tilfeldig utvalgte RA-pasienter fulgt opp ved revmatologisk poliklinikk ved Sørlandet sykehus i Kristiansand (n=100 og St. Olavs Hospital i Trondheim (n=100 ble inkludert. I henhold til protokoll ble demografiske, sykdoms- og behandlingsdata registrert.Resultater: Norske RA-pasienter skilte seg lite fra gjennomsnittet i andre land med hensyn til alder, utdannelse og sykdomsvarighet. Sykdomsalvorlighet og sykdomsstatus til norske RA-pasienter er sammenlignbare med pasienter fra land som har lavest sykdomsaktivitet og best helsestatus. I Norge er andelen som behandles med biologiske legemidler ca 30%, og Norge er blant de land med størst andel pasienter som behandles med denne legemiddelgruppen. Fortolkning: RA-pasienter i Norge er blant de i Europa som har lavest sykdomsaktivitet. En årsak antas å være den relativt utbredte bruken av biologiske legemidler i Norge.

  8. "Som natt och dag" : Kvinnors upplevelser av att leva med IBS och behandling med låg FODMAP-kost

    OpenAIRE

    Börjesson, Louise; Lindberg, Emelie

    2014-01-01

    Introduktion: Irritable Bowel Syndrome, IBS, är den vanligaste funktionella mag-tarmsjukdomen i västvärlden med en prevalens på cirka 15-20 % i befolkningen. IBS är generellt sett dubbelt så vanligt förekommande hos kvinnor som hos män och majoriteten som drabbas är kvinnor under 40 år. Behandling med låg FODMAP-kost är den mest effektiva kostbehandlingen vid IBS. Det finns få kvalitativa studier om IBS och behandling med låg FODMAP-kost och det behövs en ökad förståelse av hur det är att lev...

  9. Hvilken evidens er der for behandling af depression hos børn og unge med kognitiv terapi?

    DEFF Research Database (Denmark)

    Sørensen, Merete Juul; Thomsen, Per Hove

    2007-01-01

    Depression hos børn og unge er relativt hyppigt forekommende og kan have svære konsekvenser. Den specifikke antidepressive behandling kan være psykoterapeutisk eller medikamentel. I artiklen gennemgås på baggrund af systematisk litteratursøgning den videnskabelige evidens for effekten af kognitiv...... adfærdsterapi hos børn og unge med depression....

  10. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

    DEFF Research Database (Denmark)

    Bendtzen, Klaus; Geborek, Pierre; Svenson, Morten

    2007-01-01

    Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd...... infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies....

  11. Behandling af angste psykiatriske patienter med MusiCure - et pilotprojekt

    Directory of Open Access Journals (Sweden)

    Torben Egelund Sørensen

    2005-02-01

    Full Text Available I perioden 1.11.2003 til 1.3.2004 blev der på to åbne og en lukket sengeafdeling på psykiatrisk afdeling, Horsens sygehus, gennemført et pilotprojekt, med det formål at undersøge om brugen af speciel designet musik (MusiCure ville have en positiv effekt på angste og urolige patienter. 30 patienter fik MusiCurebehandling en eller flere gange, og af disse fik de 26 en positiv effekt af behandlingen: De blev beroliget; faldt til ro/i søvn. For en patient havde behandlingeningen effekt, og for 3 patienter havde behandlingen en negativ effekt. Interviews med patienter og plejepersonalet viste at brugen af MusiCure havde en angstdæmpende effekt, enten givet aleneeller i kombination med PN medicin og /eller kugledyne. Det konkluderes at undersøgelsens samlede resultat tyder på at MusiCure kan anvendes til såvel psykotiske som ikke-psykotiskepatienter, og at MusiCure, anvendt alene eller sammen med kugledyne, kan være et alternativ til brugen af PN medicin. Artiklen er en revideret udgave af artikel med samme titel bragt på Musica Humanas hjemmeside.

  12. Mentaliseringsbaseret behandling og musikterapi

    DEFF Research Database (Denmark)

    Hannibal, Niels

    2013-01-01

    Denne artikel behandler spørgsmålet, om mentaliseringsbaseret terapi er en metode der medfører et skift i terapeutisk forholdemåde for analytisk orienterede musikterapeuter i arbejde med patienter med personlighedsforstyrrelse. Artiklen skal ses om en del af den teoretiske integrationer af MBT i...

  13. Gentaget selvmordsforebyggende behandling

    DEFF Research Database (Denmark)

    Lind, Bertel

    2014-01-01

    mellem dem, der gentager behandling, og dem, der ikke gør det med hensyn til alder, diagnoser, misbrug af alkohol og / eller stoffer og navnlig i deres relationelle problemer. Dette støtter resultaterne af den kvalitative forskning. I den samlede population af patienter viser kronisk sygdom med smerter...

  14. Er danske sygeplejersker "klædt på" til mødet med patienter, som anvender alternativ behandling

    DEFF Research Database (Denmark)

    Lunde, Anita

    alternativ behandling forekommer af og til, dialogen indgår dog sjældent som et fast punkt i planlagte samtaler, ligesom langt de fleste sygeplejersker aldrig giver konkrete anbefalinger om alternativ behandling. Sygeplejersker anser alternativ behandling som et meget bredt felt, som også afspejler sig i...

  15. Behandling med implanterbar defibrillator

    DEFF Research Database (Denmark)

    Roseva-Nielsen, Natasha G; Svendsen, Jesper Hastrup

    2003-01-01

    About 20 years ago the first patient received an implantable cardioverter defibrillator (ICD), and since then the number of implants have increased dramatically. The ICD can terminate ventricular fibrillation and ventricular tachycardia. Studies of secondary prophylaxis show that ICD treatment can...

  16. Svær interstitiel lungesygdom på grund af Infliximab og Azathioprin hos patient med Colitis Ulcerosa

    DEFF Research Database (Denmark)

    Hansen, Lars Koch; Cecere, Stefano; Thøgersen, Thøger

    2014-01-01

    A 41-year-old man developed severe interstitial lung disease (ILD) after treatment with infliximab (IFX) and azathioprine (AZA). A relapse of ulcerative colitis was treated with corticosteroids (CS) and IFX as rescue therapy. Following remission AZA was given as prophylaxis. AZA was initiated...

  17. Svær interstitiel lungesygdom på grund af Infliximab og Azathioprin hos patient med Colitis Ulcerosa

    DEFF Research Database (Denmark)

    Hansen, Lars Koch; Cecere, Stefano; Thøgersen, Thøger

    2014-01-01

    A 41-year-old man developed severe interstitial lung disease (ILD) after treatment with infliximab (IFX) and azathioprine (AZA). A relapse of ulcerative colitis was treated with corticosteroids (CS) and IFX as rescue therapy. Following remission AZA was given as prophylaxis. AZA was initiated...

  18. Infliximab, Infliximab-dyyb Injection

    Science.gov (United States)

    Infliximab and infliximab-dyyb injection are used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system ... has not improved when treated with other medications. Infliximab may also be used to relieve symptoms of ...

  19. Strategier for udredning og behandling af dyspepsi

    DEFF Research Database (Denmark)

    Jarbøl, Dorte Ejg; Kjeldsen, H.C.; Schaffalitzky de Muckadell, Ove B.

    2004-01-01

    almen praksis er empirisk behandling med antisekretorisk medicin, med efterfølgende endoskopi for nonrespondere. Noninvasiv test for Helico-bacter pylori (Hp) efterfulgt af eradikationskur til Hp-positive (Hp- test-and-treat ) er en strategi, der anbefales i flere guidelines til yngre patienter...

  20. Behandling af insulinom med alkoholsklerosering

    DEFF Research Database (Denmark)

    Schnack, Christina; Hansen, Carina Ørts; Beck-Nielsen, Henning;

    2012-01-01

    The efficacy and safety of endoscopic ultrasound (EUS)-guided alcohol ablation of an insulinoma in a patient not candidate for surgery is being evaluated. A 89 year-old male patient with insulinoma and serious cardiac disease was treated with EUS-guided alcohol ablation. The only complication...

  1. Behandling af hydatidose med albendazol

    DEFF Research Database (Denmark)

    Magnussen, P; Gelletlie, R; Bygbjerg, Ib Christian

    1989-01-01

    Eight patients with hydatidosis treated with albendazol in daily doses of 10 mg/kg daily in courses of 28 days (4-6 courses) were analysed. The patients came from Morocco, Spain, Turkey and Yugoslavia. Seven patients had a cyst (or cysts) in the liver and one had also cysts in the kidneys. One...

  2. Gir tidlig vurdering og behandling hos spesialist i fysikalsk medisin og rehabilitering reduksjon i langtidsfravær hos sykmeldte med muskel- og skjelettsykdommer?

    Directory of Open Access Journals (Sweden)

    Harald Elvsåshagen

    2010-01-01

    Full Text Available Bakgrunn: De fleste langtidssykmeldte med muskel- og skjelettsykdommer blir utredet, behandlet og fulgt opp av fastlege. Ved lengre tids sykmelding henvises mange fra sin fastlege til spesialist i fysikalsk medisin og rehabilitering for å optimalisere behandlingsopplegget.Formålet med denne studien var å undersøke om henvisning direkte fra NAV til spesialist uten å gå veien om fastlege, medførte redusert antall sykmeldingsdager og mindre bruk av andre trygdeytelser som rehabiliteringspenger, yrkesrettet attføring og uførepensjon.Materiale og metode: I samarbeid med 14 NAV-kontor i Vestfold ble 829 sykmeldte i alder 25-50 år med 8-12 ukers sykmelding for muskel- og skjelettsykdommer randomisert til en intervensjonsgruppe (n=409 og en kontrollgruppe (n=420. Eksklusjonskriterier var manglende arbeidsforhold, revmatiske sykdommer, brudd og leddsykdommer. Intervensjonsgruppen ble undersøkt og behandlet av spesialist i fysikalsk medisin og rehabilitering, Spesialsykehuset for rehabilitering, avd. Stavern. Kontrollgruppen fortsatte behandling hos sin fastlege. Noen av disse pasientene ble henvist til samme poliklinikk eller til annen spesialist på initiativ fra sin fastlege. Data for sykmeldingsdager, uførepensjon, rehabiliteringspenger og attføringspenger ble samlet inn fra NAV-kontorene. De samme parametre ble brukt som endepunkter. Etter to år ble endepunktene analysert. Data ble analysert etter "intention to treat"- prinsippet.Resultater: I intervensjonsgruppen var gjennomsnittlig antall sykmeldingsdager 138 dager (SD 86,2 mot 147 dager (SD 88,0 i kontrollgruppen, en forskjell på ni sykmeldingsdager. Forskjellen er ikke statistisk signifikant (p=0,163. Det var heller ikke statistisk signifikant forskjell i forbruket av yrkesrettet attføring og rehabiliteringspenger mellom intervensjonsgruppen og behandlingsgruppen.Konklusjon: Henvisning til spesialist i fysikalsk medisin og rehabilitering direkte fra NAV etter 8-12 ukers sykmelding

  3. Eksperimentel bakteriofagterapi til behandling af kronisk Pseudomonas aeruginosaotitis hos hund

    DEFF Research Database (Denmark)

    Moodley, Arshnee; Mølgaard, Jesper

    2016-01-01

    Vi beskriver en case med anvendelsen af bakteriofager til behandling af kronisk otitis forårsaget af multiresistente Pseudomonas aeruginosa som en sidste behandlingsmulighed før aflivning. Trods gentagne behandlinger, både topikalt og systemisk, med op til seks forskellige antibiotika over en...

  4. Arkitektur der (be)handler – fremtidens psykiatri

    DEFF Research Database (Denmark)

    Bertelsen, Eva; Paladino, Vanessa

    2017-01-01

    Hvor dette tema behandler udviklinger i det social-psykiatriske arbejde i socialpsykiatrien, ønsker vi med dette temabidrag at vise, hvordan den danske hospitalspsykiatri aktuelt er under forandring influeret af tænkning og behandlingsideologi fra både socialpsykiatrien og uddannelsesområdet bredt...... taget. Disse forandringer kan spores i nye måder at tænke psykisk sygdom samt psykiatrisk behandling på, men afspejles også i nye måder at indrette de psykiatriske institutioners fysiske rammer på. Den nyeste trend i psykiatrien er at genindrette og bygge nye psykiatriske institutioner ’til fremtiden’ i...

  5. Behandling af digital dermatitis på KFC

    DEFF Research Database (Denmark)

    Krogh, Kenneth; Thomsen, Peter

    2008-01-01

    På Kvægbrugets Forsøgscenter blev de rutinemæssige klovbade i maj 2007 erstattet med månedlige tjek af klove i beskærerboks og behandling af klovlidelser, herunder især Digital Dermatitis. Behandlingseffekten har været høj med 90 % helbredte efter en måned. Udgivelsesdato: april 2008......På Kvægbrugets Forsøgscenter blev de rutinemæssige klovbade i maj 2007 erstattet med månedlige tjek af klove i beskærerboks og behandling af klovlidelser, herunder især Digital Dermatitis. Behandlingseffekten har været høj med 90 % helbredte efter en måned. Udgivelsesdato: april 2008...

  6. Behandling af digital dermatitis på KFC

    DEFF Research Database (Denmark)

    Krogh, Kenneth; Thomsen, Peter

    2008-01-01

    På Kvægbrugets Forsøgscenter blev de rutinemæssige klovbade i maj 2007 erstattet med månedlige tjek af klove i beskærerboks og behandling af klovlidelser, herunder især Digital Dermatitis. Behandlingseffekten har været høj med 90 % helbredte efter en måned. Udgivelsesdato: april 2008......På Kvægbrugets Forsøgscenter blev de rutinemæssige klovbade i maj 2007 erstattet med månedlige tjek af klove i beskærerboks og behandling af klovlidelser, herunder især Digital Dermatitis. Behandlingseffekten har været høj med 90 % helbredte efter en måned. Udgivelsesdato: april 2008...

  7. Hvilken evidens er der for medikamentel behandling af depression hos børn og unge?

    DEFF Research Database (Denmark)

    Thomsen, Per Hove; Sørensen, Merete Juul

    2007-01-01

    Depression hos børn og unge er relativt hyppigt forekommende og kan have svære konsekvenser. Den specifikke antidepressive behandling kan være psykoterapeutisk eller medikamentel. I artiklen gennemgås på baggrund af systematisk litteratursøgning den videnskabelige evidens for medikamentel...... behandling af depression hos børn og unge med hovedvægten lagt på de mest veldokumenterede medikamenter: selektive serotoningenoptagelseshæmmere....

  8. Behandl dig selv med honning"

    DEFF Research Database (Denmark)

    Mejrup, Kristian; Bjerring-Nielsen, Mattias

    2015-01-01

    with a heavenly figure, a potent Joseph lookalike, who reveals to her inexpressible secrets mediated in an exuberant honeycomb. The revelatory capacity of honey is stylistically rendered by means of repetition, pleonasm, chorus, reprises and gestures. The encounter with “Das ganz Andere” does not leave Aseneth...

  9. Behandling med kosmetiske bløddelsfyldere

    DEFF Research Database (Denmark)

    Thyssen, Jacob Pontoppidan; Christensen, Lise H; Zachariae, Claus O C

    2007-01-01

    An increasing number of patients undergo soft-tissue augmentation. The quality depends on the applied filler substance, the compliance of the patient and the physician. Long-term adverse reactions are referred to as nodules or granulomas. Nodules following degradable gels and polyacrylamide hydro...

  10. Bilateral akillesseneruptur efter behandling med ciprofloxacin

    DEFF Research Database (Denmark)

    Attarzadeh, Amir Pasha; Ryge, Camilla

    2013-01-01

    We report a case of spontaneous non-traumatic bilateral rupture of the Achilles tendons following ciprofloxacin treatment. A 54-year-old man presented with spontaneous Achilles tendon rupture on the left side, tendinitis and partial tear on the right side following few days of treatment with cipr......We report a case of spontaneous non-traumatic bilateral rupture of the Achilles tendons following ciprofloxacin treatment. A 54-year-old man presented with spontaneous Achilles tendon rupture on the left side, tendinitis and partial tear on the right side following few days of treatment...... with ciprofloxacin 500 mg twice daily and long-term treatment with prednisolon 10 mg once daily. This rare side effect caused by concurrent treatment with steroids and ciprofloxacin should be kept in mind. Any signs of tendinitis following this treatment should arouse the physicians' suspicion towards ciprofloxacin....

  11. Impotens forarsaget af behandling med methotrexat

    DEFF Research Database (Denmark)

    Penninga, Ida Elisabeth Irene; Larsen, H.K.; Andersen, S.E.

    2008-01-01

    Methotrexate (MTX) is used in the treatment of malignant and non-malignant diseases. This case report describes impotence as a seldom but possible overlooked adverse effect to MTX treatment. A 58 year-old man was treated for erythrodermia with a weekly dose of 7.5 mg MTX. He developed erective...... impotence nine months after initiation of treatment. Two weeks after discontinuation of MTX the impotence subsided, but when MTX treatment was reintroduced, the impotence returned after two months. Only a few other cases of impotence associated with MTX have been described previously Udgivelsesdato: 2008/1/28...

  12. Behandling af diabetes mellitus med biologiske laegemidler

    DEFF Research Database (Denmark)

    Larsen, Claus Morten; Mandrup-Poulsen, Thomas

    2008-01-01

    Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps of the patho......Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps...... of the pathogenesis of type 1 and type 2 diabetes which are targeted by biologic therapeutics and reviews the treatment results. Udgivelsesdato: 2008-Jun-9...

  13. Behandl dig selv med honning"

    DEFF Research Database (Denmark)

    Mejrup, Kristian; Bjerring-Nielsen, Mattias

    2015-01-01

    Abstract: This article has a twofold purpose: to investigate the symbolic richness and abundant sweetness of honey and to employ ‘honey treatment’ as a strategy for reading the honeycombapocalypse comprised in the Jewish legend of Joseph and Aseneth. This text tells of Aseneth’s encounter with a ...... entirely perturbed and paralysed. In fact, her free speech and wits remain as if protected by a honeysweetened agency. The article emphasizes the necessity of a ‘conversion’ by the reader enabling him to grasp the sublime potential of the aesthetics of sweetness....

  14. Behandling af Tourettes syndrom med aripiprazol

    DEFF Research Database (Denmark)

    Stenstrøm, Anne Dorte; Sindø, Ingrid

    2008-01-01

    Tourette's syndrome (TS) is a motoric disorder characterised by multiple motor and vocal tics. The treatment for patients with moderate to severe TS includes antipsychotic medication. A case report is described in which a 20 year-old male had taken antipsychotic medication since the age of five......, due to TS. The initial treatment consisted of pimozide and risperidone, both of which had an unsatisfactorily efficacy on tics and side effects in the form of weight gain and sedation. The patient is now treated with aripiprazole and there is a marked reduction of tics and no side effects...

  15. Behandling af ideopatisk hypereosinofilt syndrom med imatinib

    DEFF Research Database (Denmark)

    Sørensen, Anne Louise; Larsen, Herdis

    2008-01-01

    We here report a case of idiopathic hypereosinophilic syndrome with prompt response to treatment with imatinib. The patient presented with chest pain, myalgias, fatigue and weakness. Blood tests and bone marrow examination revealed striking eosinophilia. Clonal or reactive disorders were excluded...

  16. Omkostningseffektivitet ved hypertensionsbehandling med Losartan i Danmark

    DEFF Research Database (Denmark)

    Keiding, Hans; Hildebrandt, Per; Burke, Thomas;

    2006-01-01

    Formålet med denne analyse var set såvel fra samfundets som fra det danske sundhedsvæsens perspektiv at evaluere omkostningseffektiviteten af losartan sammenlignet med atenolol ved behandling af hypertension, baseret på Losartan Intervention For Endpoint (LIFE)-undersøgelsens data Udgivelsesdato...

  17. Omkostningseffektivitet ved hypertensionsbehandling med Losartan i Danmark

    DEFF Research Database (Denmark)

    Keiding, Hans; Hildebrandt, Per; Burke, Thomas

    2006-01-01

    Formålet med denne analyse var set såvel fra samfundets som fra det danske sundhedsvæsens perspektiv at evaluere omkostningseffektiviteten af losartan sammenlignet med atenolol ved behandling af hypertension, baseret på Losartan Intervention For Endpoint (LIFE)-undersøgelsens data Udgivelsesdato...

  18. Evidens for akupunktur til patienter med kvalme og opkastning i forbindelse med kemoterapi? Et litteraturstudie

    DEFF Research Database (Denmark)

    Pedersen, Birgith; Bundgaard Sørensen, Lene; Stricker, Lisbeth;

    2008-01-01

    Patienter, der får kemoterapi med højemetogene stoffer lider stadig af kvalme og opkastning trods understøttende behandling med moderne antieemtika som 5HT3-antagonister eksempelvis ondansetron. Akupunkturstimulation anvendes for flere lidelser i sundhedsvæsenet og det undersøges om der er evidens...

  19. Akupunktur til patienten med kvalme og opkastning i forbindelse med kemoterapi - er der evidens for dette?

    DEFF Research Database (Denmark)

    Pedersen, Birgith; Sørensen, Lene Bundgaard; Stricker, Lisbeth

    2008-01-01

      Patienter, der får kemoterapi med højemetogene stoffer lider stadig af kvalme og opkastning trods understøttende behandling med moderne antieemtika som 5HT3-antagonister eksempelvis ondansetron. Akupunkturstimulation anvendes for flere lidelser i sundhedsvæsenet og det undersøges om der er evid...

  20. Akupunktur til patienten med kvalme og opkastning i forbindelse med kemoterapi - er der evidens for dette?

    DEFF Research Database (Denmark)

    Pedersen, Birgith; Sørensen, Lene Bundgaard; Stricker, Lisbeth

    2008-01-01

      Patienter, der får kemoterapi med højemetogene stoffer lider stadig af kvalme og opkastning trods understøttende behandling med moderne antieemtika som 5HT3-antagonister eksempelvis ondansetron. Akupunkturstimulation anvendes for flere lidelser i sundhedsvæsenet og det undersøges om der er evid...

  1. Forskning i ergoterapeutisk behandling indenfor neurorehabilitering - en stor udfordring og nødvendighed!

    DEFF Research Database (Denmark)

    Schow, Trine

    2011-01-01

    Der sker i disse år meget indenfor både forskning og behandling i neurorehabilitering. Både grundforskning og kliniske studier bidrager til viden om neuroplasticitet og til udvikling og dokumentation af forskellige behandlingsformer og det er vigtigt at det ergoterapeutiske felt følger med. Denne...

  2. Mentaliseringsbaseret behandling og musikterapi

    DEFF Research Database (Denmark)

    Hannibal, Niels

    2013-01-01

    musikterapi med denne målgruppe. Artiklen ser på de forskrifter til mentaliseringsfremmende tiltag som Allan, Fonagy og Bateman (2010) beskriver. Artiklens konklusion er dels af MBT’s krav til forholdemåde og interventionsfokus er et skift i forhold til traditionel analytisk orienteret terapi, bl.a. i forhold...

  3. For gammel til behandling?

    DEFF Research Database (Denmark)

    Petersen, Thomas Søbirk

    2014-01-01

    Bør det være lovligt for sundhedspersoner at hjælpe kvinder over 45 år med kunstig befrugtning som reagensglasbefrugtning? Ifølge gældende dansk lov er dette ulovligt. En kritisk diskussion af centrale argumenter for og imod gældende lov er målet for artiklen. Argumenter for gældende lov betoner ...

  4. Biologisk behandling af spondylitis ankylopoietica

    DEFF Research Database (Denmark)

    Freiesleben, S.; Schou, M.

    2008-01-01

    All of the three well-known TNF alpha inhibitors (infliximab, adalimumab and etanercept) have a rapidly occurring and long-lasting effect in ankylosing spondylitis (AS). The IL-1 antagonist, anakinra, has been investigated in two open label studies with partially conflicting results. Apart from...

  5. Folkeretlige problemstillinger i forbindelse med konflikten mellem Ukraine og Rusland

    DEFF Research Database (Denmark)

    Buhl, Kenneth Øhlenschlæger

    Konflikten mellem Ukraine og Rusland udgør en trussel mod den internationale retsorden og dermed også hele den europæiske orden. Med henblik på at give et grundlag for at forstå omfanget af dette aspekt af konflikten behandles her lovligheden af nogle af de handlinger, som har været konfliktens...

  6. Prolonged fever after Infliximab infusion

    Institute of Scientific and Technical Information of China (English)

    Jennifer; Katz; Michael; Frank

    2012-01-01

    Pharmacologic management for ulcerative colitis (UC) has recently been expanded to include antitumor necrosis factor (TNF) therapy for severe disease. Infliximab, a chimeric monoclonal antibody directed again TNF α was first tested in patients with Crohn’s disease. In addition to serious infections, malignancy, drug induced lupus and other autoimmune diseases, serum sickness-like reactions, neurological disease, and infusion reactions further complicate the use of Infliximab. We report a case of prolonged fever after Infliximab infusion to treat steroid refractory UC.

  7. Forebyggelse og behandling af osteoporose i forbindelse med behandling af ikke-metastaserende prostatacancer

    DEFF Research Database (Denmark)

    Eiken, Pia Agnete; Langdahl, Bente Lomholt; Eiken, Frederik L;

    2011-01-01

    The prevention of cancer treatment-induced bone loss in patients with prostatae cancer due to gonadotropin-releasing hormone (GnRH)-agonist, GnRH-antagonist and orchidectomi therapy has a high priority. We present an algorithm for the prevention and treatment of osteoporosis during treatment of non...

  8. Behandling af patienter med Guillan Barré syndrom

    DEFF Research Database (Denmark)

    Oliel, Vibeke S.

    2011-01-01

    Resumè Guillain Barrés syndrom er en autoimmum sygdom karakteriseret ved motorisk, sensorisk og autonom dysfunktion. I Danmark rammes omkring 80 personer i alle aldre årligt af sygdommen. Akut inflammatorisk polyradikoloneuropati rammer de perifere nervers nerveskeder og medfører progredierende...

  9. Palliativ behandling af patienter med terminal kronisk obstruktiv lungesygdom

    DEFF Research Database (Denmark)

    von Plessen, Christian; Nielsen, Thyge L; Steffensen, Ida E;

    2011-01-01

    Terminal chronic obstructive pulmonary disease (COPD) and advanced cancer have similar prognosis and symptom burden. However, palliative care of patients with terminal COPD has been neglected in Denmark. We describe the symptoms of terminal COPD and suggest criteria for defining the palliative...... phase of the disease. Furthermore we discuss the prognostic and ethical challenges for patients, their families and their caregivers. Finally, we summarize the current evidence for palliative treatment of dyspnoea and ways to evaluate response to treatment....

  10. Karakteristik, diagnostik og behandling af patienter med autoimmun hepatitis

    DEFF Research Database (Denmark)

    Ytting, Henriette; Larsen, Fin Stolze

    2012-01-01

    Autoimmune hepatitis is a relatively rare disease that may lead to rapidly progressing liver cirrhosis and even fulminant liver failure, if diagnosis and treatment is delayed or ineffective. Diagnosing the disease can be challenging, and one in five patients respond insufficiently to standard tre...... treatment. Patients, who are diagnosed late in the disease course or only respond partly to medical treatment, are at high risk of developing severe liver insufficiency. This article summarizes the present knowledge and evidence regarding diagnostics, therapy and disease course....

  11. Behandling af peritoneal karcinose med laparoskopisk intraperitoneal kemoterapi under tryk

    DEFF Research Database (Denmark)

    Graversen, Martin; Pfeiffer, Per; Mortensen, Michael Bau

    2016-01-01

    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment option in patients with peritoneal carcinomatosis (PC). PIPAC has proven efficacious in the treatment of PC from ovarian, colon and gastric cancer. PIPAC has a favourable profile regarding safety for patients and occupati......Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment option in patients with peritoneal carcinomatosis (PC). PIPAC has proven efficacious in the treatment of PC from ovarian, colon and gastric cancer. PIPAC has a favourable profile regarding safety for patients...

  12. Bedre prognose af cystinose ved behandling med cysteamin og nyretransplantation

    DEFF Research Database (Denmark)

    Oczachowska-Kulik, Anna Ewa; Lund, Allan; Skovby, Flemming

    2011-01-01

    Cystinosis is a rare, autosomal recessive disease with cystine deposits in different tissues. First signs come from kidneys and eyes, but during progression of the disease other organs can also be affected. Previously, patients with cystinosis had a very poor prognosis, but it is now considerably...

  13. Behandling af pilonidalcyster med neodynium-yttriumaluminiumgranat-laser

    DEFF Research Database (Denmark)

    Lindholt, Christine S; Lindholt, Jes S; Lindholt, Jan

    2008-01-01

    A 23 year-old woman with a nonsupporative pilonidal cyst was successfully treated causally with Nd-YAG laser, and without any recidivate after 9 months follow-up. The mechanism is presumed to be that YAG-laser has a wave-length of 1064 nm. Consequently, the wave penetration through the skin is de...... is deeper than most other lasers before the energy is absorbed in melanin and oxyhaemoglobin, so the contents of the cyst can be reached and destroyed. The treatment could be a very attractive alternative to open surgery. Udgivelsesdato: 2008-Jun-23...

  14. Behandling af pilonidalcyster med neodynium-yttriumaluminiumgranat-laser

    DEFF Research Database (Denmark)

    Lindholt, Christine S; Lindholt, Jes Sanddal; Lindholt, Jan

    2008-01-01

    A 23 year-old woman with a nonsupporative pilonidal cyst was successfully treated causally with Nd-YAG laser, and without any recidivate after 9 months follow-up. The mechanism is presumed to be that YAG-laser has a wave-length of 1064 nm. Consequently, the wave penetration through the skin is de...... is deeper than most other lasers before the energy is absorbed in melanin and oxyhaemoglobin, so the contents of the cyst can be reached and destroyed. The treatment could be a very attractive alternative to open surgery....

  15. HIV kan og skal behandles samtidig med tuberkulose

    DEFF Research Database (Denmark)

    von der Maase, Sarah; Gerstoft, Jan; Wejse, Christian

    2014-01-01

    The proper timing of antiretroviral therapy (ART) to HIV-patients co-infected with tuberculosis has been debated. We review three studies on this matter. One study found a significant reduced mortality for patients with CD4+ T-cell counts (CD4+) ≤ 200 per mm3 who received ART early, whereas...... the other two studies found this difference for patients with CD4+ HIV after the initiation of ART....

  16. Behandling af invert papillom med endonasal endoskopisk sinuskirurgi

    DEFF Research Database (Denmark)

    Andersen, Pia Juul; Kjeldsen, Anette Drøhse; Pedersen, Arne Toft

    2002-01-01

    INTRODUCTION: Inverted papilloma is a benign sinonasal tumour and has a marked tendency to recur after surgical excision. The tumour may be associated with malignancy and during growth it may destroy surrounding tissue. The treatment is either lateral rhinotomy or endoscopic sinus surgery. The aim...... of the study was to describe the course of all patients treated with endoscopic sinus surgery at the ENT Department at Vejle County Hospital during the period 1 January to 31 December 1999. MATERIAL AND METHODS: Twenty-eight journals of patients diagnosed with inverted nasal papillomas were reviewed...... with carcinoma. We did not see any serious side effects to the treatment. DISCUSSION: Endoscopic sinus surgery in combination with Caldwell-Luc can be recommended as an alternative treatment to lateral rhinotomy in patients with inverted papillomas. Preoperative staging with CT or MR-scanning, experienced...

  17. Muskuloskeletal behandling af 11-årig med artrogrypose

    DEFF Research Database (Denmark)

    Thomsen, Maria Morandi; Thomsen, Stig Aaberg; Due, Pernille

    2010-01-01

    A two-year-old patient was diagnosed with arthrogryposis because of inflected knees (15-20 degrees) and stiff hamstrings. All joints and reflexes were normal. Activities were described as age-appropriate, but the patient walked with inflected knees and increased lumbal lordosis. Physiotherapy...

  18. Myopati hos en patient i behandling med simvastatin og fluconazol

    DEFF Research Database (Denmark)

    Pedersen, Jens Kristian; Lydolph, Magnus Christian; Somnier, Finn

    2016-01-01

    A 69-year-old female was admitted due to progressive loss of muscle strength following addition of fluconazole to long-term simvastatin treatment. Rhabdomyolysis was suspected and both drugs were discontinued. Forced diuresis was initiated together with a short course of prednisolone. After 21...

  19. Karkirurgisk behandling hos patienter med påvirket nyrefunktion

    DEFF Research Database (Denmark)

    Hensler, M K; Forrest, M; Lorentzen, Jørgen Ewald

    1994-01-01

    and blood pressure status was evaluated preoperatively and at follow-up. The perioperative mortality was 5% (n = 2) and morbidity 21% (n = 9). At discharge from hospital renal function was maintained in 38 patients (90%), including three patients who at the time of operation were without diuresis and had...

  20. Lovende resultater ved konservativ behandling med dynamisk mobilisering efter akillesseneruptur

    DEFF Research Database (Denmark)

    Tengberg, Peter Toft; Barfod, Kristoffer Weisskirchner; Krasheninnikoff, Michael

    2011-01-01

    There is no consensus regarding the optimal treatment of acute Achilles tendon ruptures. This review of the literature on the subject shows a significantly higher rate of reruptures (RR) in the conservatively treated group compared to the surgically treated group when the foot is immobilised...

  1. Graviditet i livmoderhalsen kan behandles konservativt med methotrexat

    DEFF Research Database (Denmark)

    Sørensen, Marie; Clausen, Helle Vibeke

    2011-01-01

    Two cases of cervical ectopic pregnancy after in vitro fertilization embryo transfer were managed conservatively. One living cervical ectopic pregnancy was treated with intra-amniotic and systemic injection of methotrexate, and the other cervical ectopic pregnancy with a fetal pole was treated...... with systemic methotrexate. The patient with the living cervical ectopic pregnancy had stable vital signs during the period of treatment. The patient with the fetal pole was admitted with heavy vaginal bleeding and anaemia and was stabilised before treatment was initiated. She was stable throughout...

  2. Medicinsk behandling af patienter med primær hyperparathyroidisme

    DEFF Research Database (Denmark)

    Vestergaard, Peter; Mosekilde, Leif

    2009-01-01

    Surgery is the recommended treatment for primary hyperparathyroidism. For exceptional medical treatment, the main drugs available are cinacalcet to normalize plasma calcium, and bisphosphonates to prevent bone loss. The patients eligible for medical therapy are those who cannot be operated or whose...... condition persists despite optimal surgical treatment. However, PHPT can cause other complications that need special attention regarding prevention and treatment during follow-up. Udgivelsesdato: 2009-Aug-10...

  3. Laktatacidose ved behandling af type 2-diabetes med metformin

    DEFF Research Database (Denmark)

    Holst, Helle; Eldrup, Ebbe; Guldstad, Nana Harriet;

    2012-01-01

    Metformin (MET) is the first-line agent in treatment of type 2 diabetes. However, MET has been associated with lactic acidosis (MALA), a potential but rare complication which has influenced treatment strategies in decades. Recently, guidelines have been changed in regards of age and heart failure...

  4. Behandling af pilonidalcyster med neodynium-yttriumaluminiumgranat-laser

    DEFF Research Database (Denmark)

    Lindholt, Christine S; Lindholt, Jes Sanddal; Lindholt, Jan

    2008-01-01

    A 23 year-old woman with a nonsupporative pilonidal cyst was successfully treated causally with Nd-YAG laser, and without any recidivate after 9 months follow-up. The mechanism is presumed to be that YAG-laser has a wave-length of 1064 nm. Consequently, the wave penetration through the skin is de...... is deeper than most other lasers before the energy is absorbed in melanin and oxyhaemoglobin, so the contents of the cyst can be reached and destroyed. The treatment could be a very attractive alternative to open surgery....

  5. Behandling af pilonidalcyster med neodynium-yttriumaluminiumgranat-laser

    DEFF Research Database (Denmark)

    Lindholt, Christine S; Lindholt, Jes S; Lindholt, Jan

    2008-01-01

    A 23 year-old woman with a nonsupporative pilonidal cyst was successfully treated causally with Nd-YAG laser, and without any recidivate after 9 months follow-up. The mechanism is presumed to be that YAG-laser has a wave-length of 1064 nm. Consequently, the wave penetration through the skin is de...... is deeper than most other lasers before the energy is absorbed in melanin and oxyhaemoglobin, so the contents of the cyst can be reached and destroyed. The treatment could be a very attractive alternative to open surgery. Udgivelsesdato: 2008-Jun-23...

  6. Behandling af metforminassocieret laktatacidose med hæmodialyse

    DEFF Research Database (Denmark)

    Schousboe, K.; Rasmussen, K.; El Fassi, D.

    2012-01-01

    Metformin-associated lactate acidosis is rare but serious and characterized by metabolic acidosis and elevated lactate. We describe a single-institution experience of four cases in one year. Despite pH levels of 6.85 to 7.12 and lactate levels of 11-28 mmol/l three of the patients survived. Two...

  7. Den haemostatiske balance under behandling med nyere p-pillepraeparater

    DEFF Research Database (Denmark)

    Petersen, K R; Skouby, S O; Sidelmann, Johannes Jakobsen

    1994-01-01

    of fibrinogen and factor VII increased while the capacity of coagulation inhibition was affected by increased protein C and decreased protein S levels. Increased fibrinolytic capacity was indicated by elevated activity and reduced antigen levels of tissue plasminogen activator and reduced activity...

  8. Behandling af kroniske sygdomme hos patienter med demens

    DEFF Research Database (Denmark)

    Pedersen, Hanne; Klinkby, Kristian Skikkild; Waldorff, Frans Borch

    2017-01-01

    , polypharmacy and chronic pain. Ongoing goal setting is important, and advance care planning is recommended. In general, comorbidity must be carefully and holistic assessed and managed according to each patient's general status of health and stage of dementia. As the dementia develops, focus should primarily...

  9. Behandling af metforminassocieret laktatacidose med hæmodialyse

    DEFF Research Database (Denmark)

    Schousboe, K.; Rasmussen, K.; El Fassi, D.;

    2012-01-01

    Metformin-associated lactate acidosis is rare but serious and characterized by metabolic acidosis and elevated lactate. We describe a single-institution experience of four cases in one year. Despite pH levels of 6.85 to 7.12 and lactate levels of 11-28 mmol/l three of the patients survived. Two...... of the patients had normal kidney function previous to hospitalization. Treatment includes fluid replacement, IV sodium bicarbonate and haemodialysis....

  10. Trombosering af mekanisk mitralklapprotese under behandling med dabigatran

    DEFF Research Database (Denmark)

    Thomsen, Jakob Hartvig; Kjaergaard, Jesper; Saust, Laura Trolle;

    2014-01-01

    Dabigatran has been approved for prevention of thromboembolic complications in nonvalvular atrial fibrillation. We present a case of thrombosis of a mechanical prosthetic mitral valve during anticoagulation with dabigatran, switched from warfarin. The patient presented with cardiogenic shock...

  11. Infliximab dependency in children with Crohn's disease

    DEFF Research Database (Denmark)

    Duricova, D; Pedersen, N; Lenicek, M

    2009-01-01

    BACKGROUND: Recently, infliximab dependency has been described. AIM: To assess frequency of ID in 82 consecutive Crohn's disease children treated with infliximab 2000-2006 and to describe clinical and genetic predictors of long-term infliximab response. METHODS: A phenotype model of infliximab...

  12. Mindfulness som smertehåndteringsredskab for kvinder med endometriose

    DEFF Research Database (Denmark)

    Jensen, Mette Kold; Vedsted-Hansen, Hanne; Hansen, Tia G. B.

    2011-01-01

    Endometriose er en kronisk underlivssygdom med smerter og en række afledte problemer, som ikke nødvendigvis kan behandles med lægelige tiltag. Artiklen argumenterer for, at en mindfulness-baseret tilgang med fokus på smertehåndtering kan anvendes til denne klientgruppe. I vestlig terapeutisk...... sammenhæng kan mindfulness karakteriseres som nærvær, observation og beskrivelse af sansninger uden vurdering eller reaktion. Mindfulness-træning har effekt mod andre typer stress og kroniske smerter, og artiklen opridser et koncept til anvendelse ved endometriose. Konceptet belyses med en case, hvor...

  13. Mindfulness som smertehåndteringsredskab for kvinder med endometriose

    DEFF Research Database (Denmark)

    Jensen, Mette Kold; Vedsted-Hansen, Hanne; Hansen, Tia G. B.

    2011-01-01

    Endometriose er en kronisk underlivssygdom med smerter og en række afledte problemer, som ikke nødvendigvis kan behandles med lægelige tiltag. Artiklen argumenterer for, at en mindfulness-baseret tilgang med fokus på smertehåndtering kan anvendes til denne klientgruppe. I vestlig terapeutisk...... sammenhæng kan mindfulness karakteriseres som nærvær, observation og beskrivelse af sansninger uden vurdering eller reaktion. Mindfulness-træning har effekt mod andre typer stress og kroniske smerter, og artiklen opridser et koncept til anvendelse ved endometriose. Konceptet belyses med en case, hvor...

  14. Teknologiers mellemkomst i ambulant behandling og egenomsorg

    DEFF Research Database (Denmark)

    Ballegaard, Stinne Aaløkke; Aarhus, Rikke

    2009-01-01

    Vigtige tendenser i den danske sundhedssektor i disse år er centralisering af behandling og øget egenomsorg. Teknologi ses ofte som en del af denne udvikling, omend der eksisterer både dystopiske og utopiske forestillinger om, hvorvidt teknologi fremmedgør eller støtter patienten. I denne artikel...

  15. Infraktioner i dentin - diagnostik og behandling

    DEFF Research Database (Denmark)

    Pallesen, Ulla

    2011-01-01

    . Kliniske og radiologiske fund viser ikke tegn på sygdom, og patienten ønsker behandling. Diagnosen skal stilles, uden at tandlægen har adgang til at se infraktionen i dentinen, og jo tidligere den stilles, desto større er muligheden for, at tanden kan reddes. Infraktionens retning og dybde, pulpas tilstand...

  16. EMDR-behandling  : Barns och ungdomars upplevelser en kvalitetssäkringsstudie 

    OpenAIRE

    Fredin, Ingela

    2005-01-01

    Föreliggande studie är dels ett led i att kvalitetssäkra EMDR (Eye Movement Desensitization and Reprocessing) som behandlingsmetod för barn och ungdomar och dels att utröna om behandlingen bidragit till ett förbättrat mående. EMDR som behandlingsmetod för barn och ungdomar har stöd i kontrollerade studier, men ytterligare forskning behövs. I den här studien deltog åtta barn och ungdomar med varierande diagnoser, vilka fått EMDR-behandling i barn- och ungdomspsykiatrisk öppenvård. Behandlingen...

  17. Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.

    Science.gov (United States)

    Dannepond, Carole; Maruani, Annabel; Machet, Laurent; Ternant, David; Paintaud, Gilles; Samimi, Mahtab

    2015-04-01

    The efficacy of infliximab is influenced by individual variability in its pharmacokinetics and pharmacodynamics. Serum infliximab concentrations could therefore be related to the efficacy and tolerance of infliximab, and assist adjustment of treatment. The aim of this systematic review was to assess the value of measuring serum infliximab concentrations in psoriatic patients. A bibliographic search was performed on MEDLINE, CENTRAL, EMBASE, LILACS for original studies on serum infliximab concentrations in psoriatic patients treated with infliximab. Ten articles were included, representing evaluation of serum infliximab concentrations in 733 patients. Predictive value of higher serum infliximab concentrations on long-term response maintenance was suggested in 3 studies. There was no information regarding the value of such measurements for adjustment of infliximab dosage. Trough serum infliximab concentrations that are at least detectable (>0.1 mg/L) at steady state (week 22) seem to be associated with maintaining a clinical response in the long term.

  18. Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review

    OpenAIRE

    Dannepond, Carole; Maruani, Annabel; Machet, Laurent; Ternant, David; Paintaud, Gilles

    2015-01-01

    The efficacy of infliximab is influenced by individual variability in its pharmacokinetics and pharmacodynamics. Serum infliximab concentrations could therefore be related to the efficacy and tolerance of infliximab, and assist adjustment of treatment. The aim of this systematic review was to assess the value of measuring serum infliximab concentrations in psoriatic patients. A bibliographic search was performed on MEDLINE, CENTRAL, EMBASE, LILACS for original studies on serum infliximab conc...

  19. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.

    Science.gov (United States)

    Blair, Hannah A; Deeks, Emma D

    2016-10-01

    Infliximab biosimilar (CT-P13/infliximab-dyyb; Remsima(®), Inflectra(®)) is approved in several countries for use in all indications for which reference infliximab (Remicade(®)) is approved, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Clinical data contributing to the EU approval of infliximab biosimilar were obtained from two pivotal double-blind clinical trials in patients with AS (PLANETAS) or RA (PLANETRA). Infliximab biosimilar demonstrated equivalence to reference infliximab in terms of its pharmacokinetic profile in patients with AS, patients with RA, and in healthy volunteers, and in terms of its efficacy in patients with RA. Clinical response rates in patients with RA or AS were maintained over the longer term (up to 102 weeks). In addition, the efficacy of infliximab biosimilar in patients with RA or Crohn's disease and ulcerative colitis [i.e. inflammatory bowel disease (IBD)] has been demonstrated in the real-world setting. Infliximab biosimilar was generally well tolerated, with a tolerability profile similar to that of reference infliximab. Switching from reference infliximab to infliximab biosimilar had no detrimental effect on efficacy, safety, or immunogenicity compared with continuous infliximab biosimilar therapy, according to the extensions of PLANETAS and PLANETRA, and real-world data in IBD. Current evidence therefore suggests that infliximab biosimilar is a useful alternative to reference infliximab in patients with autoimmune inflammatory diseases.

  20. Epstein-Barr-virus-associeret lymfom hos en patient med colitis ulcerosa i behandling med azathioprin

    DEFF Research Database (Denmark)

    Kofoed, Kristian; Kiszka-Kanowitz, Marianne; Albrectsen, Jens Mørch;

    2008-01-01

    A 28 year-old man with ulcerative colitis treated for 10 years with azathioprine (AZA) returned from Central Asia with fever, swollen lymph glands, hepatosplenomegaly, and pancytopenia. He was tested positive for acute Epstein-Barr virus (EBV) infection. Before the final diagnosis of EBV-associat......A 28 year-old man with ulcerative colitis treated for 10 years with azathioprine (AZA) returned from Central Asia with fever, swollen lymph glands, hepatosplenomegaly, and pancytopenia. He was tested positive for acute Epstein-Barr virus (EBV) infection. Before the final diagnosis of EBV...

  1. Angioneurotisk ødem i forbindelse med behandling med angiotensinkonverterende enzym-haemmer

    DEFF Research Database (Denmark)

    Johansen, E C; Johansen, J B; Døssing, H

    1996-01-01

    Angioneurotic oedema secondary to angiotensin-converting enzyme (ACE) inhibitors is a rare condition, but it is a side effect which is likely to be seen more frequently because of the increased use of these drugs in the treatment of heart failure and hypertension. We report two cases which...... illustrate problems in the diagnosis and management of this life-threatening condition, and also demonstrate that angioedema re-occurs if the ACE inhibitor is not discontinued. If angioedema is suspected, therapy with any angiotensin converting-enzyme inhibitor should be discontinued promptly, respiratory...

  2. Succesfuld behandling af svær dabigatranoverdosering med idarucizumab hos en patient med nyresvigt

    DEFF Research Database (Denmark)

    Poulsen, Christina Gjerlev; Bestle, Morten; Boesby, Lene

    2017-01-01

    In the course of an uncomplicated sigmoidostomy a 63-year-old male who had severe comorbidity developed a critical bleeding due to dabigatran intoxication induced by acute kidney injury. Massive blood transfusions, tranexamic acid, Octaplex and haemodialysis were not effective. Administration...

  3. Patient med nedsat leverfunktion fik myoklonier under behandling med selektive serotoningenoptagelseshæmmere

    DEFF Research Database (Denmark)

    Forsberg-Gillving, Mimmi; Bode, Matthias; Sindrup, Søren Hein

    2015-01-01

    Side effects such as myoclonus and tremor are rare when treating with selective serotonin reuptake inhibitors (SSRIs). We present a case where a patient with known liver cirrho-sis and in treatment with citalopram developed myoclonus, tremor and gait difficulties. The symptoms were reduced when...

  4. Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

    DEFF Research Database (Denmark)

    Steffensen, Maria Charlotte; Mægbæk, Merete Lund; Laurberg, Peter

    2014-01-01

    Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin...

  5. Behandling med valproat under graviditet: beskrivelse af fire cases med føtalt valproatsyndrom

    DEFF Research Database (Denmark)

    Sabers, Anne; Larsen, Katja; Blichfeldt, Susanne;

    2009-01-01

    INTRODUCTION: Treatment with valproate is associated with an increased risk of teratogenicity compared to other antiepileptic drugs and can cause a complex of serious symptoms usually referred to as "foetal valproate symdrome" which is characterised by major and minor malformations in association...

  6. Juridiske overvejelser i forbindelse med Influence Operationer

    DEFF Research Database (Denmark)

    Nissen, Thomas Elkjer

    2014-01-01

    Kapitel 8: Juridiske overvejelser i forbindelse med influence-operationer Af Thomas Elkjer Nissen Dette kapitel fokuserer ligesom kapitel 9 på de juridiske problemstillinger, som den teknologiske udvikling har bragt med sig til væbnede konflikter; i dette kapitel er der fokus på kommunikation....... Kapitlet ser nærmere på det moderne informationsmiljø, dets betydning i moderne konflikter og den stigende anvendelse af information som magtmiddel. Herefter rettes blikket mod de juridiske overvejelser, der er forbundet med influence-operationer, bl.a. tid og rum, chefansvar, mandat og juridisk grundlag....... Afsnittet behandler desuden bl.a. jus in bello’s grundlæggende princippers indflydelse på influence-operationer....

  7. Endring i adaptiv atferd hos eldre personer med utviklingshemning - en sammenligning mellom personer med Down syndrom og personer med annen utviklingshemning

    Directory of Open Access Journals (Sweden)

    Anne Marit Bygdnes

    2012-01-01

    Materiale og metode: Undersøkelsen omfatter 87 personer med utviklingshemning som tidligere har bodd på en sentralinstitusjon. Datainnsamling skjedde ved at omsorgspersoner fylte ut ABDQ.  Resultater: Det var 24 % i utvalget som hadde nedgang i adaptiv atferd. Fortolkning: ABDQ er et hjelpemiddel til å avdekke nedgang i adaptiv atferd. Det er viktig at svikt avdekkes tidligst mulig og videreformidles til helsepersonell for utredning, diagnostisering, relevant behandling og tilrettelagte helse- og omsorgstjenester. Mange personer med utviklingshemning mestrer ikke å informere om egen helsetilstand og er avhengig av at omsorgspersonalet kan avdekke sykdom og lidelser så tidlig som mulig i sykdomsforløpet.

  8. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Bendtzen, Klaus; Brynskov, Jørn

    2011-01-01

    Reasons for infliximab failure in Crohn's disease and ulcerative colitis are debated. Serum levels of infliximab and anti-infliximab antibodies have been associated with loss of response. We aimed at determining cut-off levels for infliximab and anti-infliximab antibody concentrations associated...

  9. Guidelines for treatment with infliximab for Crohn's disease

    NARCIS (Netherlands)

    Hommes, D. W.; Oldenburg, B.; van Bodegraven, A. A.; van Hogezand, R. A.; de Jong, D. J.; Romberg-Camps, M. J. L.; van der Woude, J.; Dijkstra, G.

    2006-01-01

    Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The effectiveness of infliximab has been demonstrated for both active luminal disease and for enterocutaneous fistulisation. In addition, infliximab can be administered for extraintestinal symptoms of Cr

  10. Guidelines for treatment with infliximab for Crohn's disease.

    NARCIS (Netherlands)

    Hommes, D.W.; Oldenburg, B.; Bodegraven, A.A; Hogezand, R.A. van; Jong, D.J. de; Romberg-Camps, M.; Woude, J. van der; Dijkstra, G.

    2006-01-01

    Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The effectiveness of infliximab has been demonstrated for both active luminal disease and for enterocutaneous fistulisation. In addition, infliximab can be administered for extraintestinal symptoms of Cr

  11. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

    OpenAIRE

    Vande Casteele, Niels; Khanna, Reena; Levesque, Barrett G.; Stitt, Larry; Zou, G.Y.; Singh, Sharat; Lockton, Steve; Hauenstein, Scott; Ohrmund, Linda; Greenberg, Gordon R; Rutgeerts, Paul; Gils, Ann; William J Sandborn; Vermeire, Severine; Feagan, Brian G.

    2014-01-01

    Objective Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab. Design In an observational study, 1487 trough serum samples from 483 patients with CD who participated in four clinical studies ...

  12. Hidradenite supurativa tratada com infliximabe Hidradenitis suppurativa treated with infliximab

    Directory of Open Access Journals (Sweden)

    Daniel Lago Obadia

    2009-12-01

    Full Text Available A hidradenite supurativa é doença inflamatória de difícil tratamento. Recentemente, a terapia anti-TNF alfa, com anticorpos monoclonais ("terapia biológica", tem sido apontada como uma alternativa. No entanto, ensaios clínicos avaliando a eficácia destas drogas na hidradenite supurativa, ainda não foram publicados. Apresentamos um caso no qual o uso do infliximabe não resultou em melhora clínica expressiva.Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies ("biological therapy", has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.

  13. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis

    Science.gov (United States)

    Wang, Qiang; Wen, Zhenzhen; Cao, Qian

    2016-01-01

    Infliximab is a promising drug with good outcomes demonstrated for diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthropathy (SpA). However, treatment with this drug may increase the risk of tuberculosis infection. The aim of the present study was to investigate infliximab-associated tuberculosis infection. Literature searches in PubMed, MEDLINE and EMBASE databases were performed. Randomized controlled trials with >95% of the patients >18 years-old were included. Meta-analysis was performed to investigate the incidence of tuberculosis infection after infliximab infusion. A total of 24 RCTs were included in the present meta-analysis. In total, 21 (0.51%) tuberculosis infections were detected among 4,111 patients administered infliximab therapy, compared with 0 (0%) among 2,229 patients assigned to the placebo group. Pooled odds ratio (OR) of developing tuberculosis infection was significantly higher with infliximab therapy than with placebo [2.86; 95% confidence interval (CI), 1.09–7.52]. The OR of tuberculosis infection was 3.93 (95% CI, 0.91–16.91) in RA, 2.46 (95% CI, 0.38–15.92) in SpA and 1.66 (95% CI, 0.26–10.57) in IBD. Rates of tuberculosis infection with infliximab therapy in RA, SpA and IBD were 0.70, 0.22 and 0.52%, respectively. Compared with placebo, infliximab therapy may increase the risk of developing tuberculosis. However, the ORs for the risk of infliximab-associated tuberculosis were not demonstrated to be significant in IBD, RA and SpA; therefore, these findings should be interpreted with caution. The risk of developing tuberculosis demonstrates the importance of the prevention and management of tuberculosis infection with infliximab therapy. PMID:27588089

  14. Hydrotermisk stabilitet av mikroporøse materialer med CHA topologi

    OpenAIRE

    Nilsen, Fredrik Bø

    2015-01-01

    Dette arbeidet har undersøkt to materialer, zeolitten SSZ-13 og det zeotype materialet SAPO-34, begge med CHA-topologi. Materialene ble syntetisert ut i fra tidligere utarbeidete prosedyrer før de ble hydrotermisk behandlet. Betingelsene under behandlingen var temperaturer på 600⁰C og 700⁰C med en konstant vanntilførsel på 6 ml/time over 4 timer. Før og etter behandling ble prøvene karakterisert med XRD, N2 adsorpsjon og BET beregninger, SEM, EDS, FT-IR med CO og pyridin som probemolekyler og...

  15. Parkinsonism as a side effect of infliximab.

    Science.gov (United States)

    Henriksen, Jakob Nørgaard; Eriksson, Bengt Oluf Mikael

    2016-05-05

    We present a case of a 64-year-old man with Crohn's disease who developed parkinsonism after starting treatment with infliximab (Remicade). The patient had a 30-year history of Crohn's disease with previous surgical procedures and treatment with methotrexate. Treatment was augmented with infliximab, and 3 days after the first dose of 400 mg, a resting tremor began in the left leg. Over 4 months, symptoms progressed and now involved the right leg as well as both hands. There was no clinical effect of infliximab treatment, and the treatment was withdrawn 4 months later. The patient then experienced gradual, but continual, improvement of the resting tremor after withdrawal of infliximab. To the best of our knowledge, this is the first case report describing a patient developing parkinsonism after starting treatment with infliximab, with symptoms remitting on discontinuation.

  16. Infliximab in the treatment of rheumatoid arthritis

    Directory of Open Access Journals (Sweden)

    A Perdriger

    2009-05-01

    Full Text Available A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα developed for treating rheumatoid arthritis (RA. This chimeric antibody binds with high affinity to both soluble and trans-membrane TNF and is able to reduce synovial inflammation, bone resorption and cartilage degradation. The efficacy of infliximab has been observed in active RA despite treatment with multiple disease modifying anti-rheumatic drugs (DMARDs, and in early disease with no prior treatment by methotrexate (MTX. Infliximab has been shown to reduce joint inflammation and to slow radiographic progression, in both clinical and non-clinical responders. Recent data suggest that using infliximab early in RA treatment increases the percentage of clinical remission and allows infliximab discontinuation. The recommended dosage of 3 mg/kg could be increased up to 10 mg/kg with partial efficacy of the dose escalation. Antibodies to infliximab have been observed in 7% to 61% of patients and are associated with a low trough level of infliximab and secondary response failure. Their occurrence could be prevented by co-medication with MTX. The combination of DMARDs other than MTX with infliximab was found to be safe and efficacious. Infections, principally tuberculosis, are increased in treated patients, and the risk is greater at higher dose. Even if the treatment is generally safe and well tolerated, patients treated with infliximab should be closely monitored.Keywords: infliximab, rheumatoid arthritis, disease modifying anti-rheumatic drugs

  17. DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID ADMINISTRATION

    Directory of Open Access Journals (Sweden)

    E. S. Zhugrova

    2008-01-01

    . These events were accompanied by more significant improvement of RА course and increased functional abilities of joints. In patients from group III (absence of clinical effects, the level of antibodies to Infliximab before therapy was high, and it was increased by 22 week of treatment. It was shown that, in cases of initially high levels of endogenous anti-TNFα antibodies, clinical response to Infliximab therapy is likely to be reduced. Thus, it is possible to suggest that determination of initial TNFα and IL-10 levels, as well as starting levels of antibodies to Infliximab, and their changes in the course of therapy can be used as immunological parameters, thus allowing to predict the responses to Infliximab therapy. (Med. Immunol., 2008, vol. 10, N 2-3, pp 251-260.

  18. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

    Directory of Open Access Journals (Sweden)

    Dario Sorrentino

    Full Text Available In patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg. However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies, and might loose response to therapy. To verify this hypothesis infliximab pharmacokinetics and clinical/endoscopic response were checked in a group of patients treated in the long term with low infliximab doses.Infliximab antibodies, infliximab levels, highly-sensitive CRP and fecal calprotectin were measured during the 8-week interval in 5 consecutive patients in clinical (Crohn's Disease Activity Index < 150 and endoscopic (Rutgeerts scores 0-1 remission after one year of therapy with infliximab 3 mg/Kg. For comparison with reported standards, infliximab pharmacokinetics and inflammatory parameters were also tested in 6 Crohn's disease patients who did not undergo surgery and who were in clinical remission while on infliximab 5 mg/Kg. Patients on low infliximab dose also underwent colonoscopy after 18 additional months of therapy.Highly sensitive CRP and fecal calprotectin increased in all patients during the 8-week interval. Infliximab trough levels were lower in patients treated with the low dose compared to controls (mean±SE: 2.0±0.3 vs 4.75±0.83 μg/mL respectively p<0.05. Infliximab antibodies were present in two of the subjects treated with low infliximab dose and in none of the controls. However, in low dose-treated patients after 18 additional months of therapy endoscopy continued to show mucosal remission and none of them developed clinical recurrence or side effects.Patients treated with low infliximab doses had lower trough levels compared to patients treated with 5 mg/Kg and some developed antibodies to infliximab. However, low infliximab doses sustained clinical and endoscopic remission for a total of 30 months of treatment.

  19. Response to infliximab in SAPHO syndrome

    Science.gov (United States)

    Fruehauf, Julia; Cierny-Modrè, Brigitte; Caelen, Laila El-Shabrawi; Schwarz, Thomas; Weinke, Roland; Aberer, Elisabeth

    2009-01-01

    Infliximab has become increasingly important in the treatment of SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome. There is, however, little experience with this biological agent, and treatment protocols usually follow the regimens for spondylarthropathies. We report a patient with a highly unusual and severe clinical presentation of SAPHO syndrome including widespread bone and skin disease, and collagenous colitis. Infliximab treatment (5 mg/kg) given at weeks 0, 2 and 6 and every 8 weeks thereafter, induced rapid remission of the osteoarticular symptoms, although the skin lesions improved only partially, and after 10 months continuous therapy with infliximab a bone scan even uncovered new active bone lesions. Collagenous colitis is unresponsive to tumour necrosis factor α (TNFα) blocking agents. This moderate response to infliximab may indicate that a more aggressive treatment protocol is mandatory. We further believe that remission of osteoarticular complaints should be routinely confirmed by scintigraphic findings to verify treatment response. PMID:21686446

  20. Infliximab in the treatment of ankylosing spondylitis

    Science.gov (United States)

    Grainger, Rebecca; Harrison, Andrew A

    2007-01-01

    Ankylosing spondylitis (AS) is a chronic, progressive disease characterized by inflammation in the spine and sacroiliac joints which causes pain, stiffness and the potential for spinal ankylosis. It is associated with significant functional impairment. It is common and since onset is often in young people, the burden of disease is considerable. Conventional treatment including non-steroidal antiinflammatory drugs (NSAIDs) and physiotherapy have proven but limited efficacy in controlling symptoms and preventing progression of spinal manifestations. Infliximab, a chimeric monoclonal antibody which binds to and inhibits tumor necrosis factor alpha (TNFα), is highly effective in controlling disease activity in AS. In AS, infliximab 5 mg/kg body weight is usually given as an infusion at weeks 0, 2 and 6, and then every 6–8 weeks. When infliximab is used in combination with NSAIDs a rapid improvement in disease activity by at least 50% is seen in as many as 50% of AS patients. Infliximab has been shown to have ongoing efficacy for as long as regular infusions continue and is safe in the medium term. Magnetic resonance studies show major reductions in spinal inflammation during treatment with infliximab, however ongoing studies will assess if infliximab has disease modifying effect in AS. PMID:19707326

  1. Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Ainsworth, Mark A; Tovey, Michael

    2013-01-01

    Several techniques are used to measure infliximab (IFX) and anti-IFX antibodies (Abs) in Crohn's disease. The aim of this study was to compare different assays for this purpose.......Several techniques are used to measure infliximab (IFX) and anti-IFX antibodies (Abs) in Crohn's disease. The aim of this study was to compare different assays for this purpose....

  2. Musikterapi med personer med demens

    DEFF Research Database (Denmark)

    Ridder, Hanne Mette Ochsner

    2014-01-01

    Musikterapi er forholdsvist velkendt i forhold til mennesker med neurologiske problemstillinger som erhvervet hjerneskade eller demens. Delkapitlet her giver et bredt helserelateret og udviklingspsykologisk perspektiv på neurologiske problemstillinger som følge af forandringer i hjernen. Derfor i...

  3. Infliximab, azathioprine, or combination therapy for Crohn's disease

    DEFF Research Database (Denmark)

    Colombel, Jean Frédéric; Sandborn, William J; Reinisch, Walter

    2010-01-01

    The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.......The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown....

  4. Undervisning i klynger – en artikel om erfaringer med at organisere en form for undervisning, der skaber forbindelse mellem projektarbejde og bredere faglige temaer

    Directory of Open Access Journals (Sweden)

    Thomas Gitz-Johansen

    2007-11-01

    Full Text Available Forfatterne har på RUC arbejdet med at udvikle og beskrive den form for undervisning, som til dagligt går under betegnelsen klynge, hvis hovedformål er at skabe sammenhæng mellem de studerendes projektarbejde og et bredere fagligt og socialt miljø. Artiklen behandler forfatternes erfaringer med at gennemføre et klyngeforløb samt de pædagogiske principper, der er lagt til grund for klyngeundervisningen.

  5. Gamle – og pasienter med demens – Omsorg ved livets slutt

    Directory of Open Access Journals (Sweden)

    Stein Husebø

    2012-11-01

    Full Text Available I livets siste leveår vil det store flertall gamle og pasienter med demens trenge kompetent omsorg, pleie, vurdering og behandling, med respekt for deres livsprosjekt og verdighet. Alle vil i de siste måneder, uker, dager og timer før de dør trenge kompetent omsorg ved livets slutt (palliative care, uavhengig av diagnose eller oppholdssted – til alle døgnets tider. Artikkelen drøfter utfordringer og muligheter, grunnlaget for nødvendig kompetanse: etikk, forberedende samtaler, organisering og samhandling.

  6. Acute alveolitis following infliximab therapy for psoriasis.

    Science.gov (United States)

    Bale, Jessica; Chee, Paul

    2013-02-01

    Infliximab is a high-affinity recombinant chimeric immunoglobulin-1 monoclonal antibody directed against tumour necrosis factor-alpha. It is used to treat a range of inflammatory disorders including psoriatic joint and skin changes. Acute interstitial lung disease is a rare but potentially fatal complication of therapy. We report the case of a 67-year-old man with severe psoriasis who presented with acute alveolitis shortly after his third infusion of infliximab. The infliximab was discontinued and investigations did not reveal an infective cause. His respiratory signs and symptoms improved quickly with corticosteroid therapy. Clinicians should be aware of this uncommon but potentially serious complication. © 2012 The Authors Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists.

  7. Is infliximab safe to use while breastfeeding?

    Institute of Scientific and Technical Information of China (English)

    Joel Z Stengel; Hays L Arnold

    2008-01-01

    Inflammatory bowel disease (IBD) often affects women around the age of conception and pregnancy. Most drugs used to treat IBD are safe in pregnancy, but physicians must consider the clinical implications of certain treatment regimens in young, fertile females. We report an informative case of a pregnant patient with IBD who underwent treatment with infliximab during her pregnancy and while nursing her infant. Serum and breast milk infliximab levels were monitored throughout this time period. This case report suggests that targeted monoclonal antibodies and other biologic agents can be used with caution in pregnant and breastfeeding patients.

  8. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab

    OpenAIRE

    Dario Sorrentino; Marco Marino; Themistocles Dassopoulos; Dimitra Zarifi; Tiziana Del Bianco

    2015-01-01

    Objective In patients with postoperative recurrence of Crohn’s disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies, and might loose response to therapy. To verify this hypothesis infliximab pharmacokinetics and clinical/endoscopic response were checked in a group of patients treated in the long term with low infl...

  9. Infliximab for the treatment of plaque psoriasis

    Directory of Open Access Journals (Sweden)

    Jennifer S Gall

    2008-03-01

    Full Text Available Jennifer S Gall, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Infliximab is a monoclonal antibody that targets tumor necrosis factor-α (TNFα. It is used in the treatment of a number of inflammatory disorders including severe plaque psoriasis. TNFα is thought to have a major role in psoriasis by promoting an inflammatory infiltrate into the skin and inducing keratinocyte proliferation and preventing keratinocyte apoptosis, which directly contributes to the characteristic plaque skin lesions. Based on four randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled trials of the use of infliximab in plaque psoriasis, it was found that infliximab is a highly efficacious, rapid, sustainable, and relatively safe therapy. Yet as with any biologic, caution is recommended in its use as infusion reactions, lupus-like syndromes, infections, malignancies including lymphomas, as well as other rare events have been reported.Keywords: infliximab, psoriasis, plaque

  10. Infliximab in the therapy of rheumatoid arthritis

    Directory of Open Access Journals (Sweden)

    G. V. Lukina

    2007-01-01

    Full Text Available Objective. To assess efficacy and tolerability of infliximab in pts with rheumatoid arthritis (RA in real clinical practice.Materials and methods. 75 RA pts with high disease activity according to DAS 28 in 80% who received previous antirheumatic drugs without proper effect were included in an open clinical trial. DAS 28 and ACR criteria were used as primary outcome measures.Results. Infliximab administration provided significant clinical improvement in most pts. Already in a week after the first infusion 20% ACR improvement was achieved in 74% of pts. Significant improvement of all the main treatment effect parameters was achieved after the second infusion. ESR and CRP mean values normalized after the third infusion. Rheumatoid factor decrease was noted after 6 weeks. Mean values of tender and swollen joint counts significantly decreased but arthritis signs remained in a part of pts. Clinical remission was achieved in 4 (19% from 21 pts completed a year’s course of treatment and in 4 pts the treatment was not effective. Serious adverse events requiring infliximab withdrawal (including infectious arthritis, hand phlegmon and bronchitis appeared in 7 ptsConclusion. These results show high efficacy of infliximab and prove advisability of its administration in RA

  11. A review of CT-P13: an infliximab biosimilar.

    Science.gov (United States)

    McKeage, Kate

    2014-06-01

    CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis. Infliximab is a chimeric human-murine monoclonal antibody against the proinflammatory cytokine tumour necrosis factor-α. The CT-P13 infliximab formulation is identical to that of reference infliximab and it has similar physiochemical characteristics. The approval of CT-P13 was based on the results of a rigorous, comparability exercise. This article reviews the results of that exercise, focusing on the clinical evaluation programme. In two well-designed clinical trials, CT-P13 was equivalent to reference infliximab in terms of pharmacokinetic properties in patients with ankylosing spondylitis and in terms of efficacy in patients with rheumatoid arthritis. In both studies, CT-P13 was generally well tolerated with a similar tolerability profile to that of reference infliximab. Immunogenicity evaluations demonstrated that the proportion of patients developing anti-drug antibodies was similar with each agent. Preliminary data from trial extensions demonstrated that in patients who switched from reference infliximab to CT-P13, efficacy was sustained and similar to those who were treated continuously with CT-P13. As with all biosimilar and generic agents, CT-P13 has the potential to reduce treatment costs compared with those of reference infliximab, and modelled analyses predict significant cost savings compared with reference infliximab. In conclusion, CT-P13 is an infliximab biosimilar that provides a useful alternative to reference infliximab in patients requiring infliximab therapy.

  12. Nationale domstoles behandling af internationale normkonflikter

    DEFF Research Database (Denmark)

    Kjeldgaard-Pedersen, Astrid

    2013-01-01

    Med sin dom af 12. september 2012 i sagen Nada v. Switzerland har Den Europæiske Menneskerettighedsdomstol (EMD) givet ny næring til debatten om, hvordan konflikter mellem staters forpligtelser ifølge Den Europæiske Menneskerettighedskonvention (EMRK) og deres forpligtelser efter bindende...

  13. Nationale domstoles behandling af internationale normkonflikter

    DEFF Research Database (Denmark)

    Kjeldgaard-Pedersen, Astrid

    2013-01-01

    Med sin dom af 12. september 2012 i sagen Nada v. Switzerland har Den Europæiske Menneskerettighedsdomstol (EMD) givet ny næring til debatten om, hvordan konflikter mellem staters forpligtelser ifølge Den Europæiske Menneskerettighedskonvention (EMRK) og deres forpligtelser efter bindende...

  14. Short-Term Response to Infliximab in Rheumatoid Pattern Polyarthropathy Complicating Ulcerative Colitis

    Directory of Open Access Journals (Sweden)

    ilke Coskun Benlidayi

    2015-12-01

    Full Text Available Ulcerative colitis (UC is a progressive inflammatory disease (IBD of the bowel which can be accompanied by extra-intestinal findings such as peripheral and axial arthropathies. Patients with UC sometimes display rheumatoid pattern polyarthropathy which is challenging to differ from rheumatoid arthritis. We describe a case with rheumatoid pattern polyarthropathy complicating UC and her favourable response to infliximab therapy. A 25-year-old female with a diagnosis of UC was admitted due to swelling and pain in multiple joints. Laboratory tests revealed elevated acute phase reactants. Since the patient was refractory to the combination therapy comprising methotrexate, sulphasalazine and steroid, she was started on an infliximab regimen. She experienced an improvement both in terms of pain scores and biochemical findings. The patient was asymptomatic with reduced acute phase reactants following a 6-month-course of anti-tumor necrosis factor (anti-TNF therapy. Infliximab serves as an effective treatment option for the management of rheumatoid pattern peripheral polyarthritis associated with UC. [Cukurova Med J 2015; 40(4.000: 818-821

  15. Behandling med dopaminagonister i den tidlige fase af Parkinsons sygdom: gennemgang af et Cochrane-review

    DEFF Research Database (Denmark)

    Bode, Matthias

    2009-01-01

    The Cochrane analysis confirms some well-known facts: initial therapy with dopamine agonists (DA) delays the incidence of motor complications, but is associated with inferior motor control and a higher frequency of non-motor adverse events (AE) compared with levodopa. Some serious AE are missing...

  16. Udredning og behandling af osteoporose hos patienter med prostatacancer uden knoglemetastaser

    DEFF Research Database (Denmark)

    Eiken, Pia Agnete; Langdahl, Bente Lomholt; Eiken, Frederik L;

    2011-01-01

    The prevention of cancer treatment-induced bone loss in patients with prostate cancer due to gonadotropin-releasing hormone (GnRH)-agonist, GnRH-antagonist and orchidectomi therapy has a high priority. We present an algorithm for the prevention and treatment of osteoporosis during treatment of non...

  17. Indikation for behandling med warfarin bør altid fremgå eksplicit ved sektorskifte

    DEFF Research Database (Denmark)

    Vestergaard, Thea; Hjort, Johanne; Madsen, Henrik Bjørnsgaard

    2014-01-01

    Warfarin has a narrow therapeutic window and side effects include bleeding causing e.g. hospital admission and death. Monitoring of treatment and review of indication are mandatory. We report a case of more than four years of warfarin treatment without indication. Treatment was not discontinued due...... to inadequate medical record keeping and communication among health-care providers. Medical-record keeping should follow guidelines from the National Board of Health. In addition, clearly stated treatment duration and indication may prevent unwarranted or premature termination of treatment....

  18. Udredning og behandling af osteoporose hos patienter med kronisk obstruktiv lungesygdom

    DEFF Research Database (Denmark)

    Eiken, Pia Agnete; Brask-Lindemann, Dorte; Vestbo, Jørgen;

    2012-01-01

    Patients with chronic obstructive pulmonary disease have a high risk of osteoporosis and fractures. We present an algorithm for the prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease.......Patients with chronic obstructive pulmonary disease have a high risk of osteoporosis and fractures. We present an algorithm for the prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease....

  19. Behandling og diagnostik af tuberkulose: fremad med små skridt

    DEFF Research Database (Denmark)

    Bengård Andersen, Åse; Lillebæk, Troels; Bang, Didi

    2011-01-01

    and oxazolidinones are also being assessed in human phase II and III trials. Efforts are made to develop easy-to-handle diagnostic tools that will allow early detection of potential MDR or XDR cases. The Xpert RIF/MTB is a prototype of such an invention. At long last the field is moving slowly forward....

  20. Segmentel vending af tyndtarmen til behandling af voksne patienter med korttarms syndrom

    DEFF Research Database (Denmark)

    Burgdorf, Stefan K; Qvist, Niels; Gögenur, Ismail

    2014-01-01

    Short bowel syndrome is the result of extensive surgical resection, inherited defects or loss of functional absorbing intestine. Parenteral nutrition is associated with high economical expenses, increased morbidity and decreased quality of life. Intestinal transplantation is associated with high...... morbidity and mortality rates. Segmental reversal of the small bowel can prolong the transit time in the small bowel and in many cases permanently end parenteral nutrition dependency. Segmental reversal of the small bowel should be integrated in the surgical treatment of adults with short bowel syndrome....

  1. Behandling og diagnostik af tuberkulose: fremad med små skridt

    DEFF Research Database (Denmark)

    Andersen, Ase Bengård; Lillebæk, Troels; Bang, Didi

    2011-01-01

    Development of new drugs for the treatment of drug sensitive and drug resistent tuberculosis is badly needed. Substantial progress has been made in the field and presently six new drug components are in clinical phase I and II trials. Drugs approved for other indications e.g. newer fluoroquinolones...

  2. Screening for tuberkuloseinfektion før behandling med biologiske lægemidler

    DEFF Research Database (Denmark)

    Ravn, Pernille

    2011-01-01

    Tumour necrosis factor antagonists (anti-TNFα) have become an invaluable treatment against chronic inflammatory diseases. Individuals treated with anti-TNFα have more than a fourfold increased risk of tuberculosis (TB) reactivation depending on the clinical setting and the TNF-antagonist used. All...... candidates for anti-TNFα treatment in Denmark should be evaluated for possible latent TB using history of exposure, chest X-ray and an interferon-γ release assay. Preventive chemotherapy is recommended for all individuals with latent TB infection before initiation of anti-TNFα as it is expected to reduce...

  3. Mulig forbedret behandling af kolorektal cancer med sentinel lymph node-diagnostik

    DEFF Research Database (Denmark)

    Burgdorf, Stefan K; Eriksen, Jens Ravn; Gögenür, Ismail

    2014-01-01

    Possibly improved treatment of colorectal cancer by sentinel lymph node mapping Prognosis for colorectal cancer is dependent on radical surgical intervention. Chemotherapy in patients with advanced disease has improved the survival. A considerable proportion of the patients going through radical...... surgery will subsequently relapse. Adjuvant chemotherapy is reserved for patients with lymph node metastases, why undetected malignant lymph nodes will result in understaging and exclusion from the possible benefit of adjuvant chemotherapy. With sentinel lymph node mapping it may be possible to detect...

  4. Effekt af trombolytisk behandling på udfaldet af tidlig arbejdstest hos patienter med akut myokardieinfarkt

    DEFF Research Database (Denmark)

    Svendsen, Jesper Hastrup; Madsen, J K; Saunamäki, K I;

    1994-01-01

    Exercise test variables, such as an impaired heart rate response, are known to be related to left ventricular function and patient prognosis following acute myocardial infarction. The present study was performed to compare exercise test variables in acute myocardial infarct patients following eit...

  5. Et Patientperspektivistisk Studie i Brug af Alternativ Behandling hos Danske Patienter med Diabetes

    DEFF Research Database (Denmark)

    Gerbild, Helle Nygaard

    2008-01-01

    clients, however, are positioned as user of both complementary and alternative medicine and conventional treatments, such as biological, homeopathic, and traditional Chinese medicine. The main factors that drive them to this are the aim, the hope, the belief, and knowledge how to cure diabetes. Conclusion......: The study shows that the decisive difference of how diabetics are positioned as to complementary and alternative self-care is the way in which they have the strength and hope, believe and knowledge of how to cure disease which by people in general is regarded as chronic.......Background and objectives: There have not earlier been studies focusing on experiences of Danish diabetic patients using Complementary and Alternative Medicine (CAM) – considered from the patients’ point of view. The existing studies mostly based on quantitative methods of patients with diabetes...

  6. Behandling af blødende øsofagusvaricer med selvekspanderende metalstenter

    DEFF Research Database (Denmark)

    Dahlerup, Jens F; Kruse, Aksel; Grønbaek, Henning;

    2007-01-01

    We report that haemostasis was obtained by the use of SEMS in two patients with bleeding oesophageal varices which failed conventional therapy (vasoactive drugs, antibiotics, endoscopy, and Sengstaken balloon tamponade). One patient subsequently died of sepsis; the other was treated with TIPS...

  7. Behandling af kardiogent shock med perkutan mekanisk cirkulationsstøtte

    DEFF Research Database (Denmark)

    Junker, Anders; Kaltoft, Anne; Hassager, Christian

    2013-01-01

    Despite rapid revascularisation with circulatory support using inotropes and intra-aortic balloon counterpulsation, the mortality of cardiogenic shock complicating acute myocardial infarction still exceeds 50%. An alternative treatment strategy is restoration of cardiac output by using a ventricu......Despite rapid revascularisation with circulatory support using inotropes and intra-aortic balloon counterpulsation, the mortality of cardiogenic shock complicating acute myocardial infarction still exceeds 50%. An alternative treatment strategy is restoration of cardiac output by using...... a ventricular assist device which can be inserted in the acute setting using the Impella device, a catheter-based flow pump. DanShock is a Danish multicentre study that will assess whether circulatory support using the Impella device will improve the outcome of cardiogenic shock compared to conventional...

  8. Organisation af behandling og opfølgning af patienter med type 2-diabetes

    DEFF Research Database (Denmark)

    Drivsholm, Thomas Bo; Snorgaard, Ole

    2012-01-01

    The organization of treatment and control of type 2 diabetic patients in Denmark has undergone a major development within the last decade. From being based on local hospital guidelines, treatment and control have moved towards a more organized collaboration between primary and secondary care based...

  9. Vellykket behandling af supraventrikulær takykardi med modificeret Valsalvas manøvre

    DEFF Research Database (Denmark)

    Wallentin, Johan; Sjøl, Anette

    2016-01-01

    Supraventricular tachycardia (SVT) is a frequent challenge in medical emergency units. Adenosine, the drug of choice, may cause severe discomfort. The Danish Society of Cardiology's National Treatment Guidelines for SVT recommend first aid treatment with ''vagus stimulation such as carotid massage...

  10. Diagnostik og behandling af kvinder med urin-inkontinens på danske gynaekologiske afdelinger

    DEFF Research Database (Denmark)

    Vejtorp, M; Fischer-Rasmussen, W; Blaabjerg, J

    1990-01-01

    The routine practice in the diagnosis and treatment of urinary incontinence was investigated by means of a questionnaire to which all 32 departments replied. Miction charts were employed routinely in 17 departments and for selected patients in eight departments. Weighing of diapers was employed...

  11. Sekundær prævention af apopleksi med effektiv antihypertensiv behandling

    DEFF Research Database (Denmark)

    Knudsen, Signe Boye; Strandgaard, Svend; Paulson, Olaf B.

    2013-01-01

    In this meta-analysis, four of five placebo-controlled studies showed that antihypertensive treatment prevented stroke recurrence, most markedly in a study with a combination of an angiotensin-converting enzyme inhibitor and a diuretic. Studies with beta-blockers were not included. Two head...

  12. Behandling af uraemisk osteodystrofi med laegemidler, som påvirker calcium-fosfor-omsaetningen

    DEFF Research Database (Denmark)

    Vestergaard, Peter; Eiken, Pia A

    2012-01-01

    This review discusses the mineral bone disorders in patients with chronic kidney disease. We focus on the management of these conditions by administration of calcium, vitamin D (ergocalciferol and cholecalciferol), vitamin D receptor activators (calcitriol, alphacalcidiol), phosphate binders...

  13. Akut iliofemoral venøs trombose bør behandles med kateterbaseret trombolyse

    DEFF Research Database (Denmark)

    Broholm, Rikke; Just, Sven; Jørgensen, Maja;

    2012-01-01

    Treatment of acute iliofemoral deep venous thrombosis (DVT) with catheter-directed thrombolysis (CDT) has been performed in Denmark since 1999. The purpose of CDT is to dissolve thrombus and to restore the venous lumen as fast as possible and thereby save venous valve function and prevent...... postthrombotic syndrome. Danish studies have shown that treatment of acute iliofemoral DVT using CDT results in good patency, preserves venous valve function, reduces the frequency of PTS, and is associated with a higher quality of life....

  14. Risiko for anastomoselækage ved postoperativ behandling med nonsteroide antiinflammatoriske stoffer

    DEFF Research Database (Denmark)

    Klein, M.; Gögenür, Ismayil; Rosenberg, J.

    2010-01-01

    strength and reduced deposition of hydroxyproline. Retrospective human studies have reported increased leakage rates after postoperative diclofenac and celecoxib treatment. We recommend that diclofenac and celecoxib be omitted from analgesic regimens after colorectal surgery involving an anastomosis...

  15. Kardiovaskulære risici ved behandling med nonsteroide antiinflammatoriske lægemidler

    DEFF Research Database (Denmark)

    Schmidt, Morten; Fosbøl, Emil Loldrup; Torp-Pedersen, Christian

    2016-01-01

    cyclooxygenase-2 inhibitors has been associated with a substantial vascular risk but increasing concern also relates to traditional NSAIDs, in particular diclofenac. This review summarizes the current evidence regarding the cardiovascular safety of NSAIDs and presents recommendations for their use....

  16. Manglende evidens for skadelig effekt på knogleheling ved behandling med NSAID

    DEFF Research Database (Denmark)

    Janum, Susanne; Kristensen, Billy Bjarne

    2012-01-01

    discard of NSAID for postoperative pain relief in uncomplicated cases. However, NSAID should be considered a potentiel risk factor of impaired bone healing and avoided in patients with a high risk of pseudoarthrosis. Recommended daily doses should be respected and duration of treatment should be limited....

  17. Svær laryngomalaci hos børn kan behandles med laserkirurgi

    DEFF Research Database (Denmark)

    Meyer, Lars Christian; Godballe, Christian

    2012-01-01

    Laryngomalacia is the most common cause for congenital stridor. The stridor is caused by collapse of supraglottic structures during inspiration. Two severe cases treated with laser-assisted supraglottoplasty are presented. Our cases as well as the literature describe good effect of the treatment...

  18. Behandling af højt blodtryk hos patienter med akut apopleksi

    DEFF Research Database (Denmark)

    Olsen, T S; Jørgensen, H S; Garde, E;

    1995-01-01

    The study was performed to investigate how often reduction of high blood pressure (> or = 220 mmHg systolic and or > or = 120 mmHg diastolic) was attempted in patients with acute stroke or transient ischemic attacks (TIA). Of 1351 consecutive patients with acute stroke or TIA 119 had high blood...

  19. Behandling med antidepressiva på geriatriske afdelinger. Forekomst og journalforing

    DEFF Research Database (Denmark)

    Rosholm, Jens-Ulrik; Mortensen, Hanne Hollaender; Svensson, Birthe Hjorth

    2003-01-01

    INTRODUCTION: The aim of the present study was to describe the occurrence of antidepressant treatment in geriatric departments in Denmark and assess the notes of the patient records in connection with prescription. MATERIAL AND METHODS: Patient records for consecutively referred patients in seven...... geriatric departments were examined and basic information was noted. For users of antidepressants further information about the treatment was noted. RESULTS: A total of 1211 patients records were examined and out of these 338 patients were in treatment with antidepressants (29.7%). The users...... during the admission. Depression was stated as being the main reason in 54% of those who continued an ongoing treatment, and in 78% of those who started their treatment during admission. In 98.4%, the beginning of treatment with antidepressants was based upon the file notes. In 34.8% of the records...

  20. Behandling af blødende øsofagusvaricer med selvekspanderende metalstenter

    DEFF Research Database (Denmark)

    Dahlerup, Jens F; Kruse, Aksel; Grønbaek, Henning

    2007-01-01

    We report that haemostasis was obtained by the use of SEMS in two patients with bleeding oesophageal varices which failed conventional therapy (vasoactive drugs, antibiotics, endoscopy, and Sengstaken balloon tamponade). One patient subsequently died of sepsis; the other was treated with TIPS...

  1. Blødningskomplikationer ved behandling med clopidogrel og acetylsalicylsyre efter akut koronart syndrom

    DEFF Research Database (Denmark)

    Kjær, Janus; Larsen, Christian Hastrup; Poulsen, Tina Svenstrup

    2006-01-01

    INTRODUCTION: The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that patients with unstable angina pectoris (UAP) and non-ST-elevation myocardial infarction (NSTEMI) benefit from combined therapy with acetylsalicylic acid (ASA) and clopidogrel. However, only patie...

  2. Alternativ behandling og kræft

    DEFF Research Database (Denmark)

    Lunde, Anita; Johannessen, Helle

    2010-01-01

    Guidelines Network, SIGN, er de inkluderede reviews kvalitetsvurderet og de fundne effekter bedømt efter 4 evidensniveauer.  Resultater: Ti reviews omhandler manipulativ og kropsbaseret praksis, og heraf er fem med høj kvalitet. Det mest konsistente resultat er, at massage signifikant reducerer angst hos...... kræftpatienter (evidens A). Ydermere findes effekt af massage mod depression, smerter og kvalme. Ingen reviews finder skadelige virkninger af massage, og forestillingen om, at massage kan sprede kræft, afkræftes af nyere forskning. Konklusion: Massage er en sikker terapi at kombinere med konventionel...... at differentiere effekten i forhold til typen af massage, kræftformen eller sygdomsstadie. Udgivelsesdato: 29 jan 2010...

  3. Effectiveness of infliximab after adalimumab failure in Crohn's disease

    Institute of Scientific and Technical Information of China (English)

    María Chaparro; Mireia Pe(n)alva; Javier P Gisbert; Montserrat Andreu; Manuel Barreiro-de Acosta; Esther García-Planella; Elena Ricart; Eugeni Domènech; María Esteve; Olga Merino; Pilar Nos

    2012-01-01

    AIM:To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure.METHODS:A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure.Patients were identified using a large Spanish database (ENEIDA).RESULTS:We included 15 Crohn's disease patients who received infliximab after adalimumab failure.Five patients discontinued adalimumab due to loss of response,3 due to adverse events and 7 due to partial response.After infliximab therapy was started,all patients who had interrupted adalimumab due to loss of efficacy regained response.All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab,but 2 developed adverse events.None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab.CONCLUSION:Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response,however,the benefit of infliximab in primary nonresponders was not established.

  4. Infliximab to treat severe ulcerative colitis

    Institute of Scientific and Technical Information of China (English)

    Dídia Bisamra Cury; Marcelo de Souza Cury; Geraldo Vinicius Hemerly Elias; Sender Jankiel Mizsputen

    2009-01-01

    A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. The patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. The disease remained active despite treatment with steroids and cyclosporine. The clinical and endoscopic parameters were consistent with severe disease. Infectious precipitants were ruled out. Given the severity of the disease and in order to avoid a colectomy, we started the patient on infliximab therapy. A dramatic clinical and endoscopic response was observed and she remained in remission at the end of a 1-year follow-up period. We discuss findings in the literature regarding the use of infliximab therapy in patients with ulcerative colitis who have failed steroids and cyclosporine.

  5. Erythema Multiforme Major Following Treatment with Infliximab

    Science.gov (United States)

    Edwards, Dean; Boritz, Eli; Cowen, Edward W.; Brown, Ronald S.

    2012-01-01

    Background The growth in the use of anti-TNF-α agents for treatment of inflammatory conditions has led to increased recognition of the side effects associated with this class of drugs. Case Description We report a case of a patient who developed erythema multiforme (EM) major with characteristic oral and cutaneous lesions following treatment with the anti-TNF-α medication infliximab therapy for Crohn’s Disease (CD). Clinical Implications To our knowledge, this is the first reported case of infliximab-induced EM secondary to the treatment of CD. It is important for dental clinicians evaluating patients using anti-TNF-α agents to be aware of this possible complication. PMID:23036796

  6. Dramatic Response of Nail Psoriasis to Infliximab

    Directory of Open Access Journals (Sweden)

    Gilles Safa

    2011-01-01

    Full Text Available Nail psoriasis, affecting up to 50% of psoriatic patients, is an important cause of serious psychological and physical distress. Traditional treatments for nail psoriasis, which include topical or intralesional corticosteroids, topical vitamin D analogues, photochemotherapy, oral retinoids, methotrexate, and cyclosporin, can be time-consuming, painful, or limited by significant toxicities. Biological agents may have the potential to revolutionize the management of patients with disabling nail psoriasis. We present another case of disabling nail psoriasis that responded dramatically to infliximab.

  7. Pediatric gastrointestinal sarcoidosis: Successful treatment with infliximab

    Directory of Open Access Journals (Sweden)

    Laila Alawdah

    2016-01-01

    Full Text Available Gastrointestinal sarcoidosis is a rare disease with very limited data in children. Here we report the first pediatric case of successful treatment with infliximab. The first case was an 8-year-old Saudi girl who presented with fever, weight loss, and abdominal pain that was followed in a few months with hematemesis and development of hepatosplenomegaly. The second case was a 9-year-old Sudanese boy who manifested with vomiting, epigastric pain, and weight loss. On upper endoscopy, both cases demonstrated severe erosive nodular gastric mucosa. Gastric and esophageal biopsies had shown noncaseating granulomatous inflammation. The first case had histopathological evidence of granulomatous hepatitis, and both cases demonstrated lung nodularity on computed tomography chest. The boy had elevated angiotensin-converting enzyme level. Given the multisystem involvement with significant chest findings, tissue findings of granulomatous disease, and negative workup for other causes of granulomatous inflammation, both cases were diagnosed with active disseminated sarcoidosis, and treated with corticosteroids. The girl continued to be symptom-free for 4 years after tapering steroid therapy. The boy had relapses off steroids and the disease was brought into remission for 5 years off steroid therapy by infliximab. Pediatric GI sarcoidosis is a rare disease that exhibits heterogeneity in natural course. The chronic relapsing progressive form of the disease might benefit from infliximab therapy.

  8. Evaluering af ordning med psykologbehandling af personer med let til moderat depression

    DEFF Research Database (Denmark)

    Fjeldsted, Rita; Christensen, Kaj Sparle

    tidligere evaluering af forsøgsordning af psykologbehandling af depression i perioden 2005-06. 18.419 personer i alderen 18-37 år blev henvist til psykolog i den undersøgte ordning i perioden 1.2.2009 – 31.1.2010, svarende til en henvisningshyppighed på 1,6 % af baggrundsbefolkningen i samme aldersgruppe...... samme niveau som fandtes i evalueringen fra 2007. Remissionsraten for personer med depression ved behandlingsstart er 87 % målt med MDI. Patienters selvrapporterede effekt er 95 %. I opfølgningsgruppen har 89 % ingen depression 3 år efter afsluttet behandling, 56 % har oplevet mindst én ny...... for begge køn, og der ses et fald på 40 % for kvinder og 70 % for mænd over de givne 3 år. Tidsperspektivet er for denne gruppe mere relevant for overordnet vurdering, men der savnes en sammenligningsgruppe. Ifølge spørgeskemadata øges andelen af personer, der er i arbejde, selvforsørgelse eller på SU fra...

  9. Infliximab-induced autoantibodies: a multicenter study.

    Science.gov (United States)

    Vaz, João Luiz Pereira; Fernandes, Vander; Nogueira, Felipe; Arnóbio, Adriano; Levy, Roger A

    2016-02-01

    The purpose of this study was to assess autoantibody incidence in patients treated with infliximab for various diseases, and the development of autoimmune diseases using a multicenter, longitudinal, open-label, phase IV observational study. All patients received anti-tumor necrosis factor (anti-TNF) according to local treatment guidelines. The autoantibodies assessed before and after infliximab treatment were ANA, anti-Sm, anti-dsDNA, anticardiolipin IgM/IgG, anti-Scl70, anti-centromere B, anti-chromatin, anti-ribosomal P, anti-Sm-RNP, anti-RNP A, anti-RNP 68 kD, anti-La/SSB, anti-Ro/SSA 52 kD and 60 kD, and anti-Jo1. ANA was determined by indirect immunofluorescence on HEp-2 cells (INOVA); the remaining was assessed using BioPlexTM 2200. The Fisher exact test, Wilcoxon test, and the McNemar were used when appropriate.Two hundred eighty-six patients were included (139 with rheumatoid arthritis, 77 with ankylosing spondylitis, 29 with inflammatory bowel disease, 27 with psoriatic arthritis, and 14 with psoriasis), 167 females and 119 males, with mean age of 46.3 years. Subjects received at least five infusions of infliximab (6-month treatment). A significant difference was observed in antinuclear antibody (ANA) detection between samplings (p = 0.001). Among patients that had ANA before treatment (n = 92), six became ANA-negative, 48 had increased titers, 29 maintained, and nine decreased titers after treatment; a total of 186 patients had a positive ANA after treatment. Fine speckled nuclear pattern was most commonly observed (both before and after infliximab treatment). The number of patients with anti-dsDNA had a statistically significant increase (p = 0.003). No significant differences were noted for anticardiolipin and the remaining autoantibodies tested. Among the 286 patients included in the study, only one (0.35 %) showed clinical signs of drug-induced lupus, presenting elevated ANA and anti-dsDNA titers that normalized once treatment was

  10. Infliximab stability after reconstitution, dilution, and storage under refrigeration.

    Science.gov (United States)

    Beer, Paul M; Wong, Susan J; Schartman, Jerome P; Kulas, Karen E; Hartman, Coby L; Giganti, Monica; Falk, Naomi S

    2010-01-01

    The purpose of this study was to investigate the stability of reconstituted infliximab solutions and determine whether infliximab is suitable for compounding for potential intravitreal use. Infliximab was reconstituted, and the solution was aliquoted and stored refrigerated. On each day of testing, an aliquot was serially diluted to concentrations ranging from 50,000 pg/mL to 69 pg/mL. Each dilution was assayed by microsphere immunoassay daily for 5 days and weekly for a total of 6 weeks. The outcome measure was median fluorescence intensity measured by dual laser flow analysis of fluorochrome-labeled secondary antibodies to infliximab bound to tumor necrosis factor-alpha-coated microspheres. There was an increasing median fluorescence intensity for increasing infliximab concentration in a sigmoidal dose-response curve with a variable slope that was equivalent for each time point. Each respective concentration of infliximab showed nearly equivalent median fluorescence intensity for every time point over the 6-week period. The authors found that the immunoreactivity of 2 different concentrations of infliximab stored at 4 degrees C over a 6-week period remained stable. Infliximab is suitable for compounding and could be a cost-effective intravitreal medication for use in clinical practice if further study supports its safety and efficacy.

  11. Detection of infliximab levels and anti-infliximab antibodies : a comparison of three different assays

    NARCIS (Netherlands)

    Casteele, N. Vande; Buurman, D. J.; Sturkenboom, M. G. G.; Kleibeuker, J. H.; Vermeire, S.; Rispens, T.; van der Kleij, D.; Gils, A.; Dijkstra, G.

    2012-01-01

    Background Formation of antibodies to infliximab (ATI) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti-drug antibody monitoring is hampered by lack of standardisation. Aim To determine the correlation between three different assays for measur

  12. Listeria Meningitis Complicating Infliximab Treatment for Crohn’s Disease

    Directory of Open Access Journals (Sweden)

    Geoffrey Williams

    2005-01-01

    Full Text Available Infliximab, a monoclonal antibody directed against tumour necrosis factor-alpha, is an effective therapy for Crohn's disease. Though uncommon, serious opportunistic infections, including reactivation of tuberculosis, have occurred in patients after infliximab administration. Meningitis caused by Listeria monocytogenes developed in a 37-year-old man six days after the second infusion of infliximab. The patient, who also was treated with azathioprine and corticosteroids, had an uneventful recovery after a course of antibiotics. Several other recent reports have implicated infliximab therapy in the development of severe Listeria infections, particularly meningitis and sepsis. With the increasing use of tumour necrosis factor-alpha-neutralizing agents, clinicians should be aware of the risk of opportunistic infections caused by L monocytogenes in patients with Crohn's disease following infliximab treatment.

  13. Musik og billeddannelse (GIM med PTSD-ramte flygtninge: Introduktion til tre single case-studier

    Directory of Open Access Journals (Sweden)

    Bolette Daniels Beck

    2016-12-01

    Full Text Available Mange flygtninge kommer fra kulturer med helt andre forestillinger og begreber om årsager til og forventninger om behandling af psykisk lidelse end man almindeligvis anvender i psykiatrien. F.eks. er psykisk lidelse i mange mellemøstlige kulturer forbundet med skam, og udtrykkes måske derfor snarere i form af fysisk smerte. For at et behandlingsforløb skal lykkes, er der behov for kulturel sensitivitet hos behandleren, når der skal samarbejdes med tolken, skabes et møde på tværs af kulturer samt etableres en fælles forståelse af behandlingens formål og proces.

  14. Gensyn med Firenze- og med store kunstnere

    DEFF Research Database (Denmark)

    Davidsen-Nielsen, Niels

    2015-01-01

    Eftertanken. Med Michelangelo og E. M. Forster som rejseførere kan et besøg i den italienske renæssanceby Firenze blive livsforandrende.......Eftertanken. Med Michelangelo og E. M. Forster som rejseførere kan et besøg i den italienske renæssanceby Firenze blive livsforandrende....

  15. GOUT – induced by Infliximab?- case report

    Directory of Open Access Journals (Sweden)

    Anca Chiriac

    2012-10-01

    Full Text Available Gout is a metabolic disease caused by a disturbance in purine metabolism; crystals of monosodium urate are deposited in tissues, such as joints, kidneys, and soft tissues, producing an inflammatory response. A 52-year-old woman presented in our department with 1 month history of firm, white papules, nodules and plaques over digits. She has been suffered from Rheumatoid Arthritis for many years, she has been under Infliximab therapy for more than 2 years, with good evolution of the disease. She had marked joint deformities of the proximal interphalangeal joints and slight ulnar deviation at the metacarpophalangeal joints bilaterally.

  16. Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort

    OpenAIRE

    De Ridder, Lissy; Rings, Edmond; Damen, Gerard; Kneepkens, Frank; Schweizer, J; Kokke, Freddy; Benninga, Marc; Norbruis, Obbe; Hoekstra, Hans; Gijsbers, Carolien; Escher, Johanna

    2008-01-01

    textabstractBackground: Infliximab is effective for induction and maintenance of remission in Crohn's disease. It is unknown how long patients should be kept on infliximab therapy. The primary aim of this study was to assess duration of effective maintenance therapy and infliximab dependency in pediatric CD patients initially responding to infliximab therapy. Methods: All pediatric patients treated with infliximab by pediatric gastroenterologists in the Netherlands because of severe luminal o...

  17. Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

    OpenAIRE

    George Alex; Di Simpson; Catto-Smith, Anthony G.; Oliver Gouldthorpe

    2013-01-01

    Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn’s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth. We retrospectively audited patients on maintenance infliximab at a single centre. Data included...

  18. Inflammatory bowel disease of the lung: The role of infliximab?

    Directory of Open Access Journals (Sweden)

    Adam J. Hayek

    2015-01-01

    Full Text Available Pulmonary extra-intestinal manifestations (EIM of inflammatory bowel disease are well described with a variable incidence. We present a case of Crohn's disease with pulmonary EIM including chronic bronchitis with non-resolving bilateral cavitary pulmonary nodules and mediastinal lymphadenopathy successfully treated with infliximab. Additionally, we present a case summary from a literature review on pulmonary EIM successfully treated with infliximab. Current treatment recommendations include an inhaled and/or systemic corticosteroid regimen which is largely based on case reports and expert opinion. We offer infliximab as an adjunctive therapy or alternative to corticosteroids for treatment of inflammatory bowel disease related pulmonary EIM.

  19. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

    Science.gov (United States)

    Lyseng-Williamson, Katherine A; Foster, Rachel H

    2004-01-01

    Infliximab (Remicade), a biological disease-modifying antirheumatic drug (DMARD), binds to and inhibits the activity of tumour necrosis factor-alpha, which is thought to play an important role in the pathophysiology of rheumatoid arthritis. Intravenous infliximab plus methotrexate is recommended in patients with rheumatoid arthritis who have not achieved satisfactory disease control with adequate courses of other DMARDs. Pharmacoeconomic analyses have been based on efficacy data from the pivotal placebo-controlled Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) trial in patients with active, refractory rheumatoid arthritis. Infliximab every 8 weeks plus methotrexate demonstrated rapid and sustainable improvements in clinical response, delayed radiographic progression, and/or improved functional status and health-related QOL compared with placebo plus methotrexate at weeks 30, 54 and 102. In cost-utility analyses of infliximab plus methotrexate conducted from a healthcare payer and/or societal perspective in the US, Europe, Portugal, Sweden and the UK, infliximab 3 mg/kg every 8 weeks plus methotrexate was associated with acceptable (cost-utility ratios relative to methotrexate alone in patients with active, refractory rheumatoid arthritis. When only direct costs were considered, the lifetime incremental cost per discounted QALY gained with infliximab plus methotrexate relative to methotrexate alone was $US30,500-38,700 (year of costing 1998 or not reported; treatment duration 54 or 102 weeks or lifelong) in the US and Europe analyses, and euro39 500 (year of costing not reported; lifelong treatment) in the Portuguese analysis. The cost-utility ratios were more favourable when lost productivity costs or the additional benefit of infliximab on radiographic stabilisation were considered. In the Swedish and UK analyses with a 10-year time horizon, infliximab plus methotrexate for 1 or 2 years was associated with cost

  20. MedSun Reports

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Medical Product Safety Network (MedSun) is an adverse event reporting program launched in 2002. The primary goal for MedSun is to work collaboratively with the...

  1. MedSun Reports

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Medical Product Safety Network (MedSun) is an adverse event reporting program launched in 2002. The primary goal for MedSun is to work collaboratively with the...

  2. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

    DEFF Research Database (Denmark)

    Ainsworth, Mark A; Bendtzen, Klaus; Brynskov, Jørn

    2007-01-01

    To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD)....

  3. Advancing PubMed?

    DEFF Research Database (Denmark)

    Wildgaard, Lorna Elizabeth; Lund, Haakon

    2016-01-01

    the efficiency of biomedical literature searches. PubMed remains the primary resource for biomedical literature, and as PubMed makes the Medline data and Entrez PubMed Programming utilities freely available, any developer can produce alternative tools to search the database. The authors question if PubMed still...... provides the superior search interface for systematic searches or if the innovativeness of third-party tools provide alternatives worth considering. The paper aims to discuss these issues. Design/methodology/approach In all, 76 third-party tools that build on PubMed content were identified in a Pub...

  4. Respiratory failure due to infliximab induced interstitial lung disease.

    Science.gov (United States)

    Kakavas, Sotiris; Balis, Evangelos; Lazarou, Vasiliki; Kouvela, Marousa; Tatsis, Georgios

    2013-01-01

    Although poorly understood, interstitial lung disease has been reported as a possible complication of tumor necrosis factor alpha inhibitors. We report a case of interstitial lung disease in a 64-year-old man with psoriasis 3 weeks after the initiation of infliximab treatment. The patient had received two fortnightly infusions of infliximab following a short course of methotrexate. Thoracic computed tomography showed bilateral ground glass and interstitial infiltrates, while the results of microbiology and immunologic workup were negative. Likewise, bronchoalveolar lavage detected neither typical nor atypical pathogens. Infliximab-induced interstitial lung injury was suspected and corticosteroid therapy was administered which resulted in rapid clinical and radiological improvement. This is one of the few reported cases of interstitial lung disease due to infliximab in the psoriasis population. The patient had no pre-existing lung pathology, while his previous exposure to methotrexate was minimal and was not temporally associated with the induction of interstitial lung disease.

  5. Infliximab and complications after colectomy in patients with ulcerative colitis

    DEFF Research Database (Denmark)

    Bregnbak, David; Mortensen, Christian; Bendtsen, Flemming

    2012-01-01

    Infliximab treatment may increase the risk of subsequent postoperative complications in patients with ulcerative colitis. The main purpose of the present study therefore was to assess postoperative complications in patients who have undergone colectomy for ulcerative colitis with and without...

  6. Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis.

    Science.gov (United States)

    Krishnan, V S Gokul; Madhyastha, Sharath; Ramamoorthi, Kusugodlu; Acharya, Raviraj V; Gopalaswamy, Vinaya

    2017-01-01

    We present a case of pleural tuberculosis (TB) in a patient on infliximab for ankylosing spondylitis. A 36-year-old male presented to our hospital with low back ache of inflammatory type along with multiple symmetric inflammatory type of joint pain. Further clinical examination, laboratory and radiological investigations were suggestive of ankylosing spondylitis. He was initially treated with nonsteroidal anti-inflammatory drugs but citing poor response it was decided to initiate biologic therapy using infliximab (antitumor necrosis factor-alpha). Mantoux test and chest radiograph were done before the therapy to rule out TB. Following three doses of infliximab, patient came with complaints of fever and cough for 1 week. On investigation, it was found to be a case of pulmonary TB. This shows the importance of close monitoring of patient for TB among patients on infliximab even though the screening test has come out to be negative.

  7. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.

    Science.gov (United States)

    Vaz, João Luiz Pereira; Andrade, Carlos Augusto Ferreira; Pereira, Alessandra Cardoso; Martins, Maria de Fátima M; Levy, Roger Abramino

    2013-08-01

    The present systematic review aims to discuss infliximab-induced autoantibodies and subsequent onset of systemic lupus erythematosus (SLE) through the analyses of primary reports measuring autoantibodies both before and after the administration of infliximab for the treatment of several diseases - e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease. Our literature search was performed in nine databases - PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, EMBASE, Scielo and LILACS, and the search query retrieved 998 primary reports, from which 24 articles were selected and further narrowed down to 14, based on our inclusion criteria. Two independent reviewers performed the article selection and a third reviewer solved discrepancies. Our inclusion criteria comprised primary reports of phase IV clinical trials with duration of at least three months. In total, 760 patients were evaluated and the most prevalent assays performed in the studies were anti-nuclear antibodies (ANA), anti-double stranded DNA antibodies (anti-dsDNA), and antibodies to saline-extracted antigens (ENA panel). Of all patients evaluated, 10 (1.3%) showed clinical signs and laboratorial evidence of infliximabinduced SLE.

  8. Diffused suberitrodermic psoriasis induced by infliximab

    Directory of Open Access Journals (Sweden)

    V. Bruzzese

    2011-09-01

    Full Text Available The case of a young male is described, affected by Crohn disease with reactive Spondoloarthritis essay with Infliximab to the dose of 3 mg/kgs. After 15 days from the 3° infusion, the patient developed a first psoriasic eruption to the palm of the hands and the plant of the feet, for which was begun topical therapy with cortisone. After an initial improvement, the patient introduced a diffusion of the psoriasic eruption to the whole trunk and the limbs with a suberitrodermic aspect. The possible pathogenesis of this paradoxical effect of the anti-TNF is considered. Also being still partly the causes, is important the inhibition of the TNF-alpha with consequent expansion of the INF-alpha, in tum potential inductor of psoriasis.

  9. Dramatic response to infliximab in refractory neurosarcoidosis

    Directory of Open Access Journals (Sweden)

    Chintamaneni Sreekanth

    2010-01-01

    Full Text Available Sarcoidosis is a systemic disease characterized by noncaseating granulomas in the involved organs. Neurologic manifestations involving the central and/or peripheral nervous system occur in about 5% of patients. Neurosarcoidosis is often refractory to conventional treatment and therefore more effective treatment options are needed. While the etiology of the disease is still unknown, there is now a better understanding of its pathogenesis on a molecular level. It is clear that tumor necrosis factor-α (TNFα plays a pivotal role in the development of the granulomas and it is believed to be a key cytokine involved in the pathogenesis of the disease. Taking advantage of this better understanding of disease pathogenesis, anti-TNFα agents are being increasingly used to treat refractory sarcoidosis. We report a patient with refractory neurosarcoidosis who showed dramatic improvement in the clinical and radiological manifestations following treatment with infliximab; he suffered a relapse upon discontinuation of the medication.

  10. Infliximab for peripheral ulcerative keratitis treatment.

    Science.gov (United States)

    Huerva, Valentín; Ascaso, Francisco J; Grzybowski, Andrzej

    2014-11-01

    Biologic agents such as anti-TNFα have been employed in treatment paradigms for ocular inflammation. Peripheral corneal ulceration (PUK) is a devastating disorder consisting of a crescent-shaped area of destructive inflammation at the margin of the corneal stroma. It is associated with an epithelial defect, the presence of stromal inflammatory cells, and progressive stromal degradation and thinning, leading to ocular perforation and devastating visual loss. Macroulcerative PUK is usually a local manifestation of a systemic vasculitis. In many cases, the disease may be resistant to high doses of systemic corticosteroids and immunosuppressants. Chimeric anti-TNFα has been employed when all other treatments have failed. Isolated cases and short series of cases have been reported. This paper summarizes the available reports on the use, efficacy, and safety of infliximab in the treatment of PUK.

  11. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.

    Science.gov (United States)

    Vorselaars, Adriane D M; Crommelin, Heleen A; Deneer, Vera H M; Meek, Bob; Claessen, Anke M E; Keijsers, Ruth G M; van Moorsel, Coline H M; Grutters, Jan C

    2015-07-01

    Inconclusive evidence for the efficacy of infliximab in sarcoidosis hinders the global use of this potentially beneficial drug. To study infliximab efficacy in a clinical setting, we performed a prospective open-label trial in patients refractory to conventional treatment. Patients (n=56) received eight infusions of 5 mg·kg(-1) infliximab. Pulmonary function, disease activity measured by (18)F-fluorodeoxyglucose (FDG) by positron emission tomography (PET) and quality of life were part of the clinical work-up. Infliximab levels were measured before every infusion. After 26 weeks of infliximab treatment, mean improvement in forced vital capacity (FVC) was 6.6% predicted (p=0.0007), whereas in the 6 months before start of treatment, lung function decreased. Maximum standardised uptake value (SUVmax) of pulmonary parenchyma on (18)F-FDG PET decreased by 3.93 (pinfliximab trough level (mean 18.0 µg·mL(-1)) and initial response was found. In conclusion, infliximab causes significant improvement in FVC in refractory (18)F-FDG PET positive sarcoidosis. Especially in pulmonary disease, high (18)F-FDG PET SUVmax values at treatment initiation predict clinically relevant lung function improvement. These results suggest that inclusion of (18)F-FDG PET is useful in therapeutic decision-making in complex sarcoidosis.

  12. EFFECTIVENESS OF INFLIXIMAB IN PATIENTS WITH JUVENILE ANKYLOSING SPONDYLARTHRITIS

    Directory of Open Access Journals (Sweden)

    A.L. Kozlova

    2009-01-01

    Full Text Available The objective of open-labeled study was estimation of effectiveness and safety of infliximab — monoclonal antibodies to tumor necrosis factor (TNF - in treatment of 48 patients with juvenile ankylosing spondylarthritis. Duration of observation was 6 weeks — 1,5 years. Anticytokine treatment was administrated on the ground of therapy with immunosuppressive agents in 96% of patients. Infliximab was administrated in median dose 7,4 ± 3,7 mg/kg of body weight by standard scheme (0–2–6 — week and further every 8 weeks intravenously. Results of a trial showed that infliximab has evident anti-inflammatory effect. Treatment with infliximab provided development of remission of articular syndrome, decreasing and normalization of laboratory indices of activity of disease, the rate of disability, and increasing of quality of life in 84% of patients. Effect of this medication was registered after first infusion and continued during all period of follow up. Adverse effects included transfusion reactions: fever, head ache, nausea/vomiting in 10% of patients, allergic arthritis — in 2% of patients. Thus, treatment of infliximab is pathogenetically grounded, effective and safe in patients with juvenile ankylosing spondylarthritis.Key words: children, juvenile ankylosing spondylarthritis, infliximab, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2:20-26

  13. Nostalgitrip med Pikachu

    DEFF Research Database (Denmark)

    Konzack, Lars

    2016-01-01

    Sommeren 2016 vil blive husket for den omsiggribende dille, Pokémon Go, med over 100 millioner downloads. Tusindvis af især børn og unge, men også forældre med barnevogne og hele familier, kunne pludselig ses på gader og stræder, i parker og grønne områder med en smartphone i hånden på jagt efter...

  14. Processeringsoptimering med Canons software

    DEFF Research Database (Denmark)

    Precht, Helle

    2009-01-01

    . Muligheder i software optimering blev studeret i relation til optimal billedkvalitet og kontrol optagelser, for at undersøge om det var muligt at acceptere diagnostisk billedkvalitet og derved tage afsæt i ALARA. Metode og materialer Et kvantitativt eksperimentelt studie baseret på forsøg med teknisk og...... humant fantom. CD Rad fantom anvendes som teknisk fantom, hvor billederne blev analyseret med CD Rad software, og resultatet var en objektiv IQF værdi. Det humane fantom var et lamme pelvis med femur, der via NRPB’ er sammenlignelig med absorptionen ved et femårigt barn. De humane forsøgsbilleder blev...

  15. Skoleudvikling med it

    DEFF Research Database (Denmark)

    Gylling, Martin; Christiansen, René Boyer; Ryberg, Birgit

    En af ambitionerne med demonstrationsskoleprojektet har været at skabe skoler i fortsat udvikling med it. I slutningen af projektet møder vi dog fortsat lærere og skoleledere, der betragter det som udfordrende at arbejde processuelt med ledelse i skoleudvikling for at fremme innovativ undervisning...... med integration af it. Det er en grundlæggende problemstilling i skolehverdagen, at der eksisterer relativt lidt viden om, hvilke ledelsespraksisser der faciliterer at lærere og ledere arbejder processuelt og gør skoleudvikling i et hverdagsperspektiv. I vores artikel vil vi derfor sætte situationer...

  16. Virtuelt skrivebord med open office

    DEFF Research Database (Denmark)

    Nielsen, Kurt Gammelgaard

    2009-01-01

    SDUs erfaringer med projektet Port 22: en virtuel platform med Open Office som kontorpakke til studerende.......SDUs erfaringer med projektet Port 22: en virtuel platform med Open Office som kontorpakke til studerende....

  17. Virtuelt skrivebord med open office

    DEFF Research Database (Denmark)

    Nielsen, Kurt Gammelgaard

    2009-01-01

    SDUs erfaringer med projektet Port 22: en virtuel platform med Open Office som kontorpakke til studerende.......SDUs erfaringer med projektet Port 22: en virtuel platform med Open Office som kontorpakke til studerende....

  18. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis.

    LENUS (Irish Health Repository)

    Veerappan, Sundaram G

    2012-02-01

    Here we describe a patient with ulcerative colitis who developed alveolitis after infliximab therapy. With earlier case reports of development of alveolitis in rheumatoid arthritis patients after infliximab infusion, the temporal relationship between the infliximab therapy and the development of alveolitis in this case, raises the possibility that the two might be causally related. With an increasing trend towards treating moderate to severely active ulcerative colitis patients with infliximab as a rescue therapy, clinicians should be aware of this potentially serious complication.

  19. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis.

    Science.gov (United States)

    Veerappan, Sundaram G; O'Morain, Colm A

    2009-07-01

    Here we describe a patient with ulcerative colitis who developed alveolitis after infliximab therapy. With earlier case reports of development of alveolitis in rheumatoid arthritis patients after infliximab infusion, the temporal relationship between the infliximab therapy and the development of alveolitis in this case, raises the possibility that the two might be causally related. With an increasing trend towards treating moderate to severely active ulcerative colitis patients with infliximab as a rescue therapy, clinicians should be aware of this potentially serious complication.

  20. B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera

    OpenAIRE

    Homann, Arne; Röckendorf, Niels; Kromminga, Arno; Frey, Andreas; Jappe, Uta

    2015-01-01

    Background Autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease are treated with TNF-alpha-blocking antibodies such as infliximab and adalimumab. A common side effect of therapeutic antibodies is the induction of anti-drug antibodies, which may reduce therapeutic efficacy. Methods In order to reveal immunogenic epitopes on infliximab which are responsible for the adverse effects, sera from patients treated with infliximab were screened by ELISA for anti-infliximab anti...

  1. En mening med galskaben

    DEFF Research Database (Denmark)

    Toft-Nielsen, Claus

    2003-01-01

    Hvorfor kan en så feteret og professionel skuespiller som Jack Nicholson overhovedet slippe af sted med at levere en så overspillet og forceret præstation, som den han kommer med i Stanley Kubricks The Shining? Og hvorfor har den til fingerspidserne perfektionistiske Kubrick ikke stoppet Nicholson...

  2. Meningspause med forstyrrelser

    DEFF Research Database (Denmark)

    Dehs, Jørgen

    1986-01-01

    Jürgen Habermas: "Der philosophische Diskurs der Moderne" - Æstetikken som krisesymptom, opgør med den fornuftskritiske tradition.......Jürgen Habermas: "Der philosophische Diskurs der Moderne" - Æstetikken som krisesymptom, opgør med den fornuftskritiske tradition....

  3. Erfaringer med fotografi

    DEFF Research Database (Denmark)

    Rasmussen, Kim

    2013-01-01

    Kapitlet fortæller og reflekterer over metodiske erfaringer med at benytte fotografering og fotografier i børneforskning og pædagogisk udviklingsarbejde......Kapitlet fortæller og reflekterer over metodiske erfaringer med at benytte fotografering og fotografier i børneforskning og pædagogisk udviklingsarbejde...

  4. Erfaringer med uddannelsydelsesordningen

    DEFF Research Database (Denmark)

    Rasmussen, Preben Horsholt

    En landsdækkende undersøgelse af erfaringerne med uddannelsesydelsesordningen i Danmark i perioden 1985-86. 2. del baseret på interviews.......En landsdækkende undersøgelse af erfaringerne med uddannelsesydelsesordningen i Danmark i perioden 1985-86. 2. del baseret på interviews....

  5. Leg med vision

    DEFF Research Database (Denmark)

    Munk, Mette; Bertelsen, Katrine

    2011-01-01

    alle med interesse for leg og bevægelse i daginstitutioner. Bogen er skrevet i et samarbejde mellem Ringsted Kommune og det nationale videncenter for sundhed, kost og motion for børn og unge, KOSMOS (www.vicekosmos.dk).Der er i samarbejde med to daginstitutioner indhentet vigtige og kvalificerede...

  6. Stop hassardspil med fondsmodellen

    DEFF Research Database (Denmark)

    Thomsen, Steen

    2015-01-01

    Lynbeskatning af fonde får konsekvenser, der ikke står mål med sølle 200 mio. kr. i udbytte.......Lynbeskatning af fonde får konsekvenser, der ikke står mål med sølle 200 mio. kr. i udbytte....

  7. En mening med galskaben

    DEFF Research Database (Denmark)

    Toft-Nielsen, Claus

    2003-01-01

    Hvorfor kan en så feteret og professionel skuespiller som Jack Nicholson overhovedet slippe af sted med at levere en så overspillet og forceret præstation, som den han kommer med i Stanley Kubricks The Shining? Og hvorfor har den til fingerspidserne perfektionistiske Kubrick ikke stoppet Nicholson...

  8. Advancing PubMed?

    DEFF Research Database (Denmark)

    Wildgaard, Lorna Elizabeth; Lund, Haakon

    2016-01-01

    Purpose Systematic reviews of biomedical literature are used to inform patient treatment. Yet the acquisition of relevant literature is proving increasingly challenging due to the large volume of information that needs to be searched, filtered and collocated. There is a need to improve...... provides the superior search interface for systematic searches or if the innovativeness of third-party tools provide alternatives worth considering. The paper aims to discuss these issues. Design/methodology/approach In all, 76 third-party tools that build on PubMed content were identified in a Pub...... the efficiency of biomedical literature searches. PubMed remains the primary resource for biomedical literature, and as PubMed makes the Medline data and Entrez PubMed Programming utilities freely available, any developer can produce alternative tools to search the database. The authors question if PubMed still...

  9. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.

    NARCIS (Netherlands)

    Ridder, L.; Rings, E.H.; Damen, G.M.; Kneepkens, C.M.; Schweizer, J.J.; Kokke, F.T.; Benninga, M.A.; Norbruis, O.F.; Hoekstra, J.H.; Gijsbers, C.F.M.; Escher, J.C.

    2008-01-01

    BACKGROUND: Infliximab is effective for induction and maintenance of remission in Crohn's disease. It is unknown how long patients should be kept on infliximab therapy. The primary aim of this study was to assess duration of effective maintenance therapy and infliximab dependency in pediatric CD pat

  10. Infliximab dependency in pediatric Crohn's disease : Long-term follow-up of an unselected cohort

    NARCIS (Netherlands)

    de Ridder, Lissy; Rings, Edmond H. H. M.; Damen, Gerard M.; Kneepkens, C. M. Frank; Schweizer, Joachim J.; Kokke, Freddy T. M.; Benninga, Marc A.; Norbruis, Obbe F.; Hoekstra, J. Hans; Gijsbers, Carolien F. M.; Escher, Johanna C.

    2008-01-01

    Background: Infliximab is effective for induction and maintenance of remission in Crohn's disease. It is unknown how long patients should be kept on infliximab therapy. The primary aim of this study was to assess duration of effective maintenance therapy and infliximab dependency in pediatric CD pat

  11. Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort

    NARCIS (Netherlands)

    L. de Ridder (Lissy); E.H.H.M. Rings (Edmond); G.M. Damen (Gerard); C.M.F. Kneepkens (Frank); J. Schweizer; F.T.M. Kokke (Freddy); M.A. Benninga (Marc); O.F. Norbruis (Obbe); J.H. Hoekstra (Hans); C.F.M. Gijsbers (Carolien); J.C. Escher (Johanna)

    2008-01-01

    textabstractBackground: Infliximab is effective for induction and maintenance of remission in Crohn's disease. It is unknown how long patients should be kept on infliximab therapy. The primary aim of this study was to assess duration of effective maintenance therapy and infliximab dependency in pedi

  12. A lupus-like syndrome associated with infliximab therapy.

    Science.gov (United States)

    Klapman, Jason B; Ene-Stroescu, Daniel; Becker, Michael A; Hanauer, Stephen B

    2003-05-01

    Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNF-alpha), is efficacious in the treatment of rheumatoid arthritis and Crohn's disease. We report in detail an unusual adverse reaction to infliximab therapy, a drug-induced lupus-like clinical syndrome. A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion. This was characterized by inflammatory arthritis and an urticarial and papulosquamous rash and was accompanied by high titers of antinuclear, double-stranded DNA, glomerular-binding, and histone antibodies and by reduced levels of the C4 component of complement. After discontinuance of infliximab infusions and treatment of symptoms with intermittent courses of prednisone, the patient's arthritis progressively improved, with accompanying decrements in autoantibody titers. One year later, she has minimal joint discomfort and no rash or gastrointestinal symptoms despite also discontinuing prednisone and methotrexate. Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent. These findings support recent evidence identifying TNF-alpha as an inhibitor of autoantibody formation.

  13. Infliximab in the treatment of plaque type psoriasis

    Directory of Open Access Journals (Sweden)

    Rosita Saraceno

    2009-04-01

    Full Text Available Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.Keywords: psoriasis, nail psoriasis, infliximab, long-term treatment

  14. Antitrombotisk behandling ved iskæmisk apopleksi og transitorisk cerebral iskæmi

    DEFF Research Database (Denmark)

    Overgaard, Karsten; Poulsen, Tina Svenstrup; Husted, Steen

    2007-01-01

    Nærværende statusartikel omhandler antitrombotisk behandling ved transitorisk cerebral iskæmi (TCI) og iskæmisk apopleksi, dog omtales trombolyse ikke. Behandlingen bør individualiseres efter evidensbaserede principper som anbefalet i nationale og internationale kliniske retningslinjer. Ofte er der...

  15. Orale senfølger af behandling for hoved-halscancer

    DEFF Research Database (Denmark)

    Assaad, Hala; Dynesen, Anja Weirsøe; Thisted, Lise Bjerrum;

    2014-01-01

    Forebyggelse af orale senfølger af behandling for hoved-hals-cancer er vigtig for orale funktioner og livskvalitet Patienter, der er strålebehandlet for hovedhals-cancer, oplever betydelige senfølger i mundhulen; herunder xerostomi og hyposalivation, oral candidose, ubehag og smerte fra...... orale senfølger....

  16. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study

    OpenAIRE

    Christopher Ma; Evaschesen, Chad J; Grenvil Gracias; Huang, Vivian W; Fedorak, Darryl K; Kroeker, Karen I; Dieleman, Levinus A; Halloran, Brendan P; Fedorak, Richard N.

    2015-01-01

    BACKGROUND: Adherence to maintenance medication regimens in inflammatory bowel disease patients has traditionally been poor. Although infliximab has demonstrated efficacy in inducing and maintaining disease remission, adherence to regularly scheduled infliximab infusions is required to maintain therapeutic trough drug levels and prevent the development of anti-infliximab antibodies.OBJECTIVES: To characterize patient adherence to regularly scheduled induction and maintenance infliximab infusi...

  17. Stabilization of Bilateral Progressive Rheumatoid Corneal Melt with Infliximab

    Directory of Open Access Journals (Sweden)

    Sheelah F. Antao

    2012-01-01

    Results. A patient with rheumatoid arthritis presented with bilateral PUK following a 2-month history of ocular discomfort and redness. His systemic prednisolone (PDN and methotrexate (MTX were increased and, despite an initial favorable response, bilateral recurrent corneal perforations ensued. Both eyes underwent cyanoacrylate glue repair, amniotic membrane transplantation (AMT, and penetrating keratoplasty (PKP. Recurrence of the disease and bilateral perforations of the second PKP in both eyes prompted administration of intravenous infliximab immediately after the fourth PKP. The disease activity rapidly settled in both eyes, and at eighteen-month followup, after 12 infliximab infusions, the PUK remains quiescent with no further graft thinning or perforation. Conclusion. Infliximab can be used to arrest the progression of severe bilateral rheumatoid PUK in cases that are refractory to conventional treatment.

  18. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients

    DEFF Research Database (Denmark)

    Pedersen, N.; Duricova, D.; Lenicek, M.

    2010-01-01

    Background Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. Aim To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic...... predictors. Methods Two hundred and forty-five CD patients treated with infliximab were included from Danish and Czech Crohn Colitis Database (1999-2006). Infliximab response was assessed as immediate outcome, 1 month after infliximab start: complete, partial, and no response. Three months outcome, after...

  19. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Svenson, Morten; Bendtzen, Klaus;

    2012-01-01

    infusion, but an acute severe anaphylactoid reaction occurred immediately after start of the infusion. Anti-infliximab IgG antibody concentration was high (100 U/ml) prior to the 8th infusion and up to 1 year after infliximab discontinuation (81 U/ml). Anti-infliximab IgE antibodies were not found...... generated anti-adalimumab IgG antibodies (45 U/ml), as these antibodies appeared to be specific for adalimumab in that infliximab failed to compete with adalimumab/anti-adalimumab antibody binding ex vivo. In conclusion, immunogenicity to infliximab and adalimumab may be associated with both acute...

  20. Baderum med finurlige kontraster

    DEFF Research Database (Denmark)

    Dickson, Thomas

    2004-01-01

    Indledes med:Hvorfor skal badeværelser være så kedelige, tænkte Jannik Larsen, da han skulle glæde sin kone med et nyrenoveret badeværelse. Han havde hverken mange kvadratmeter eller penge til rådighed, men arbejdskraft og en god fantasi.......Indledes med:Hvorfor skal badeværelser være så kedelige, tænkte Jannik Larsen, da han skulle glæde sin kone med et nyrenoveret badeværelse. Han havde hverken mange kvadratmeter eller penge til rådighed, men arbejdskraft og en god fantasi....

  1. DailyMed

    Data.gov (United States)

    U.S. Department of Health & Human Services — DailyMed provides high quality information about marketed drugs. This information includes FDA labels (package inserts). This Web site provides health information...

  2. DailyMed Webservices

    Data.gov (United States)

    U.S. Department of Health & Human Services — The DailyMed RESTful API is a web service for accessing current SPL information. It is implemented using HTTP and can be thought of as a collection of resources,...

  3. Barn med Asperger syndrom

    OpenAIRE

    Ahlström, Hanna

    2003-01-01

    Det här examensarbetet handlar om barn med Asperger syndrom. Syftet med arbetet var att ta reda på vad Asperger syndrom är och hur man som lärare kan hjälpa dessa elever på bästa sätt. Jag är intresserad av elever som har det svårt och antar att jag någon gång under min tid som lärare kommer att stöta på dessa elever. Arbetet inleds med en teorigenomgång där jag främst går igenom de utmärkande dragen hos barn med Asperger syndrom. Där går jag också bl a igenom orsaker till Asperger och diagn...

  4. PubMed

    CERN Document Server

    PubMed is the National Library of Medicine's search service that provides access to over 10 million citations in MEDLINE, PreMEDLINE, and other related databases, with links to participating online journals.

  5. PubMed

    Data.gov (United States)

    U.S. Department of Health & Human Services — PubMed comprises more than 26 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to...

  6. A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies.

    Science.gov (United States)

    Takahashi, Kenichiro; Fujimoto, Takehide; Shioya, Makoto; Nishida, Atsushi; Bamba, Shigeki; Inatomi, Osamu; Imaeda, Hirotsugu; Kitoh, Katsuyuki; Andoh, Akira

    2015-04-01

    There are few reports about the rapid appearance of anti-adalimumab antibodies in patients with Crohn's disease positive for anti-infliximab antibodies. We report the case of a 29-year-old female patient with a diagnosis of Crohn's disease who revealed a loss of response to infliximab due to high levels of antibodies to infliximab, and did not respond to the subsequent therapy by adalimumab, with a rapid appearance of antibodies to adalimumab. As one of the possible mechanisms of non-response to adalimumab, immunologic reactivity of infliximab to adalimumab was suspected, since the patient's IgG that was obtained just before the induction of adalimumab reacted with infliximab and adalimumab. We should pay attention to the easy appearance of anti-adalimumab antibodies in association with reactivity of anti-infliximab antibodies to adalimumab in patients with high levels of anti-infliximab antibodies.

  7. Infliximab Dependency in a National Cohort of Children with Crohn's Disease

    DEFF Research Database (Denmark)

    Wewer, Anne Vibeke; Riis, L; Vind, Ida;

    2006-01-01

    AIM: The aim was to evaluate the pattern of responsiveness and to monitor side effects of episodic administration of infliximab in children with active Crohn's disease (CD) treated in Denmark from 1999 to 2003. MATERIAL AND METHODS: The National Danish Crohn Colitis Database of infliximab was used...... to identify all Danish CD patients treated at pediatric departments with infliximab. The clinical outcome was assessed by pattern recognition of the disease course 30 days after the first infliximab infusion and 90 days after intended end of treatment. RESULTS: During a 3 year period, infliximab was given...... of symptoms requiring reinfusions of infliximab to regain CR or PR, and 6 (25%) had NR. Six (25%) patients needed surgery during or after treatment with infliximab. Side effects were seen in four (17%) patients. No serious events were noted. CONCLUSION: Seventy-one percent of the children appeared to benefit...

  8. Kritik med objektets forrang

    DEFF Research Database (Denmark)

    Liebst, Lasse Suonperä; Stamer, Naja Buono

    2010-01-01

    Nærværende artikel vil i lyset af den idealistiske epistemologis fremtrædende position i sociologien foreslå, at et fremadrettet brud med denne idealisme kan ske med en tilbagevenden til Theodor W. Adornos negative dialektik. Det frugtbare ved denne særegne dialektik er, hvordan den med en...... tildeling af forrang til objektet insisterer på ikke-identiteten mellem de subjektive (ideale) og objektive (reale) momenter. Vores tese er, at Slavoj Žižek kan anses som dén teoretiske arvtager Adorno aldrig fik. Således argumenteres der for, at en revitalisering af Adornos negative dialektik og hermed den...... tidlige Frankfurterskoles kritiske ærinde skal ske med afsæt i netop Žižeks dialektiske psykoanalyse. Ved at placere objektet 'internt' for det symbolsk-sproglige – og ikke 'eksternt' som hos Adorno – er det med udgangspunkt i Žižek muligt at formulere en mere ikke-identisk og derved mindre pessimistisk...

  9. Infliximab en pacientes con enfermedad ocular inflamatoria, refractarios a DARMES

    Directory of Open Access Journals (Sweden)

    Elmer R. García-Salazar

    2013-07-01

    Full Text Available Se describe la experiencia con infliximab (anticuerpo monoclonal con una potente acción antiinflamatoria en el tratamiento de enfermedades oculares inflamatorias secundarias a patologías reumáticas y refractarias a drogas antirreumáticas modificadoras de la enfermedad (DARMES. Se evaluó el caso de una paciente de 50 años con artritis reumatoide (AR de fondo activo y una paciente de 37 años con vasculitis anticuerpos anticitoplasma de neutrófilos especifico para mieloperoxidasa (ANCA MPO sin compromiso de órgano noble, ambas con escleritis bilateral y perforación con prolapso de iris del ojo izquierdo. Ellas recibieron infliximab EV en dosis de 3 a 5 mg/kg/dosis, según el esquema, a las 0, 2, 6 y 8 semanas. Infliximab resultó eficaz y seguro para el tratamiento de escleritis asociada a AR y vasculitis ANCA MPO positivo, refractaria a tratamiento con DARMES y corticoides en dosis altas. Los injertos de tejido esclerocorneal evolucionaron favorablemente con infliximab.

  10. INFLIXIMAB (REMICADE: POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Directory of Open Access Journals (Sweden)

    Nataliya Vladimirovna Chichasova

    2011-03-01

    Full Text Available The paper considers the possibilities of suppressing rheumatoid arthritis (RA activity and progression in the use of infliximab. It discusses its place in the treatment of patients with early- and extended-stage RA with regard to the current international recommendations.

  11. INFLIXIMAB (REMICADE: POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Directory of Open Access Journals (Sweden)

    Nataliya Vladimirovna Chichasova

    2011-01-01

    Full Text Available The paper considers the possibilities of suppressing rheumatoid arthritis (RA activity and progression in the use of infliximab. It discusses its place in the treatment of patients with early- and extended-stage RA with regard to the current international recommendations.

  12. The Effect of Infliximab on Intestinal Anastomosis Healing in Rats.

    Science.gov (United States)

    Karaköse, Oktay; Eken, Hüseyin; Ulusoy, Ali Naki; Topgül, Hüseyin Koray; Bilgin, Mehmet; Yürüker, Saim Savaş; Gülbahar, Mustafa Yavuz

    Intestinal anastomosis healing is a complex physiological process in which many local and systemic factors play a role. One of the significant cytokines in this process is TNF-α. Infliximab is a chimeric monoclonal antibody which binds to TNF-α with high affinity. Although this agent is used in ulcerative colitis and Crohn's disease, intestinal surgery may be required in these patients. In this study it was aimed to determine whether or not there was any negative effect of preoperative single dose infliximab treatment on intestinal anastomosis healing. Two groups of 10 rats were formed. One of these groups was administered with a single dose of infliximab 8 mg/kg as a 20-minute intravenous infusion from the femoral vein. Four days after the infusion, a full layer incision was made to the colon and anastomosis was applied to all the rats. At 7 days after anastomosis, the subjects were sacrificed. The anastomosis segment was removed and the bursting pressure was measured. Tissue samples were taken from this segment for hydroxyproline concentration and histopathological examination. A blood sample was taken to measure TNF-α values. No statistically significant difference was determined between the groups in terms of bursting pressure, tissue hydroxyproline concentration or histopathological scoring. A single dose of 8 mg/kg infliximab administered 4 days preoperatively was not found to have any negative effect on intestinal anastomosis healing in rats.

  13. Stjerneroller med stort K

    DEFF Research Database (Denmark)

    Redvall, Eva Novrup

    2017-01-01

    Der er langt mellem de spændende roller til kvinder over 40 i amerikansk film og tv. Det har flere kvindelige filmstjerner før og nu arbejdet aktivt på at ændre ved at søsætte egne projekter. To vellykkede eksempler på det kan for tiden ses på HBO i 'Big Little Lies' med Reese Witherspoon og Nicole...... Kidman som igangsættere og i 'Feud' med Jessica Lange og Susan Sarandon som divaerne Joan Crawford og Bette Davis, der rivaliserede voldsomt under indspilningen af klassiskeren 'What Ever Happened to Baby Jane?...

  14. Infliximab protects against pulmonary emphysema in smoking rats

    Institute of Scientific and Technical Information of China (English)

    ZHANG Xiang-yan; HAN Jing; ZHANG Cheng; SUN Qian-yun; LI Dan; LUO Rong-rong; WAN Zi-fen; YE Xian-wei; LIU Wei-jia; RAO Shan-shan

    2011-01-01

    Background It is widely accepted that tumor necrosis factor-α (TNF-a) plays an important role in the pathogenesis of emphysema. This study aimed at investigating the protective effects of anti-TNF-α antibody, infliximab, in the development of emphysema induced by passive smoking in rats.Methods Thirty-nine rats were randomly divided into a normal control group (group 1), an emphysema group (group 2),and an infliximab-intervention group (group 3). Rat models of emphysema were established by exposure to cigarette smoking daily for 74 days. After 1 month, the infliximab intervention group was treated with infliximab via subcutaneous injection. The levels of TNF-α, iL-8 and vascular endothelial growth factor (VEGF) in bronchoalveolar lavage fluid (BALF)were measured with enzyme linked immunosorbent assay (ELISA). The number and classification of cells in the BALF were measured. Lung tissue sections stained by hematoxylin and eosin (HE) were observed, and mean linear intercept (MLI) and mean alveolar numbers (MAN) were measured. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) methods were used to examine the percentage of positive cells and distribution of apoptotic cells.Results The levels of TNF-α and IL-8 in BALF were higher in group 2 than in group 1 and group 3. The MLI was greater in group 2 than that in group 1 and group 3 while MAN was decreased. The concentration of VEGF in BALF of group 2 was significantly decreased as compared with group 1. The total cells and neutrophils number was significantly increased in group 2 as compared with group 1 and group 3, so was the percentage of neutrophils. The number of TUNEL positive cells in the alveolar septa was significantly increased in group 2 as compared with group 1 and group 3.Conclusion Infliximab protects against cigarette smoking-induced emphysema by reducing airway inflammation,attenuating alveolar septa cell apoptosis and improving pathological changes.

  15. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab

    Directory of Open Access Journals (Sweden)

    A. López San Román

    2004-06-01

    Full Text Available Pyoderma gangrenosum is an extraintestinal manifestation of inflammatory bowel disease that can be therapeutically troublesome. We comment on the case of a patient with clinically inactive ulcerat-ive colitis who progressively developed necrotic lesions on both tibial aspects of his legs, which corresponded both clinically and histologically to pyoderma gangrenosum. Treatment with steroids and azathioprine could not control this complication. A single dose of infliximab 5 mg/kg was given, achieving an impressive response of the skin lesions followed by complete healing 3 months later. Infliximab can be useful in the management of refractory extraintestinal manifestations of inflammatory bowel disease.Dentro de las manifestaciones extraintestinales de la enfermedad inflamatoria intestinal, el pioderma gangrenoso plantea con frecuencia dificultades terapéuticas. Presentamos el caso de un enfermo diagnosticado de colitis ulcerosa, inactiva en ese momento, que presentó un pioderma gangrenoso en miembros inferiores y no respondió a esteroides y azatioprina. Se administró una dosis de 5 mg/kg de infliximab obteniendo una rápida mejoría de las lesiones y la completa curación a los 3 meses. Infliximab puede ser útil en manifestaciones extraintestinales de la enfermedad inflamatoria intestinal, como el pioderma gangrenoso, si no responden a los tratamientos habituales.

  16. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

    DEFF Research Database (Denmark)

    Svenson, M; Geborek, P; Saxne, T

    2007-01-01

    Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mouse-human IgG1/kappa antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases. Unfortunately, response failure and side-effects due to immunogenicity of the drug are not rare. In this study, we...

  17. Infliximab no tratamento da artrite psoriásica grave Infliximab in treatment of severe psoriatic arthritis

    Directory of Open Access Journals (Sweden)

    Adriano Jaime Consorte Loyola

    2005-10-01

    Full Text Available A artrite psoriásica tem sido reconhecida como doença imunomediada, em que há participação de células T produtoras de citocinas (fator de necrose tumoral-alfa. O infliximab é anticorpo monoclonal que se liga e inativa o fator de necrose tumoral-alfa. Relata-se um caso de artrite psoriásica grave, refratária a várias terapêuticas sistêmicas, tratado com infliximab 5mg/kg, em infusão venosa de três horas, nas semanas 0, 2, 6 e 14, associado com baixa dose de metotrexato, que apresentou excelente resposta terapêutica.Psoriatic arthritis has been recognized as an auto-immune disease in which there is participation of the cytokine-producing T cells (tumor necrosis factor-alpha. Infliximab is a monoclonal antibody that binds to and inactivates tumor necrosis factor-alpha. Reported is a case of severe psoriatic arthritis which was unresponsive to multiple systemic therapies and treated with an intravenous infusion of infliximab, 5mg/Kg in three hours, in weeks 0,2,6 and 14, associated with a low dose of methotrexate, with an excellent therapeutical response.

  18. Kommunale aktiveringsprojekter med produktion

    DEFF Research Database (Denmark)

    Rosdahl, Anders

    .a. at opkvalificere de ledige og styrke deres muligheder for at få et job på almindelige vilkår. På baggrund af data fra alle landets kommuner kortlægger rapporten omfanget og arten af disse særligt tilrettelagte aktiveringsprojekter med produktion og beskriver gruppen af aktiverede. Desuden berører rapporten...

  19. Byggematerialer med asbest

    DEFF Research Database (Denmark)

    , de er anvendt. Oplysningerne er indsamlet i 1986 og revideret og udvidet 2010. Anvisningen er knyttet til SBi-anvisning 228, Asbest i bygninger, der beskriver håndtering af asbest i praksis i overensstemmelse med krav i lovgivningen på en sikker og sundhedsmæssig forsvarlig måde. SBi-anvisning 228 og...

  20. Professionalisme med innovativt potentiale

    DEFF Research Database (Denmark)

    Nielsen, Inger Marie

    To teoretiske sværvægtere bliver koblet sammen i Inger Marie Larsen-Nielsen arbejdspapir om professionalisme med innovativt potentiale. De to teoretikere er læringsteoretikeren John Dewey og socialpsykologen Georg Herbert Mead, som er sat sammen i en teoretisk forståelsesramme omkring professionel...

  1. Selskabsloven med kommentarer

    DEFF Research Database (Denmark)

    Schaumburg-Müller, Peer; Werlauff, Erik

    Selskabsloven med kommentarer er bibelen på området for kapitalselskaber. Den er et juridisk arbejdsredskab for praktikere, rådgivere, forskere og studerende. Bogen indeholder en komplet opdatering af kommentarerne i forhold til de mange ændringer i selskabsloven siden 1.-udgaven, men bygger i øv...

  2. At leve med osteoporose

    DEFF Research Database (Denmark)

    Hansen, Carrinna; Abrahamsen, Bo; Konradsen, Hanne

    Baggrund: Livet med kronisk sygdom, heriblandt osteoporose, giver anledning til verdensomspændende udfordringer. Osteoporose er ofte en usynlig tilstand før knoglebrud opstår, det er anslået, at hver tredje kvinde og en af fire mænd over 50 år i Europa vil opleve disse typer af knoglebrud og det ...

  3. Professionalisme med innovativt potentiale

    DEFF Research Database (Denmark)

    Nielsen, Inger Marie

    To teoretiske sværvægtere bliver koblet sammen i Inger Marie Larsen-Nielsen arbejdspapir om professionalisme med innovativt potentiale. De to teoretikere er læringsteoretikeren John Dewey og socialpsykologen Georg Herbert Mead, som er sat sammen i en teoretisk forståelsesramme omkring professionel...

  4. Vinterbyggeri med forhindringer

    DEFF Research Database (Denmark)

    Hansen, Ernst Jan de Place; Larsen, Jacob Norvig

    2009-01-01

    Lav aktivitet i byggeriet om vinteren forbindes normalt med klimaets indflydelse på forholdene på byggepladsen, ikke mindst på nordlige breddegrader. Det er en udbredt holdning, at en ujævn aktivitet fører til en fordyrelse af byggeriet, som følge af at materiel og arbejdskraft ikke udnyttes opti...

  5. Med-E-Tel

    Science.gov (United States)

    2006-04-01

    Y Sistemas De Información Geográfica: Nuevas Perspectivas Para El Manejo De Problemas En Salud Pública, Caso Particular La Malaria en el Estado...representatives, academia, researchers, local and international government representatives, health insurers, homecare services. The Med-e-Tel 2006...organizations, association executives, health insurers, military and government management (both at local /national and international level), academia

  6. Forebyggelse af infektioner hos patienter, der har kronisk inflammatorisk tarmsygdom og er i behandling med TNF-hæmmere

    DEFF Research Database (Denmark)

    Risager Christensen, Katrine; Steenholdt, Casper

    2014-01-01

    suppression of the immune system. National and international guidelines recommend screening and vaccination for selected infectious agents prior to anti-TNF initiation as well as during ongoing anti-TNF therapy. This review focuses on current available recommendations and discusses physicians’ and patients...

  7. En krobjektiv lidelse? Forståelse og behandling af kroniske, diffuse smertelidelser med fibromyalgi som eksempel

    Directory of Open Access Journals (Sweden)

    Rie Lykke Danielsen

    2011-12-01

    Full Text Available The article deals with the disease field chronic diffuse pains, here exemplified by fibromyalgia, where patients are frequently rendered homeless in an objectivity focused medical treatment system, whose specialities (ideally seen are mutually exclusive, and where the absence of a diagnosis therefore poses a fundamental problem. In the treatment field there is, however, also a bio-psycho-social approach, and these two treatment regimes are respectively termed as a chrObjective approach and a holistic subject approach.By empirical examples, from stories by both therapists and patients, the article describes how the actors navigate between the two treatment regimes, to which the patients must necessarily adapt in their wish for acceptance and assistance from both sides. The authors further discuss to which degree the two treatment regimes are actually incompatible. The interviews and observation of participants, which constitute the empirical basis for the article, were carried out among therapists and patients in Denmark in 2010.

  8. Medicinsk vs. kirurgisk behandling af svært overvægtige patienter med type 2-diabetes

    DEFF Research Database (Denmark)

    Svane, Maria Saur; Bojsen-Møller, Kirstine Nyvold; Madsbad, Sten

    2016-01-01

    Bariatric surgery induces large and sustainable weight loss in obese patients and improves glycaemic control in patients with Type 2 diabetes. Eleven randomized controlled trials have shown superior glycaemic outcomes after bariatric procedures vs. medical therapy/intensive lifestyle interventions...... in obese patients with Type 2 diabetes. Furthermore, many patients experience remission of Type 2 diabetes after surgery but relapse may occur during follow-up. Data from observational studies show reduced incidence of micro- and macrovascular complications in addition to reduced cardiovascular and total...... mortality after surgery....

  9. Behandling med duodenal-jejunal bypass-sleeve ved svær overvægt

    DEFF Research Database (Denmark)

    Rohde, Ulrich; Gylvin, Silas; Vilmann, Peter

    2014-01-01

    Overweight and obesity are risk factors for several co-morbidities reducing life expectancy. Conservative treatment of obesity is generally ineffective in the long-term. Bariatric surgery has proven effective, but is associated with potential complications. Duodenal-jejunal bypass sleeve is a novel...

  10. Udvikling af cerebrale infarkter hos en 17-årig mand i behandling med sertralin og lisdexamfetamin

    DEFF Research Database (Denmark)

    Martinussen, Malene; Debes, Nanette Mol; Christensen, Catrine

    2016-01-01

    A 17-year-old male with ADHD who was treated with sertraline and lisdexamfetamine presented with transient episodes of speech impairment and right-sided hemiparesis preceded by headaches. Magnetic resonance imaging revealed three cerebral ischaemic lesions. Treatment was initiated with aspirin...

  11. Udvikling af cerebrale infarkter hos en 17-årig mand i behandling med sertralin og lisdexamfetamin

    DEFF Research Database (Denmark)

    Martinussen, Malene; Debes, Nanette Mol; Christensen, Catrine

    2017-01-01

    A 17-year-old male with ADHD who was treated with sertraline and lisdexamfetamine presented with transient episodes of speech impairment and right-sided hemiparesis preceded by headaches. Magnetic resonance imaging revealed three cerebral ischaemic lesions. Treatment was initiated with aspirin...

  12. Heterotop graviditet efter IVF-behandling med excision af rumperet interstitiel graviditet og senere kejsersnit nær termin

    DEFF Research Database (Denmark)

    Elers, Jimmi; Zingenberg, Helle; Bing, Mette H;

    2016-01-01

    We describe a rare case of heterotopic pregnancy following in vitro fertilization with transferring of two embryos in a 39-year-old woman with previous bilateral salpingectomy. An ultrasound examination was performed on the day before admission showing a vital intrauterine pregnancy and no ectopic...... pregnancy. The woman was admitted with a ruptured cornual pregnancy at ten weeks of gestation. Laparotomy was performed on vital indication with excision of the ruptured haemorrhagic cornual pregnancy. The intrauterine pregnancy continued uneventfully with obstetric and fetal medicine specialist monitoring...

  13. Cadmium in willow plantations - municipal waste products as fertilizers; Kadmiumhalt i Salixodlingar efter behandling med kommunala restprodukter

    Energy Technology Data Exchange (ETDEWEB)

    Hasselgren, K. [ENVIRO Miljoekonsult (Sweden)

    1995-07-01

    Plantations of willows (i.e. Salix spp) seem to absorb cadmium (Cd) from arable land to a greater extent than other plant cultivations. Thus, energy forestry, based upon cultivation of Salix, could possibly be used for biofuel production in combination with biological purification of arable land contaminated with Cd by atmospheric deposition and P fertilizers during the passed 100 years. Application of sewage sludge (5-7 ppm Cd of dry solids) up to 550 g Cd per hectare, or 140 g Cd hectare and year, resulted in clearly increased concentrations of Cd in the upper 10 cm layer of the soil. In deeper soil layers the differences compared with control plots were small. Lower rates of sludge application, corresponding to less than 70 g added per hectare and year, did not materially affect the Cd-content in the soil irrespective of layer. A general pattern was that the content of Cd in plant tissues decreased with increased stem diameter, increased age of stems and stands as well as increased biomass growth. Thus, concentrations of Cd in Salix material, in clones from some of the first generation of energy forest plants (S. viminalis, S. dasyclados and S. schwerinii). were fairly high in young stands. In general, 1-year-old shoots contained 5-6 ppm Cd of dry solids in stems and 10-15 ppm in leaves. In older shoots, up to three years, and older stands, up to six years, the Cd contents decreased to 1-2 ppm Cd and 2-4 ppm Cd of dry solids for stems and leaves, respectively. Abundant supplies of water and nutrients seem to stimulate the Cd uptake in Salix in terms of higher concentrations in plant tissues as well as higher plant growth levels compared with conventional energy forestry. Stands with older stems, not irrigated and not fully fertilized resulted in uptake rates in the range of 10-30 g Cd per hectare and year. 14 refs, 9 figs, 1 tab

  14. Behandling af renovaskulær hypertension med transluminal angioplastik--13 års erfaring--sekundærpublikation

    DEFF Research Database (Denmark)

    Øvrehus, Kristian Altern; Andersen, Poul Erik; Jacobsen, Ib Abildgaard

    2008-01-01

    The result of treatment of renovascular hypertension by renal angioplasty over a period of 13 years was analysed. Patients with a positive diagnostic work-up with renography or renal vein renin measurement had renal angiography performed and in cases of renal artery stenosis, transluminal...... angioplasty. A total of 124 patients were treated; 31% were normotensive immediately after angioplasty, 59% had improved blood pressure control and 10% had unchanged hypertension. The corresponding figures after six months and at the latest follow-up were 13, 72 and 15%. Udgivelsesdato: 2008-Jan-21...

  15. Skandinaviske kliniske retningslinjer for præhospital behandling af patienter med svære hovedtraumer

    DEFF Research Database (Denmark)

    Juul, Niels; Sollid, Snorre; Sundstrøm, Terje

    2008-01-01

    Head trauma causes the death of many young persons. The number of fatalities can be reduced through systematic management. Preventing secondary brain injury together with the fastest possible transport to a neurosurgical unit has been shown to be effective in reducing mortality and morbidity....... Evidence-based guidelines already exist that focus on all steps in the management. This article, which was written by members of the Scandinavian Neurotrauma Committee, presents recommendations on the pre-hospital management of traumatic brain injury adapted to the infrastructure of Scandinavia...

  16. Fatal blødning ved operation for hoftenær fraktur hos en patient i behandling med dabigatran

    DEFF Research Database (Denmark)

    Rasmussen, Lasse Enkebølle; Viberg, Bjarke L; Pottegård, Anton

    2015-01-01

    An 82-year-old woman in treatment with the thrombin inhibitor dabigatran etexilate (a new oral anticoagulant (NOAC)) was admitted with a subtrochanteric femoral fracture and surgery was initiated 15 hours after admittance. She had a blood loss of 6,000 ml and died the next morning from multi......-organ failure. In 2013 1.8% of hip fracture patients in Funen received NOACs. Surgery is recommended within 24 hours for hip fracture patients to reduce mortality, but patients in treatment with NOACs should wait at least 48 hours before major surgery. Care should be taken when prescribing NOACs to patients...

  17. Intrauterin insemination med donorsaed. Behandling af ufrivillig barnløshed på grund af mandlig infertilitet

    DEFF Research Database (Denmark)

    Vilsbøll, Tina; Helmsøe-Zinck, Lise; Andersen, A N

    1994-01-01

    of conception and expected delivery was respectively 96% and 86%. The results show that intrauterine insemination with donor semen is a good treatment for couples with male infertility. Ultrasonic measurement of the follicles and timing of hCG injection were used for optimal timing of intrauterine donor...

  18. Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review

    DEFF Research Database (Denmark)

    Bloch, Sara Brandi; Larsen, Michael

    2009-01-01

    a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity. Udgivelsesdato: 2009-Nov......This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include...

  19. Role of scintigraphy with Tc-99m-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis

    NARCIS (Netherlands)

    Conti, F.; Malviya, G.; Ceccarelli, F.; Priori, R.; Iagnocco, A.; Valesini, G.; Signore, A.

    2012-01-01

    The rationale for the present study was to evaluate the predictive role of Tc-99m-infliximab scintigraphy in therapy decision-making in patients with refractory monoarthritis and also candidates for intraarticular (IA) infliximab treatment. We studied 12 patients (5 with rheumatoid arthritis and 7 w

  20. Blødningsforstyrrelser hos kvinder. Undersøgelse og behandling i almen praksis

    DEFF Research Database (Denmark)

    Astrup, Karen

    1994-01-01

    Artiklen omfatter resultaterne af en spørgeskemaundersøgelse til 200 praktiserende læger efteråret 1992 om lægernes undersøgelse og behandling af forskellige former for blødningsforstyrrelser hos kvinder i almen praksis. Undersøgelsen blev udført mhp. Karen Astrup's deltagelse i expertpanelet til...... konsensuskonferencen "Blødningsforstyrrelser hos kvinder" febr. 1993. Udgivelsesdato: 1994......Artiklen omfatter resultaterne af en spørgeskemaundersøgelse til 200 praktiserende læger efteråret 1992 om lægernes undersøgelse og behandling af forskellige former for blødningsforstyrrelser hos kvinder i almen praksis. Undersøgelsen blev udført mhp. Karen Astrup's deltagelse i expertpanelet til...

  1. Revisão sistemática da indução de autoanticorpos e lúpus eritematoso pelo infliximabe

    Directory of Open Access Journals (Sweden)

    João Luiz Pereira Vaz

    2013-08-01

    Full Text Available Nesta revisão sistemática abordamos a indução de autoanticorpos e lúpus eritematoso pelo infliximabe, analisando estudos que dosaram vários autoanticorpos antes e após o uso do infliximabe em diversas doenças (artrite reumatoide, espondilite anquilosante, artrite psoriásica e doença de Crohn. Nossa busca foi realizada em nove bases de dados (Pub-Med, ScienceDirect, Scopus, Web of Knowledge, Scirus, Cochrane, EMBASE, Scielo e LILACS. Foram encontradas 998 referências; 24 artigos foram separados na íntegra, dos quais 10 foram excluídos por não entrarem em nossos critérios de seleção. A escolha dos artigos foi realizada por dois revisores, e as divergências foram resolvidas por um terceiro revisor. Incluímos estudos de fase IV, com no mínimo três meses de duração. No total foram estudados 760 pacientes; o fator antinuclear, o anticorpo anti-DNA de dupla hélice e os antígenos extraídos pela salina foram os mais verificados. De todos os pacientes, apenas 10 (1,3% apresentaram manifestações clínico-laboratoriais de lúpus induzido por infliximabe.

  2. Behandling af defaekationsblokade som følge af dyb fossa recto-genitalis med total baekkenbundsrekonstruktion med Prolene-net

    DEFF Research Database (Denmark)

    Møller, P; Monrad, H; Kehlet, H

    1992-01-01

    of the abdominal pain and dependence on morphine in two of the patients. Rectal compression resulting from an abnormally deep recto-genital fossa should be included in the differential diagnostic deliberations in patients with severe constipation and defaecation blockage. Complete reconstruction of the pelvic......The causes of severe defaecation blockage resulting from compression of the rectum and deep recto-genital fossa are reviewed and are illustrated by three patients who had previously undergone hysterectomy and who had incapacitating defaecation blockage and abdominal pain requiring morphine in two...... of the patients. The condition had not been diagnosed despite previous hospital contact for many years in two of the patients. Complete reconstruction of the pelvic floor with prolene net was performed. Subsequent defaecography showed normalization of defaecation without rectal compression and with relief...

  3. Infliximab dependency in a national cohort of children with Crohn's disease

    DEFF Research Database (Denmark)

    Wewer, Anne Vibeke; Riis, Lene; Vind, Ida

    2006-01-01

    AIM: The aim was to evaluate the pattern of responsiveness and to monitor side effects of episodic administration of infliximab in children with active Crohn's disease (CD) treated in Denmark from 1999 to 2003. MATERIAL AND METHODS: The National Danish Crohn Colitis Database of infliximab was used...... to identify all Danish CD patients treated at pediatric departments with infliximab. The clinical outcome was assessed by pattern recognition of the disease course 30 days after the first infliximab infusion and 90 days after intended end of treatment. RESULTS: During a 3 year period, infliximab was given...... to 24 CD patients (9 male/15 female) aged median 15.4 (range 9.8-18.6) years with a median disease duration of 26 (range 0.7-93) months and a median number of infusions of 6 (range 2-11). Five milligrams of infliximab per kilogram infusions were given intravenously. Immediate response was as follows: 8...

  4. Farlig sex med engle

    DEFF Research Database (Denmark)

    Mejrup, Kristian

    2013-01-01

    De fleste af os tænker ikke på engle som kønnede væsner med en seksualitet, og selv om vi er i stand til at acceptere engle i alle mulige afskygninger, fra juletræets tyksakker i glitrende guld til frygtindgydende skikkelser i de bibelske skrifter, så er vi tilbøjelig til at ignorere spørgsmålet ...

  5. Advancing PubMed?

    DEFF Research Database (Denmark)

    Wildgaard, Lorna Elizabeth; Lund, Haakon

    2016-01-01

    Purpose Systematic reviews of biomedical literature are used to inform patient treatment. Yet the acquisition of relevant literature is proving increasingly challenging due to the large volume of information that needs to be searched, filtered and collocated. There is a need to improve the effici......Med remains the superior provider for searching, identifying, and exporting biomedical literature for systematic reviews. Originality/value The work contributes to the discussion of how librarians can help researchers navigate the biomedical literature in systematic reviews....

  6. Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission

    DEFF Research Database (Denmark)

    Eng, Grith P; Bendtzen, Klaus; Bliddal, Henning;

    2015-01-01

    Objective. To investigate if antibodies towards biological TNF-α inhibitors (anti-TNFi Abs) are present in patients with rheumatoid arthritis (RA) in clinical remission and to relate any anti-TNFi Abs to circulating level of TNF-α inhibitor (TNFi). Methods. Patients with RA, treated with infliximab....... These data suggest that continued infliximab treatment may be redundant in a proportion of RA patients treated with infliximab and in clinical remission....

  7. Cat scratch disease during infliximab therapy: a case report and literature review.

    Science.gov (United States)

    Zhou, Yi; Yin, Geng; Tan, Chunyu; Liu, Yi

    2015-05-01

    Cat scratch disease may occur during etanercept therapy, but there has been no report on infliximab-associated cat scratch disease. We report a case of a 23-year-old woman who developed right inguinal lymph node enlargement following a cat scratch. The patient had received infliximab therapy for spondyloarthropathy. She was successfully managed by discontinuing infliximab and by treatment with moxifloxacin and amikacin.

  8. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.

    Science.gov (United States)

    Youn, Youngmin; Kim, Jisoo; Hong, Young Mi; Sohn, Sejung

    2016-04-01

    Forty-three patients with Kawasaki disease who were resistant to initial intravenous immunoglobulin (IVIG) were randomized to receive either a second dose of IVIG (n = 32) or an infliximab (n = 11). With IVIG retreatment 21 patients (65.6%) responded, and with infliximab 10 patients (90.9%) responded. The infliximab group had shorter duration of fever and fewer days of hospitalization. Coronary artery outcomes and adverse events were similar.

  9. Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism

    Directory of Open Access Journals (Sweden)

    Brett Cerniglia

    2013-01-01

    Full Text Available We report a patient with cutaneous sarcoidosis who developed hypothyroidism following 17 months of infliximab therapy. To our knowledge, this is the first reported case of hypothyroidism following infliximab administration. While it is possible that the patient’s hypothyroidism was unrelated to the use of infliximab, the time course and lack of alternative explanations make such an association plausible. We postulate that hypothyroidism in this patient may have been related to the development of autoantibodies to infliximab that triggered the development of an autoimmune thyroiditis. Regardless of the mechanism, we would encourage clinicians to keep the potential mechanisms of TNF- in mind when treating patients with TNF- antagonist medications.

  10. Successful treatment of idiopathic orbital inflammation with infliximab: an alternative to conventional steroid-sparing agents.

    Science.gov (United States)

    Miquel, Tiphaine; Abad, Sébastien; Badelon, Isabelle; Vignal, Catherine; Warzocha, Ursula; Larroche, Claire; Morax, Serge; Dhote, Robin

    2008-01-01

    Therapy for orbital pseudotumor, also called idiopathic orbital inflammation, is nonspecific and mainly based on the use of corticosteroids. Two patients with steroid-dependent idiopathic orbital inflammation, one with myositis and the other with dacryoadenitis, and intolerant of standard steroid sparing agents (methotrexate or azathioprine), were treated with infliximab, a monoclonal antitumor necrosis factor alpha antibody. In both patients, orbital manifestations disappeared following treatment. After follow-up for at least 20 months, the 2 patients still receiving infliximab remained event free. Infliximab enabled steroid tapering to less than 5 mg per day, suggesting that infliximab could constitute an alternative to conventional steroid sparing agents.

  11. BRIEF ARTICLELong-term efficacy of infliximab maintenance therapy for perianal Crohn’s disease

    Institute of Scientific and Technical Information of China (English)

    Motoi Uchino; Hiroki Ikeuchi; Toshihiro Bando; Hiroki Matsuoka; Yoshio Takesue; Yoshiko Takahashi; Takayuki Matsumoto; Naohiro Tomita

    2011-01-01

    AIM: To assess the long-term efficacy of seton drain-age with infliximab maintenance therapy in treatment of stricture for perianal Crohn’s disease (CD).METHODS: Sixty-two patients with perianal CD who required surgical treatment with or without infliximab between September 2000 and April 2010 were identified from our clinic’s database. The activities of the perianal lesions were evaluated using the modified perianal CD activity index (mPDAI) score. The primary endpoint was a clinical response at 12-15 wk after surgery as a short-term efficacy. Secondary endpoints were recurrence as reflected in the mPDAI score, defined as increased points in every major element. The clinical responses were classified as completely healed (mPDAI = 0), partially improved (mPDAI score decreased more than 4 points), and failure or recurrence (mPDAI score in-creased or decreased less than 3 points). RESULTS: There were 43 males and 19 females, of whom 26 were consecutively treated with infliximab after surgery as maintenance therapy. Complete heal-ing was not seen. Failure was seen in 10/36 (27.8%) patients without infliximab and 4/26 (15.4%) patients with infliximab (P = 0.25). Partial improvement was seen in 26/36 (72.2%) patients without infliximab and 22/26 (88.5%) patients with infliximab (P = 0.25). Short-term improvement was achieved in 48/62 (77.4%) patients. Although the mPDAI score improved signifi-cantly with surgery regardless of infliximab, it decreased more from baseline in patients with infliximab (50.0%) than in those without infliximab (28.6%), (P = 0.003). In the long-term, recurrence rates were low regardless of infliximab in patients without anorectal stricture. In patients with anorectal stricture, cumulative recurrence incidences increased gradually and exceeded 40% at 5 years regardless of infliximab. No efficacy of infliximab treatment was found (P = 0.97). Although the cumula-tive rate of ostomy creation was also low in patients without stricture and high

  12. Infliximab Dependency in a National Cohort of Children with Crohn's Disease

    DEFF Research Database (Denmark)

    Wewer, Anne Vibeke; Riis, L; Vind, Ida

    2006-01-01

    AIM: The aim was to evaluate the pattern of responsiveness and to monitor side effects of episodic administration of infliximab in children with active Crohn's disease (CD) treated in Denmark from 1999 to 2003. MATERIAL AND METHODS: The National Danish Crohn Colitis Database of infliximab was used...... of symptoms requiring reinfusions of infliximab to regain CR or PR, and 6 (25%) had NR. Six (25%) patients needed surgery during or after treatment with infliximab. Side effects were seen in four (17%) patients. No serious events were noted. CONCLUSION: Seventy-one percent of the children appeared to benefit...

  13. Infliximab in the treatment of amyloidosis secondary to Crohn's disease.

    Science.gov (United States)

    Cabezuelo, Juan B; Egea, Juan P; Ramos, Fernanda; Torrella, Emilio; Muray, Salomé; Alcázar, Concepción

    2012-05-14

    Secondary amyloidosis (AA) is a severe complication of progressed Crohn’s disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.

  14. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.

    Science.gov (United States)

    Ozorio, Gerard; McGarity, Bruce; Bak, Haesung; Jordan, Andrew S; Lau, Henry; Marshall, Cathy

    2007-11-01

    Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-alpha (TNF-alpha) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-alpha agents, and periodic monitoring for the development of hepatitis is important.

  15. Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab

    Directory of Open Access Journals (Sweden)

    E. Filippucci

    2011-06-01

    Full Text Available Over the last ten years, the treatment of seronegative spondyloarthropathies has changed dramatically with the introduction of the anti-tumor necrosis factor alpha (TNFα agents. Nevertheless, there is a growing number of studies describing several adverse reactions in patients treated with biological agents. In the present report we describe the case of a 22-year-old male patient with ankylosing spondylitis who developed a “paradoxic” adverse reaction, while receiving infliximab.

  16. Akut dissemineret encefalomyelitis. Afgraensning, behandling, prognose og evidens

    DEFF Research Database (Denmark)

    Christensen, Pia Sønderby; Østergaard, John R

    2008-01-01

    and prognosis for children with ADEM and to evaluate the level of evidence in treatment. MATERIALS AND METHODS: Medical records were found by searching for diagnoses and reviewed retrospectively. The level of evidence in treatment was evaluated by searching PubMed, EMBASE and The Cochrane Library. RESULTS: 11...

  17. Infliximab stopped severe gastrointestinal bleeding in Crohn's disease

    Institute of Scientific and Technical Information of China (English)

    Satimai Aniwan; Surasak Eakpongpaisit; Boonlert Imraporn; Surachai Amornsawadwatana; Rungsun Rerknimitr

    2012-01-01

    To report the result of rapid ulcer healing by infliximab in Crohn's patients with severe enterocolic bleeding.During 2005 and 2010,inflammatory bowel disease database of King Chulalongkorn Memorial and Samitivej hospitals were reviewed.There were seven Crohn's disease (CD) patients (4 women and 3 men; mean age 52 ± 10.4 years; range:11-86 years).Two of the seven patients developed severe gastrointestinal bleeding (GIB) as a flare up of CD whereas the other five patients presented with GIB as their first symptom for CD.Their mean hemoglobin level dropped from 12 ± 1.3 g/dL to 8.7 ± 1.3 g/dL in a 3-d period.Median packed red blood cells units needed for resuscitation was 4 units.Because of uncontrolled bleeding,surgical resection was considered.However,due to the poor surgical candidacy of these patients (n =3) and/or possible development of short bowel syndrome (n =6),surgery was not pursued.Likewise angiographic embolization was not considered in any due to the risk of large infarction.All severe GIBs successfully stopped by one or two doses of intravenous infliximab.Our data suggests that infliximab is an alternative therapy for CD with severe GIB when surgery has limitation or patient is a high risk.

  18. Matrixregning med SAS

    DEFF Research Database (Denmark)

    Andersen, Aage T.; Feilberg, Michael; Milhøj, Anders

    IML i SAS anvendes til matrixberegninger som en integreret del af SAS pakken. Den anvendes typisk til matrixberegninger i tilknytning til andre SAS applikationer, fx kan matricer let dannes ud fra datasæt i SAS. Desuden indeholder IML en række videregående matematiske og statistiske subroutiner......, der ikke findes andre steder i SAS.I bogen gennemgås matrixregning svarende til et indledende matematikkursus ved en højere læreanstalt. Den teoretiske gennemgang understøttes og demonstreres konsekvent med IML programmering, så fokus er på praktiske anvendelser af matricer....

  19. MedPAC Data Book

    Data.gov (United States)

    U.S. Department of Health & Human Services — MedPACs Data Book is the result of discussions with congressional staff members regarding ways that MedPAC can better support them. Some of the information it...

  20. Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases : A Single-Center Cohort Study

    NARCIS (Netherlands)

    Breynaert, Christine; Ferrante, Marc; Fidder, Herma; Van Steen, Kristel; Noman, Maja; Ballet, Vera; Vermeire, Severine; Rutgeerts, Paul; Van Assche, Gert

    2011-01-01

    OBJECTIVES: Scheduled maintenance therapy with infliximab decreases the risk of infusion reactions. Many centers have accelerated infusion times to 1 h in selected patients who tolerate 5 mg/kg infliximab infusions. The aim of this study was to compare the tolerability of 1-h and 2-h infliximab infu

  1. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

    NARCIS (Netherlands)

    Bemt, B.J. van den; Broeder, AA den; Snijders, G.F.; Hekster, Y.A.; Riel, P.L.C.M. van; Benraad, B.; Wolbink, G.J.; Hoogen, F.H.J. van den

    2008-01-01

    OBJECTIVES: In clinical trials only a small subset of patients with rheumatoid arthritis (RA) benefits from higher than standard dose of infliximab (>3 mg/kg/8 weeks). However, dose escalation of infliximab is frequently applied in clinical practice. Individual adjustment of infliximab treatment

  2. Development and potential application of an oral ColoPulse infliximab tablet with colon specific release : A feasibility study

    NARCIS (Netherlands)

    Maurer, Jacoba M.; Hofmana, Susan; Schellekens, Reinout C.A.; Tonnis, Wouter F.; Dubois, Annelien O.T.; Woerdenbag, Herman J.; Hinrichs, Wouter L.J.; Kosterink, Jos G.W.; Frijlink, Henderik W.

    2016-01-01

    The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5mg infliximab tablets were developed. To stabilize the antibody dur

  3. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals

    DEFF Research Database (Denmark)

    Mortensen, Christian; Caspersen, Sarah; Christensen, Niels Lyhne

    2011-01-01

    In acute steroid-refractory ulcerative colitis, rescue therapy with infliximab has become a therapeutic option in patients facing colectomy. Data on efficacy and safety in this setting are sparse.......In acute steroid-refractory ulcerative colitis, rescue therapy with infliximab has become a therapeutic option in patients facing colectomy. Data on efficacy and safety in this setting are sparse....

  4. Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease

    Directory of Open Access Journals (Sweden)

    Junko Ikewaki

    2010-06-01

    Full Text Available Aim: Infliximab, an anti-tumor necrosis factor (TNF-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease. Because it has been used clinically for a short time, information on its adverse effects is limited. We report a patient who developed cystoid macular edema (CME following infliximab use for uveoretinitis associated with Behçet’s disease. Case Report: A 27-year-old man had refractory uveoretinitis and neuro-Behçet’s disease, and intravenous infliximab was administered. Results: One day after infliximab infusion, the patient complained of a decrease in the vision in his left eye. The visual acuity had decreased from 1.2 to 0.5. Daily optical coherence tomographic evaluations showed a progressive worsening of the CME, and fluorescein angiography showed a typical staining with a cystic pattern. Two weeks later, the height of CME appeared to reach a maximum level and thereafter gradually resolved in spite of the continuation of infliximab administration. The visual acuity improved while the patient was treated with repeated subtenon injections of steroids in addition to continuation of infliximab and finally increased from 0.15 to 1.2. Conclusions: Although the mechanism of CME is not known, clinicians should be aware that infliximab therapy might cause a development and worsening of CME. Thus, it is crucial to rule out preexisting abnormalities in the macula prior to commencing infliximab infusion.

  5. [Treatment of patients with severe glucocorticoid-refractory ulcerative colitis: cyclosporine or infliximab?

    NARCIS (Netherlands)

    Lowenberg, M.; Boer, N.K. de; Dewint, P.; Hoentjen, F.

    2013-01-01

    - Cyclosporine and infliximab are so-called 'rescue-therapies' as last resort for the treatment of patients with severe glucocorticoid-refractory ulcerative colitis.- A recent study found that cyclosporine and infliximab are similar in terms of efficacy in the treatment of patients with severe ulcer

  6. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited

    NARCIS (Netherlands)

    de Bie, C. I.; Kindermann, A.; Kokke, F. T. M.; Damen, G. M.; Kneepkens, C. M. F.; van Rheenen, P. F.; Schweizer, J. J.; Hoekstra, J. H.; Norbruis, O. F.; Ten, W. E. Tjon A.; Vreugdenhil, A. C.; Deckers-Kocken, J. M.; Gijsbers, C. F. M.; Escher, J. C.; de Ridder, L.; Hummel, T.

    2011-01-01

    P>Background Infliximab is effective for induction and maintenance of remission in children with moderately to severely active Crohn's disease (CD). Aim To evaluate the long-term efficacy of infliximab treatment in paediatric CD. Methods In this observational, multicentre study, all paediatric CD pa

  7. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

    NARCIS (Netherlands)

    Crommelin, Heleen A; van der Burg, Leone M; Vorselaars, Adriane D M; Drent, Marjolein; van Moorsel, CHM; Rijkers, Ger T; Deneer, Vera H M; Grutters, JC

    2016-01-01

    BACKGROUND: Tumor necrosis factor-alpha (TNF-α) inhibitors are regarded as the third-line therapy in sarcoidosis, the first choice generally being infliximab. To date, data regarding response to adalimumab in sarcoidosis patients intolerant to infliximab are lacking. The objective of this retrospect

  8. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.

    NARCIS (Netherlands)

    Bie, C.I. De; Hummel, T.Z.; Kindermann, A.; Kokke, F.T.; Damen, G.M.; Kneepkens, C.M.; Rheenen, P.F. van; Schweizer, J.J.; Hoekstra, J.H.; Norbruis, O.F.; Tjon a Ren, W.E.; Vreugdenhil, A.C.; Deckers-Kocken, J.M.; Gijsbers, C.F.; Escher, J.C.; Ridder, L. de

    2011-01-01

    BACKGROUND: Infliximab is effective for induction and maintenance of remission in children with moderately to severely active Crohn's disease (CD). AIM: To evaluate the long-term efficacy of infliximab treatment in paediatric CD. METHODS: In this observational, multicentre study, all paediatric CD

  9. Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy.

    Science.gov (United States)

    Sipsas, Nikolaos V; Papaparaskevas, Joseph; Stefanou, Ioanna; Kalatzis, Konstantinos; Vlachoyiannopoulos, Panayiotis; Avlamis, Athina

    2006-08-01

    We report a case of septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. This is the first report of septic arthritis due to R. mucosa, and infliximab therapy might be a predisposing factor because this infection was never reported in the pre-anti-tumor necrosis factor alpha therapy period.

  10. New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris.

    Science.gov (United States)

    Mattox, Adam R; Chappell, Jeaneen A; Hurley, M Yadira

    2013-02-01

    Incidents of new-onset vitiligo attributed to infliximab therapy for rheumatoid arthritis and ulcerative colitis have been reported. Reported cases share a common theme in that symptoms manifested in close proximity to the initiation or significant dose increase of the medication. This case describes the presentation of infliximab-induced vitiligo in a patient using it for long-term treatment of stable pityriasis rubra pilaris. The patient was initiated and titrated to a stable dose of infliximab totaling 27 months' duration. He was able to achieve near-complete resolution of symptoms before developing depigmented patches consistent with vitiligo. Infliximab was discontinued. Tacrolimus 0.1% ointment and narrow-band ultraviolet B light successfully repigmented the patches. The association of discontinuing infliximab and resolution of vitiligo suggests infliximab had a role in this case. Though the mechanism of involvement is undetermined, infliximab may have induced an autoimmune process by paradoxically activating lymphocytes. Alternatively, infliximab antibodies may have led to the process by disrupting the normal balance of cytokines.

  11. Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.

    NARCIS (Netherlands)

    Vries, H.S. de; Heij, T. de; Schaap-Roelofs, H.M.J.; Morsche, R.H.M. te; Peters, W.H.M.; Jong, D.J. de

    2012-01-01

    BACKGROUND: Infliximab-induced hepatotoxicity is reported in several case studies involving patients with inflammatory bowel disease (IBD) and a direct hepatotoxic effect has been proposed. OBJECTIVE: The aim of this study was to determine the direct in vitro toxicity of infliximab. As a proof of

  12. I bad med Picasso

    DEFF Research Database (Denmark)

    Tanggaard, Lene; Stadil, Christian Nicolas

    Alle er kreative! I denne bog viser Lene Tanggaard (professor i kreativitet) og Christian N. Stadil (ejer af bl.a. Hummel), at alle kan blive endnu mere kreative. De har interviewet en række af Danmarks mest kreative mennesker, for at finde ud af, hvordan de gør. Picasso gik i bad, når han skulle...... få nye ideer. I bogen hører du om Ingolf Gabolds blå elefanter, Kenneth Bagers bad, Bjarke Ingels visioner, René Redzepis lørdagssessioner, Jørgen Leth gåture og Søren Rasteds tvivl. Du får inspiration til at udfordre dig selv og arbejde med din egen kreativitet....

  13. I bad med Picasso

    DEFF Research Database (Denmark)

    Tanggaard, Lene; Stadil, Christian Nicolas

    Alle er kreative! I denne bog viser Lene Tanggaard (professor i kreativitet) og Christian N. Stadil (ejer af bl.a. Hummel), at alle kan blive endnu mere kreative. De har interviewet en række af Danmarks mest kreative mennesker, for at finde ud af, hvordan de gør. Picasso gik i bad, når han skulle...... få nye ideer. I bogen hører du om Ingolf Gabolds blå elefanter, Kenneth Bagers bad, Bjarke Ingels visioner, René Redzepis lørdagssessioner, Jørgen Leth gåture og Søren Rasteds tvivl. Du får inspiration til at udfordre dig selv og arbejde med din egen kreativitet....

  14. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients

    DEFF Research Database (Denmark)

    Pedersen, N.; Duricova, D.; Lenicek, M.

    2010-01-01

    last intended infusion: prolonged response (maintenance of complete/partial response), infliximab dependency (relapse requiring repeated infusions to regain complete/partial response or need of infliximab > 12 months to sustain response). Results Forty-seven percent obtained prolonged response, 29...... on maintenance versus on demand regime was 33 and 31%, respectively (P = 0.63). No relevant clinical or genetic predictors were identified. Conclusion The infliximab dependency response seems to be equivalent to the prolonged response in adult CD patients when comparing surgery rates. Eur J Gastroenterol Hepatol......Background Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. Aim To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic...

  15. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

    DEFF Research Database (Denmark)

    Denton, C P; Engelhart, M; Tvede, N

    2008-01-01

    AIM: The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: A 26-week open-label pilot study in which 16 cases of dcSSc received five infusions of infliximab (5 mg...... of type I collagen by dermal fibroblasts was reduced at 26 weeks compared with baseline (p = 0.02). There were no deaths during the study and no suspected unexpected serious adverse reactions. 21 serious adverse events (AE) occurred in seven subjects, mostly attributable to dcSSc. 127 distinct AE occurred...... in 16 subjects. Of these, 19 AE (15%) were probably or definitely related to infliximab treatment. Eight (50%) patients prematurely discontinued infliximab. Anti-infliximab antibodies developed during the study in five subjects and were significantly associated with suspected infusion reactions (p = 0...

  16. Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

    NARCIS (Netherlands)

    Bemt, B.J.F van den; Broeder, A. den; Wolbink, G.J.; Hekster, Y.A.; Riel, P.L. van; Benraad, B.; Hoogen, F.H. Van den

    2011-01-01

    BACKGROUND: This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and/or detectable anti-infliximab levels. METHODS:

  17. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness

    Institute of Scientific and Technical Information of China (English)

    John; McConnell; Simona; Parvulescu-Codrea; Brian; Behm; Beth; Hill; Elizabeth; Dunkle; Karen; Finke; Kathryn; Snyder; Anne; Tuskey; Debbie; Cox; Beth; Woodward

    2012-01-01

    AIM:To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease(IBD).METHODS:Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min.Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions.To be eligible for the study,patients needed a minimum of four prior infusions.An initial infusion of 90-min was given to each patient;those tolerating the accelerated infusion were transitioned to a 60-min infusion protocol at their next and all subsequent visits.Any patient having significant infusion reactions would be reverted to the standard 120-min protocol.A change in a patient’s dose mandated a single 120-min infusion before accelerated infusions could be administered again.RESULTS:The University of Virginia Medical Center’s Institutional Review Board approved this study.Fifty IBD patients treated with infliximab 5mg/kg,7.5mg/kg and 10mg/kg were offered accelerated infusions.Forty-six patients consented to participate in the study.Nineteen(41.3%) were female,five(10.9%) were African American and nine(19.6%) had ulcerative colitis.The mean age was 42.6 years old.Patients under age 18 were excluded.Ten patients used immunosuppressive drugs concurrently out of which six were taking azathioprine,three were taking 6-mercaptopurine and one was taking methotrexate.One of the 46 study patients used corticosteroid therapy for his IBD.Seventeen of the patients used prophylactic medications prior to receiving infusions;six patients received corticosteroids as pre-medication.Four patients had a history of distant transfusion reactions to infliximab.These reactions included shortness of breath,chest tightness,flushing,pruritus and urticaria.These patients all took prophylactic medications before receiving infusions.46 patients(27 males and 19 females) received a total of fifty 90-min infusions and ninety

  18. Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.

    Science.gov (United States)

    Vegh, Zsuzsanna; Kurti, Zsuzsanna; Lakatos, Peter L

    2017-01-01

    Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.

  19. Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis

    Directory of Open Access Journals (Sweden)

    Richard Hariman

    2016-01-01

    Full Text Available Eosinophilic fasciitis (EF is a rare disorder involving chronic inflammation of the fascia and connective tissue surrounding muscles, nerves, and blood vessels. While its pathogenesis is not entirely understood, this disorder is thought to be autoimmune or allergic in nature. We present here a case of a 59-year-old male who developed peripheral eosinophilia and subsequent eosinophilic fasciitis during treatment with infliximab. To our knowledge, eosinophilic fasciitis has not been previously described in patients during treatment with an inhibitor of tumor necrosis factor α.

  20. Med patientens øjne

    DEFF Research Database (Denmark)

    2008-01-01

    Med patientens øjne viser patientens møde med sundhedsvæsenet på en dårlig dag og på en god dag. Omhandler kommunikation, medinddragelse, kontinuitet samt eksempler på intern og ekstern service. Indeholder CD-rom med brugerguide, forslag til 3 undervisningslektion incl. powerpointshow Medforfattere......: Anne Kragh-Sørensen, Birte Hagen, Katja Holm Hansen, Helle Vagner...

  1. Mødet med Nanoscience

    DEFF Research Database (Denmark)

    Holmegaard, Henriette Tolstrup; Malm, Rie Hjørnegaard; Madsen, Lene Møller

    Formålet med undersøgelsen er at undersøge de studerendes møde med studiet, deres integration på studiet og de studerendes overvejelser om at blive eller forlade studiet. Undersøgelsen formidler de studerendes perspektiv på første studieår på nanoscience og bidrager med input, der kan bruges...

  2. Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis

    Directory of Open Access Journals (Sweden)

    Elalouf O

    2015-11-01

    Full Text Available Ofir Elalouf, Ori Elkayam Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel Abstract: The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS. The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiological response. The general consensus of this literature search was that infliximab is highly efficacious in the treatment of AS. Most studies have demonstrated good clinical outcomes after 3 years of treatment, as measured by Spondyloarthritis International Society response in 75%–85% of treated AS patients. Reports on the long-term effects of infliximab as documented by radiological findings, however, are controversial. While some studies reported a similar progression rate as that of the historical OASIS cohort, others have suggested that infliximab may halt new bone formation. The long-term safety of infliximab is well known, mainly from data stored in national registries. While it has been suggested that side effects of infliximab may be fewer in AS compared to rheumatoid arthritis, data on this issue are sparse, with most of the information on long-term safety pertaining to rheumatoid arthritis. It can however be concluded that the long-term efficacy of infliximab is apparently maintained in AS and with an acceptable safety profile. Keywords: spondylitis, long-term efficacy, safety, TNFα blockers

  3. [Drug-induced alveolitis associated with infliximab/azathioprine therapy].

    Science.gov (United States)

    El-Hag, K; Dercken, H-G; Prenzel, R; Hölzle, E

    2008-04-01

    TNF-alpha is known to play a decisive role as a pro-inflammatory cytokine in several autoimmune conditions. Its neutralisation by TNF-alpha antagonists such as infliximab (Remicade), a chimeric monoclonal anti-TNF-alpha antibody, may be beneficial in patients with active disease. These anticytokine drugs have been approved and are being increasingly used in the therapy of rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthropathy and generalised psoriasis after established treatments have failed. Whenever therapy options are few, TNF-alpha antagonists are regarded as an effective, relatively safe and generally well-tolerated alternative, even if there is no detailed knowledge of their safety profile and possible long-term adverse events. In the respiratory tract an increased risk of viral, (myco-)bacterial, fungal and opportunistic infections has been observed. Furthermore, rare cases of severe fibrosing alveolitis in patients with concomitant immunosuppressant therapy or underlying lung disease have been reviewed recently. We present a case of drug-induced alveolitis following infliximab and azathioprine for the treatment of severe, generalised psoriasis and atopic eczema without pre-existing lung disease. Withdrawal of both drugs achieved clinical and functional stabilisation, and the addition of prednisolone resulted in a rapid improvement. As the pathophysiology of the pulmonary insult is unknown and since there are potentially serious adverse effects, we advise caution and close screening before and after initiation of TNF-alpha blockade, especially in patients with an underlying lung disease or with a combination of pneumotoxic agents.

  4. The role of infliximab on paracetamol-induced hepatotoxicity in rats.

    Science.gov (United States)

    Ferah, Irmak; Halici, Zekai; Bayir, Yasin; Demirci, Elif; Unal, Bunyami; Cadirci, Elif

    2013-06-01

    Paracetamol has a reasonable safety profile when consumed in therapeutic doses. However, it could induce hepatotoxicity and even acute liver failure when taken at an overdose. Infliximab is tumor necrosis factor alpha (TNF-α) inhibitor agent, which has been developed as a therapeutic agent for TNF-α-mediated disease. It acts by binding and neutralizing TNF. The aim of our study was to evaluate the hepatoprotective activity of infliximab on paracetamol-induced hepatotoxicity and to understand the relationship between the TNF-α and paracetamol-induced liver injury. Fifty-six rats were divided into eight groups as each composed of seven rats: (1) intact, (2) 7 mg/kg infliximab, (3) 140 mg/kg NAC, (4) 2 g/kg paracetamol, (5) 2 g/kg paracetamol + 140 mg/kg NAC, (6) 2 g/kg paracetamol + 3 mg/kg infliximab, (7) 2 g/kg paracetamol + 5 mg/kg infliximab and (8) 2 g/kg paracetamol + 7 mg/kg infliximab groups. Liver function tests including lipid peroxidation levels were analyzed and histopathological changes of liver were also observed. There were statistically significant increases in the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), levels of TNF-α and malondialdehyde (MDA) and decreases in the activity of superoxide dismutase (SOD) and level of glutathione (GSH) in the group treated with paracetamol. Infliximab administration dramatically reduced serum ALT, AST and TNF-α level. Also, it restored GSH, SOD and decreased MDA levels in liver. Liver histopathological examination showed that infliximab administration antagonized paracetamol-induced liver pathological damage. The results of present study suggest that infliximab has significant hepatoprotective activity on paracetamol-induced hepatotoxicity.

  5. Videntransformationer i forbindelsen med intrapreneurskab

    DEFF Research Database (Denmark)

    Nielsen, Anders Paarup

    2006-01-01

    Intrapreneurskab kan være en vigtig faktor i forbindelse med udvikling af ny viden for virksomheden. Intrapreneurskab kan derudover også spille en central rolle i forbindelse med transformationen af allerede eksisterende viden i virksomheden. Videntransformation er vigtig, idet denne muliggør en ...

  6. Med det sociale som designmateriale

    DEFF Research Database (Denmark)

    Brandt, Eva; Binder, Thomas

    2016-01-01

    Samarbejde, samskabelse og social nysgerrighed er i dag en præmis for den nyskabende designer. Det sociale er det nye designmateriale som unge designere giver sig i kast med når f.eks. Emmy Linde samarbejder med plejehjemsbeboere, deres pårørende, plejepersonale og fysioterapeuter for at designe ...

  7. Sygeplejersken skal tale med selvmordstruede

    DEFF Research Database (Denmark)

    Jensen, Inger; Bech, Søren

    2005-01-01

    Dødstanker. Hvert år tager omkring 730 mennesker i Danmark deres eget liv, mens 10 gange så mange forsøger på det. Sygeplejersker kan med en aktiv indsats være med til at forebygge problemet....

  8. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.

    Science.gov (United States)

    Vitale, David S; Greenley, Rachel N; Lerner, Diana G; Mavis, Alisha M; Werlin, Steven L

    2015-10-01

    The aims of the study were to describe infliximab adherence in a pediatric inflammatory bowel disease cohort, to identify demographic and disease factors associated with adherence, and to examine differences in acute care use among adherent and nonadherent patients. Charts of patients who received infliximab at the Children's Hospital of Wisconsin (CHW) between October 2010 and October 2012 were retrospectively reviewed. A total of 151 patients met the inclusion criteria; 91.4% of the patients were adherent. Nonadherent patients had more emergency room visits and hospitalizations than adherent patients. The study is the first to show high adherence rates to infliximab in a pediatric cohort.

  9. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection - Reply

    Directory of Open Access Journals (Sweden)

    M. Galeazzi

    2011-09-01

    Full Text Available Il trattamento del morbo di Crohn con infliximab rappresenta una importante terapia nei pazienti con la forma fistolizzata della malattia, refrattaria al trattamento con farmaci convenzionali. Tuttavia esistono preoccupazioni nell’usare questo farmaco in pazienti con concomitante infezione cronica da HCV. Tali preoccupazioni sono determinate dal rischio teorico di un accelerato scompenso epatico dovuto all’effetto immunomodulante dell’Infliximab. Noi descriviamo il caso di un paziente affetto da morbo di Crohn e concomitante infezione attiva da epatite C sottoposto a terapia con Infliximab che non ha mostrato alcun peggioramento della funzionalità epatica e dei livelli di carica virale testati con PCR.

  10. Infliximab dependency in a national cohort of children with Crohn's disease

    DEFF Research Database (Denmark)

    Wever, Anne Vibeke; Riis, Lene; Vind, Ida

    2006-01-01

    to 24 CD patients (9 male/15 female) aged median 15.4 (range 9.8-18.6) years with a median disease duration of 26 (range 0.7-93) months and a median number of infusions of 6 (range 2-11). Five milligrams of infliximab per kilogram infusions were given intravenously. Immediate response was as follows: 8...... of symptoms requiring reinfusions of infliximab to regain CR or PR, and 6 (25%) had NR. Six (25%) patients needed surgery during or after treatment with infliximab. Side effects were seen in four (17%) patients. No serious events were noted. CONCLUSION: Seventy-one percent of the children appeared to benefit...

  11. Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease

    Science.gov (United States)

    Concepcion, Orestes; Schlachterman, Alexander; Glover, Sarah; Forsmark, Christopher Y.

    2016-01-01

    We present a 29-year-old male with Crohn's disease who developed chronic inflammatory demyelinating polyneuropathy (CIDP) related to infliximab therapy. He developed lower extremity weakness and dysesthesia 3 weeks after a fourth infliximab dose. Laboratory examination revealed an elevated cerebrospinal fluid protein without pleocytosis. The patient initially responded to plasmapheresis therapy with marked symptomatic improvement, but relapsed and was refractory to subsequent treatments with plasmaphereisis, intravenous immunoglobulin, and glucocorticoids. While a causal relationship between infliximab and CIDP cannot be proven, clinicians should monitor Crohn's disease patients who are receiving TNF-α antagonists for neurologic symptoms suggestive of demyelinating disease. PMID:27144200

  12. A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide.

    Science.gov (United States)

    Ferguson, Ian D; Weiser, Peter; Torok, Kathryn S

    2015-01-01

    Herein we report successful treatment of an adolescent Caucasian female with severe progressive localized scleroderma (mixed subtype, including generalized morphea and linear scleroderma of the trunk/limb) using infliximab and leflunomide. The patient demonstrated improvement after the first 9 months of therapy based on her clinical examination, objective measures, and patient and parent global assessments. Infliximab is a potential treatment option for pediatric localized scleroderma patients who have progression of disease or who are unable to tolerate the side effect profile of more standard systemic therapy. Larger longitudinal studies or case series are needed to confirm and further investigate infliximab's role in localized scleroderma.

  13. Inflammatory bowel disease of the lung: The role of infliximab?☆

    Science.gov (United States)

    Hayek, Adam J.; Pfanner, Timothy P.; White, Heath D.

    2015-01-01

    Pulmonary extra-intestinal manifestations (EIM) of inflammatory bowel disease are well described with a variable incidence. We present a case of Crohn's disease with pulmonary EIM including chronic bronchitis with non-resolving bilateral cavitary pulmonary nodules and mediastinal lymphadenopathy successfully treated with infliximab. Additionally, we present a case summary from a literature review on pulmonary EIM successfully treated with infliximab. Current treatment recommendations include an inhaled and/or systemic corticosteroid regimen which is largely based on case reports and expert opinion. We offer infliximab as an adjunctive therapy or alternative to corticosteroids for treatment of inflammatory bowel disease related pulmonary EIM. PMID:26236612

  14. Tuberculose esplênica durante tratamento de psoríase com infliximabe Splenic tuberculosis during psoriasis treatment with infliximab

    Directory of Open Access Journals (Sweden)

    Gleyce Tavares de Melo Fortaleza

    2009-08-01

    Full Text Available A psoríase é doença crônica que afeta a pele e, eventualmente, as articulações. A terapia biológica age bloqueando citocinas inflamatórias implicadas na patogênese da doença, dentre elas o fator de necrose tumoral alfa. Este também tem papel na defesa do hospedeiro contra o Mycobacterium tuberculosis. Relata-se um caso de psoríase com boa resposta ao infliximabe, porém com desenvolvimento de tuberculose esplênica durante o tratamento.Psoriasis is a chronic inflammatory disease affecting the skin and occasionally the joints. The biological agents have been engineered to target a specific step in the inflammatory cascade that leads to psoriasis, including tumor necrosis factor, which has a central role in the host defense against Mycobacterium tuberculosis. This is a case report about a psoriatic patient who presented splenic tuberculosis during treatment with infliximab.

  15. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product.

    Science.gov (United States)

    Abdalla, Abuelmagd; Byrne, Niamh; Conway, Richard; Walsh, Thomas; Mannion, Geraldine; Hanly, Michael; O'Sullivan, Miriam; Curran, Ann Maria; Carey, John J

    2017-01-01

    To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory arthritis switched from reference product in our center. In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval. Around 34 patients with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12.9), mean disease duration 14.79 years (9.7), median duration on infliximab 57 months, and two-thirds on oral disease-modifying antirheumatic drugs. There was no difference in efficacy or safety in the first 6 months of therapy. By the end of 2015, the mean follow-up on biosimilar infliximab was 15.8 (standard deviation=6.3) months. Our results showed no significant difference in Health Assessment Questionnaire score, patient global assessment of disease activity, number of disease flares, or the medication dose between the originator and the biosimilar infliximab. However, reported pain and C-reactive protein values were significantly higher during the longer follow-up period (p=0.043, 0.001 respectively). There was no significant difference in the number of adverse events or infusion reactions during follow-up periods. Only five (14.7%) patients discontinued the biosimilar infliximab. Our patients experienced similar efficacy and safety for managing their arthritis with the biosimilar infliximab as the reference product infliximab, but at a much lower cost.

  16. Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante

    Directory of Open Access Journals (Sweden)

    M. Luna-Chadid

    2004-06-01

    Full Text Available Objective: to evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. Methods: consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from base-line in the number of draining fistulae. Complete response was defined as the closure of all fistulae. The influence of different variables on the efficacy of infliximab was evaluated. Results: 108 patients were included. The disease was inflammatory plus fistulizing in 18% and only fistulizing in 82%. After the third infusion of infliximab the response was partial in 26% and complete in 57%. Response (% rates (partial/complete depending on fistula location were: enterocutaneous (25/68%, perianal (35/60%, rectovaginal (36/64%, and enterovesical (20/40%. None of the studied variables (including concomitant immunosuppressive therapy correlated with efficacy of infliximab in the multivariate analysis. Incidence of adverse effects (21% depending on the dose of infliximab was: first dose (5.6%, second (7.4%, and third (11.1%. Conclusions: infliximab is an efficacious treatment for fistulizing Crohn's disease. Partial response was achieved in approximately one third of the patients, and complete response in more than half. No studied variable was predictive of response. Adverse effects were relatively infrequent and mild.Objetivo: evaluar la eficacia e identificar los factores predictivos de respuesta al tratamiento con infliximab en la enfermedad de Crohn fistulizante. Métodos: se realizó un estudio prospectivo en pacientes con enfermedad de Crohn fistulizante que recibían tratamiento con infliximab. La respuesta parcial se definió como una reducción del 50% o más de la línea base en el número de fístulas que drenan. La respuesta completa se definió como el cierre de todas las fístulas. Se evaluó la influencia de diferentes variables sobre la

  17. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.

    Science.gov (United States)

    Iqbal, Marvi; Kolodney, Michael S

    2005-05-01

    Acne fulminans is a syndrome of sudden onset hemorrhagic and ulcerative acne involving the back, chest, and face combined with systemic symptoms. It can be the dermatologic manifestation of the synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome. Current therapy for acne fulminans consists of wound care, topical and systemic corticosteroids, isotretinoin, and nonsteroidal anti-inflammatory drugs (NSAIDs). Infliximab, a recently developed monoclonal antibody against tumor necrosis factor-alfa, has shown efficacy in the treatment of psoriatic arthritis and ankylosing spondylitis both of which share clinical similarities to the SAPHO syndrome. We report the case of a patient with the SAPHO syndrome and acne fulminans who was treated with infliximab. Ten months after initiating therapy with infliximab, the area of the patient's ulcerative lesions was reduced by 70%. Infliximab might be considered as a treatment option for patients with acne fulminans unresponsive to conventional therapies.

  18. Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative Colitis.

    Science.gov (United States)

    Hoffmann, Jochen; Hadaschik, Eva; Enk, Alexander; Stremmel, Wolfgang; Gauss, Annika

    2015-01-01

    Linear IgA bullous disease (LABD) is a rare vesiculobullous autoimmune skin disorder whose etiology and pathogenesis are not completely understood. Its occurrence has been related to malignancies, inflammatory diseases and several drugs. This report describes a 49-year-old Caucasian male with a 14-year history of ulcerative colitis who received infliximab to treat the refractory course of his bowel disease. During induction therapy with infliximab, he developed LABD. Treatment with infliximab was discontinued, and the skin lesions were successfully treated with oral steroids and dapsone. Considering the close chronological relation between administration of the tumor necrosis factor-α inhibitor and onset of the skin disease, we hypothesize that this is the first reported case of infliximab-induced LABD. Similar to psoriasis, it may represent a 'paradoxical' autoimmune reaction triggered by anti-tumor necrosis factor-α therapy.

  19. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis

    DEFF Research Database (Denmark)

    Eng, Grith; Stoltenberg, Michael B; Szkudlarek, Marcin;

    2013-01-01

    To summarize the empirical evidence regarding the effect of treatment intensification on clinical outcomes in patients with rheumatoid arthritis treated with one of the TNF-α-inhibitors, adalimumab, etanercept or infliximab.......To summarize the empirical evidence regarding the effect of treatment intensification on clinical outcomes in patients with rheumatoid arthritis treated with one of the TNF-α-inhibitors, adalimumab, etanercept or infliximab....

  20. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis

    Science.gov (United States)

    Nishida, Yu; Yamagami, Hirokazu; Yukawa, Tomomi; Otani, Koji; Nagami, Yasuaki; Tanaka, Fumio; Taira, Koichi; Kamata, Noriko; Tanigawa, Tetsuya; Shiba, Masatsugu; Watanabe, Kenji; Watanabe, Toshio; Tominaga, Kazunari; Fujiwara, Yasuhiro

    2017-01-01

    Objectives Neutrophil-to-lymphocyte ratio (NLR) has been used to determine the outcome in malignancies and coronary heart disease. Some reports considered the value of NLR as a predictor of response to infliximab in patients with Crohn’s disease or rheumatoid arthritis; however, no similar studies have been reported for ulcerative colitis (UC). This study aimed to evaluate the clinical significance of the baseline NLR in patients with UC treated by infliximab. Materials and Methods Patients with moderate-to-severe active UC who received the first infliximab infusion in our hospital between 2010 and 2015, who showed clinical response during the induction period, were retrospectively evaluated for long-term outcomes and risk factors for loss of response (LOR) during infliximab maintenance therapy. Baseline inflammatory markers including NLR were measured within one week before the initiation of infliximab. Results Fifty-nine patients with moderate-to-severe active UC started treatment with infliximab and 37 patients (62.7%) experienced clinical response after induction therapy. Fourteen of 37 patients on maintenance therapy lost the response during follow-up. Baseline NLR of patients with LOR was significantly higher than in patients with sustained response. The NLR cut-off value of 4.488 was predictive of LOR, using receiver operating characteristic analysis (sensitivity: 78.6%, specificity: 78.3%). A univariate analysis revealed a significant relationship between relapse-free survival and the NLR (P = 0.018). Multivariate analysis indicated the NLR as an independent prognostic factor for LOR (hazard ratio = 3.86, 95% confidence interval: 1.20–12.4, P = 0.023). Conclusions Baseline NLR is a useful prognostic marker in patients with moderate-to-severe active UC treated with infliximab, and may contribute to appropriate use of infliximab. PMID:28076386

  1. Efficacy of early treatment with infliximab in pediatric Crohn’s disease

    Institute of Scientific and Technical Information of China (English)

    Jong; Seung; Lee; Jee; Hyun; Lee; Ji; Hyuk; Lee; Hye; Jin; Lee; Mi; Jin; Kim; Hae; Jeong; Lee; Yon; Ho; Choe

    2010-01-01

    AIM: To investigate the effectiveness of early infliximab use for induction and maintenance therapy in pediatric Crohn’s disease. METHODS: We performed a retrospective chart review of 36 patients with Crohn’s disease. Ten patients (group A) were treated with mesalamine after induction therapy with oral prednisolone, and 13 patients (group B) were treated with azathioprine after induction therapy with oral prednisolone. Thirteen patients (group C) received infliximab and azathioprine for induction and mainte...

  2. Cystic fibrosis and Crohn’s disease:Successful treatment and long term remission with infliximab

    Institute of Scientific and Technical Information of China (English)

    Francesca; Vincenzi; Barbara; Bizzarri; Alessia; Ghiselli; Nicola; de; Angelis; Fabiola; Fornaroli; Gian; Luigi; de; Angelis

    2010-01-01

    The association of cystic fibrosis and Crohn's disease (CD) is well known, but to date, there are very few cas-es in the literature of patients suffering from mucovisci-dosis who have required treatment with infliximab. We report the case of a 23-year-old patient suffering from cystic fibrosis and severe CD treated successfully with infliximab without any infective complications or wors-ening of the pulmonary disease and with a long term (2 years) complete remission.

  3. Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update

    OpenAIRE

    Yuan Guo; Nonghua Lu; Aiping Bai

    2013-01-01

    The pathogenesis and treatment of inflammatory bowel disease (IBD) have been recently advanced, while it is still challenged with high morbidity and poor prognosis. Infliximab, a monoclonal antibody of tumor necrosis factor (TNF), has emerged as an efficient treatment with many clinical benefits such as quick disease activity reduction and IBD patient life quality improvement. However, the biological effects of infliximab on IBD need to be elucidated. This paper reviewed the clinical use and ...

  4. A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide

    OpenAIRE

    Ferguson, Ian D; Weiser, Peter; Torok, Kathryn S

    2015-01-01

    Herein we report successful treatment of an adolescent Caucasian female with severe progressive localized scleroderma (mixed subtype, including generalized morphea and linear scleroderma of the trunk/limb) using infliximab and leflunomide. The patient demonstrated improvement after the first 9 months of therapy based on her clinical examination, objective measures, and patient and parent global assessments. Infliximab is a potential treatment option for pediatric localized scleroderma patient...

  5. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.

    Directory of Open Access Journals (Sweden)

    Kacper A Wojtal

    Full Text Available BACKGROUND: Tumor necrosis factor (TNF is an important cytokine in the pathogenesis of inflammatory bowel disease (IBD. Anti-TNF antibodies have been successfully implemented in IBD therapy, however their efficacies differ among IBD patients. Here we investigate the influence of CD64 Fc receptor on the inhibitory activity of anti-TNFs in cells of intestinal wall. METHODS: Intestinal cell lines, monocytes/macrophages and peripheral blood mononuclear cells (PBMCs were used as models. The efficacies of adalimumab, infliximab and certolizumab-pegol were assessed by RT-PCR for target genes. Protein levels and localizations were examined by Western blotting and immunofluorescence. Antibody fragments were obtained by proteolytic digestion, immunoprecipitation and protein chip analysis. Knock-down of specific gene expression was performed using siRNAs. RESULTS: Infliximab had limited efficacy towards soluble TNF in cell types expressing Fc gamma receptor CD64. Both adalimumab and infliximab had lower efficacies in PBMCs of IBD patients, which express elevated levels of CD64. Infliximab-TNF complexes were more potent in activating CD64 in THP-1 cells than adalimumab, which was accompanied by distinct phospho-tyrosine signals. Blocking Fc parts and isolation of Fab fragments of infliximab improved its efficacy. IFN-γ-induced expression of CD64 correlated with a loss of efficacy of infliximab, whereas reduction of CD64 expression by either siRNA or PMA treatment improved inhibitory activity of this drug. Colonic mRNA expression levels of CD64 and other Fc gamma receptors were significantly increased in the inflamed tissues of infliximab non-responders. CONCLUSIONS: CD64 modulates the efficacy of infliximab both in vitro and ex vivo, whereas the presence of this receptor has no impact on the inhibitory activity of certolizumab-pegol, which lacks Fc fragment. These data could be helpful in both predicting and evaluating the outcome of anti-TNF therapy in

  6. [High frequency of cutaneous adverse effects under infliximab. Geneva experience, 1999-2008].

    Science.gov (United States)

    Seydtaghia, Floriane; De Saussure, Philippe; Hadengue, Antoine

    2011-03-16

    Geneva experience, 1999-2008 Infliximab has been used for 10 years in the treatment of chronic inflammatory bowel diseases in the gastroenterology and hepatology department at the University Hospitals of Geneva. This retrospective study shows the follow-up of these patients treated with infliximab and reveals a high rate of cutaneous adverse events, which, although often mild, can sign a definitive intolerance to treatment.

  7. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis

    DEFF Research Database (Denmark)

    Sjöberg, Mats; Walch, Andrea; Meshkat, Mina

    2012-01-01

    Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC). There are no data comparing the efficacy of these two alternatives.......Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC). There are no data comparing the efficacy of these two alternatives....

  8. Er det forskningsmessig interessant å koble data fra Medisinsk fødselsregister med data fra Kreftregisteret?

    Directory of Open Access Journals (Sweden)

    Steinar Tretli

    2009-10-01

    Full Text Available Medisinsk fødselsregister og Kreftregisteret inneholder personidentifiserbare data som via fødselsnummeret kan kobles sammen innenfor de rammer som lovverket gir. Denne sammenkoblingen gir oss interessante muligheter til å studere fødselskarakteristikas betydning for risikoen for å få kreft senere i livet. På den måten vil vi også kunne få informasjon om hvilke mekanismer som er med å påvirke vår kreftrisiko. Det gir oss også muligheter til å studere hvilke konsekvenser kreftforekomst med påfølgende behandling kan ha både for senere svangerskap og barn som blir født.Per 2006 er det akkumulert 12 443 krefttilfeller blant de barn som er registrert i Medisinsk fødselsregister siden det ble etablert i 1967. Selv om dette er et betydelig antall krefttilfeller, er de fordelt på mange krefttyper, noe som har begrenset nytteverdien i kreftforskningen så langt. Imidlertid vil forskningsmuligheteneøke med alderen til registeret. Også andre nordiske land har muligheter for slike koblinger, og til sammen gir dette unike muligheter til å gjennomføre interessant forskning.I denne fremstillingen gis en kort presentasjon av gjennomførte og pågående vitenskapelige studier basert på sammenkobling mellom data fra Medisinsk fødselsregister og Kreftregisteret.

  9. Er det forskningsmessig interessant å koble data fra Medisinsk fødselsregister med data fra Kreftregisteret?

    Directory of Open Access Journals (Sweden)

    Steinar Tretli

    2007-01-01

    Full Text Available Medisinsk fødselsregister og Kreftregisteret inneholder personidentifiserbare data som via fødselsnummeret kan kobles sammen innenfor de rammer som lovverket gir. Denne sammenkoblingen gir oss interessante muligheter til å studere fødselskarakteristikas betydning for risikoen for å få kreft senere i livet. På den måten vil vi også kunne få informasjon om hvilke mekanismer som er med å påvirke vår kreftrisiko. Det gir oss også muligheter til å studere hvilke konsekvenser kreftforekomst med påfølgende behandling kan ha både for senere svangerskap og barn som blir født.Per 2006 er det akkumulert 12 443 krefttilfeller blant de barn som er registrert i Medisinsk fødselsregister siden det ble etablert i 1967. Selv om dette er et betydelig antall krefttilfeller, er de fordelt på mange krefttyper, noe som har begrenset nytteverdien i kreftforskningen så langt. Imidlertid vil forskningsmuligheteneøke med alderen til registeret. Også andre nordiske land har muligheter for slike koblinger, og til sammen gir dette unike muligheter til å gjennomføre interessant forskning.I denne fremstillingen gis en kort presentasjon av gjennomførte og pågående vitenskapelige studier basert på sammenkobling mellom data fra Medisinsk fødselsregister og Kreftregisteret

  10. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report

    Directory of Open Access Journals (Sweden)

    Yoon Young Kyung

    2009-04-01

    Full Text Available Abstract Introduction The use of the drug infliximab for the treatment of patients with Crohn's disease can be complicated by tuberculosis. A paradoxical reaction during antituberculosis chemotherapy and immunologic reconstitution after discontinuation of infliximab can result in severe disseminated tuberculosis. Case presentation A 38-year-old Korean man with severe Crohn's disease presented with fever and diffuse abdominal pain. Infliximab had been started 2 months before admission. A chest X-ray and abdominal computed tomography scan revealed numerous miliary nodules in both lung fields and microabscesses in the spleen. Given the diagnosis of disseminated tuberculosis, the infliximab therapy was discontinued and antituberculosis therapy was promptly started. Over the next 3 months, the patient was diagnosed with tuberculosis lymphadenitis on a right supraclavicular lymph node and surgical excision of the lesion was performed. With the diagnosis of a paradoxical response, anti-tuberculous therapy was continued for 12 months. Conclusion Our case suggests that patients who develop tuberculosis after infliximab exposure are at an increased risk of developing a paradoxical reaction. The current recommendation of discontinuing infliximab during tuberculosis treatment should be re-evaluated.

  11. Høreapparat med identifikationsenhed

    DEFF Research Database (Denmark)

    2006-01-01

    Denne frembringelse vedrører et høreapparat, der omfatter en identifikationsenhed med en antenne tilpasset til at modtage et aktiveringssignal og til at sende et svarsignal samt med en signalgenerator tilpasset til at genere svarsignalet når aktiveret af aktiveringssignalet, og ligeledes vedrører...... denne frembringelse en høreapparatskanner, der omfatter en antenne tilpasset til at udsende et aktiveringssignal og til at modtage et svarsignal fra identifikationsenheden i høreapparatet....

  12. Role of scintigraphy with {sup 99m}Tc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis

    Energy Technology Data Exchange (ETDEWEB)

    Conti, F.; Ceccarelli, F.; Priori, R.; Iagnocco, A.; Valesini, G. [University of Rome, Rheumatology Unit, Faculty of Medicine and Dentistry, Rome (Italy); Malviya, G.; Signore, A. [University of Rome, Nuclear Medicine Unit, Faculty of Medicine and Psychology, Rome (Italy)

    2012-08-15

    The rationale for the present study was to evaluate the predictive role of {sup 99m}Tc-infliximab scintigraphy in therapy decision-making in patients with refractory monoarthritis and also candidates for intraarticular (IA) infliximab treatment. We studied 12 patients (5 with rheumatoid arthritis and 7 with spondyloarthropathy) with active monoarthritis (11 knees and 1 ankle) that had lasted for at least 3 months. Patients were evaluated clinically and ultrasonographically at baseline and 12 weeks after IA administration of infliximab. At the same time-points, {sup 99m}Tc-infliximab scintigraphy was performed: planar anterior and posterior images of arthritic joints were acquired at 6 and 20 h after injection and target-to-background (T/B) ratios were calculated. After treatment, a significant improvement in clinical and ultrasonographic parameters was recorded in six patients. Three patients had a partial response and three did not respond. Regarding scintigraphic evaluation, the T/B ratio analysis showed a significantly higher uptake in affected than in nonaffected joints before therapy (1.78 {+-} 0.46 vs. 1.29 {+-} 0.27, p = 0.006 at 6 h; 2.05 {+-} 0.50 vs. 1.41 {+-} 0.36 at 20 h, p = 0.002), and mean uptake at 20 h was also significantly higher than at 6 h (p = 0.0004). Scintigraphy showed a significant decrease in posttherapy T/B ratios of the affected joints (p = 0.0001 at 6 h and p = 0.0001 at 20 h), indicating a reduction in TNF into the affected joints. Most importantly, responders showed a significantly higher percentage increase in pretherapy uptake from 6 h to 20 h in the affected joints than nonresponders (p = 0.00001). The results of the present investigation suggest that {sup 99m}Tc-infliximab scintigraphy could be a useful tool to predict the clinical response to IA infliximab treatment in patients with refractory monoarthritis. (orig.)

  13. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

    OpenAIRE

    Kim, Eun Hye; Kim, Duk Hwan; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, Jae Hee

    2014-01-01

    Background/Aims In patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission. Here, we aimed to compare the efficacy of cyclosporine and infliximab. Methods Between January 1995 and May 2012, the medical records of 43 patients with corticosteroid-refractory UC who received either infliximab or cyclosporine as a rescue therapy at a tertiary care hospital in Korea were reviewed. Results Among the 43 pati...

  14. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation.

    Science.gov (United States)

    Arana, Alejandro; Allen, Sam; Burkowitz, Jörg; Fantoni, Valerio; Ghatnekar, Ola; Rico, María Teresa; Vanhaverbeke, Nathalie; Wentworth, Charles E; Brosa, Max; Arellano, Felix M

    2010-06-01

    The infliximab (Remicade; Schering-Plough, Kenilworth, NJ, USA) Risk Management Plan included the development, execution and tracking of an education programme directed towards prescribers of infliximab for patients with paediatric Crohn's disease (the Infliximab Paediatric Crohn's Disease Educational Plan). The programme content consisted of educational materials and communications aimed at educating prescribers on the risks associated with infliximab use. To evaluate the effectiveness of the risk minimization plan. Evaluation focused on two components: documentation of training of sponsors' personnel, and evaluation of awareness among prescribing physicians in European countries. Treating physicians, identified both independently of the sponsor (6 countries) and by the sponsor (24 countries), were surveyed using a structured questionnaire. Training of internal staff on the educational programme was performed and completed by every person designated an appropriate candidate for the programme in all European countries. The independent survey conducted in Germany, France, Italy, Spain, Sweden and the UK indicated that around 90% of the physicians were either paediatric gastroenterologists (57%) or paediatricians (33%). The great majority (96%) of the interviewed physicians were currently treating paediatric Crohn's disease, and most were currently using infliximab in their treatment of the disease. More specifically, 82% of gastroentrologists treating paediatric Crohn's disease were using infliximab; among paediatricians, the proportion was lower (42%). Ninety-six percent of paediatric gastroenterologists or gastroenterologists declared themselves aware of the benefits and risks of using infliximab for the treatment of paediatric Crohn's disease; in comparison, fewer paediatricians (82%) declared themselves aware of these benefits and risks. The majority initially gained awareness through congresses and workshops, and at the time of the survey only 25% declared that

  15. Uso de infliximab en pacientes de un centro reumatológico Use of infliximab in patients of a rheumatologic center

    OpenAIRE

    Ingrid Strusberg; Bertoli, Ana M.; Ruth C de Pizzolato; Gonzalo Fierro; Alberto M. Strusberg

    2005-01-01

    El objetivo de este estudio fue obtener información postmarketing sobre el uso de infliximab en un centro reumatológico de atención ambulatoria. Se realizó un análisis retrospectivo y prospectivo de las historias clínicas de pacientes con diagnóstico de artritis reumatoidea ( n=37 ), artritis psoriásica ( n=5 ), enfermedad mixta del tejido conectivo ( n=1 ) y espondilitis anquilosante ( n=2 ) que recibieron infliximab (3 mg / kg ) desde agosto de 2000 a junio de 2003. El análisis descriptivo ...

  16. Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

    NARCIS (Netherlands)

    Maas, A. van der; Bemt, B.J. van den; Wolbink, G.; Hoogen, F.H.J. van den; Riel, P.L. van; Broeder, A.A. den

    2012-01-01

    ABSTRACT: BACKGROUND: To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study METHODS: In a longitudinal, observational cohort of

  17. Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn’s Disease

    Science.gov (United States)

    Kulairi, Zain; Kam, Michael

    2017-01-01

    Crohn’s disease is characterized by inflammation of the mucosal lining of the gastrointestinal tract. Infliximab is a tumor necrosis factor-α inhibitor that has been associated with increased remission and decreased disease flare-ups. Biological agents such as infliximab have been associated with adverse events. We present a rare case of cardiac tamponade caused by infliximab treatment for Crohn’s disease in a 30-year-old female. She was treated with emergent pericardial window and drainage of pericardial fluid. Infliximab was discontinued, and serositis was treated with steroids. The patient was later successfully rechallenged with vedolizumab. PMID:28138445

  18. Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

    Science.gov (United States)

    Bruges-Armas, Jácome; Couto, Ana R.; Lima, Manuela; Rodrigues, Ana M.; Vastesaeger, Nathan; Brown, Matthew A.

    2014-01-01

    Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with infliximab, a TNF-α receptor antagonist, for nine years. Results. Treatment with infliximab resulted in major clinical and laboratory improvements without relevant side effects. Conclusions. These results suggest that infliximab may be an effective treatment of severe CPDD. PMID:25436167

  19. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

    Science.gov (United States)

    Kim, Eun Hye; Kim, Duk Hwan; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, Jae Hee

    2015-01-01

    Background/Aims In patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission. Here, we aimed to compare the efficacy of cyclosporine and infliximab. Methods Between January 1995 and May 2012, the medical records of 43 patients with corticosteroid-refractory UC who received either infliximab or cyclosporine as a rescue therapy at a tertiary care hospital in Korea were reviewed. Results Among the 43 patients, 10 underwent rescue therapy with cyclosporine and the remaining 33 patients received infliximab. A follow-up of 12 months was completed for all patients. The colectomy rate at 12 months was 30% and 3% in the cyclosporine and the infliximab groups, respectively (p=0.034). However, the Cox proportional hazard model indicated that the treatment of rescue therapy was not an independent associate factor for preventing colectomy (p=0.164). In the subgroup analysis, infliximab with azathioprine was superior to cyclosporine for preventing colectomy (hazard ratio of infliximab with azathioprine compared with cyclosporine only, 0.073; 95% confidence interval, 0.008 to 0.629). Conclusions No difference between infliximab and cyclosporine with respect to preventing colectomy was noted. However, infliximab with azathioprine may be more effective than cyclosporine alone for preventing colectomy. PMID:25473080

  20. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease

    Science.gov (United States)

    Oh, Eun Hye; Ko, Dae-Hyun; Seo, Hyungil; Chang, Kiju; Kim, Gwang-Un; Song, Eun Mi; Seo, Myeongsook; Lee, Ho-Su; Hwang, Sung Wook; Yang, Dong-Hoon; Ye, Byong Duk; Byeon, Jeong-Sik; Myung, Seung-Jae; Yang, Suk-Kyun; Park, Sang Hyoung

    2017-01-01

    AIM To investigate the clinical implications of infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATI) levels in Crohn’s disease (CD) patients in Asian countries. METHODS IFX-TL and ATI level were measured using prospectively collected samples obtained with informed consent from CD patients being treated at Asan Medical Center, South Korea. We analyzed the correlations between IFX-TLs/ATI levels and the clinical activity of CD (quiescent vs active disease) based on the CD activity index, C-reactive protein level, and physician’s judgment of patients’ clinical status at enrollment. The impact of concomitant immunomodulators was also investigated. RESULTS This study enrolled 138 patients with CD (84 with quiescent and 54 with active disease). In patients with quiescent and active diseases, the median IFX-TLs were 1.423 μg/mL and 0.163 μg/mL, respectively (P < 0.001) and the median ATI levels were 8.064 AU/mL and 11.209 AU/mL, respectively (P < 0.001). In the ATI-negative and -positive groups, the median IFX-TLs were 1.415 μg/mL and 0.141 μg/mL, respectively (P < 0.001). In patients with and without concomitant immunomodulator use, there were no differences in IFX-TLs (0.632 μg/mL and 1.150 μg/mL, respectively; P = 0.274) or ATI levels (8.655 AU/mL and 9.017 AU/mL, respectively; P = 0.083). CONCLUSION IFX-TL/ATI levels were well correlated with the clinical activity in South Korean CD patients. Our findings support the usefulness of IFX-TLs/ATI levels in treating CD patients receiving IFX in clinical practice. PMID:28293096

  1. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis

    Institute of Scientific and Technical Information of China (English)

    John K Triantafillidis; Helen Sotiriou; Apostolos E Papalois; Aikaterini Parasi; Emmanuel Anagnostakis; Stavros Burnazos; Aristofanis Gikas; Emmanuel G Merikas; Emmanuel Douzinas; Maria Karagianni

    2005-01-01

    AIM: To investigate the influence of infliximab (Remicade)on experimental colitis produced by 2,4,6,trinitrobenzene sulfonic acid (TNBS) in rats.METHODS: Thirty-six Wistar rats were allocated into four groups (three groups of six animals each and a fourth of 12 animals). Six more healthy animals served as normal controls (Group 5). Group 1:colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at a dose of 5 mg/kg BW; Group 2: colitis was induced and infliximab was subcutaneously administered at a dose of 10 mg/kg BW; Group 3: colitis was induced and infliximab was subcutaneously administered at a dose of 15 mg/kg BW; Group 4: colitis was induced without treatment with infliximab. Infliximab was administered on d 2-6. On the 7th d, all animals were killed. The colon was fixed in 10%buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. Tumor necrosis factor-alpha (TNF-α) and malondialdehyde (MDA) were also measured.RESULTS: Significant differences concerning the presence of reparable lesions and the extent of bowel mucosa without active inflammation in all groups of animals treated with infliximab compared with controls were found. Significant reduction of the tissue levels of TNF-α in all groups of treated animals as compared withthe untreated ones was found (0.47±0.44, 1.09±0.86,0.43±0.31 vs 18.73±10.53 respectively). Significant reduction in the tissue levels of MDA was noticed in group 1 as compared to group 4, as well as between groups 2 and 4.CONCLUSION: Subcutaneous administration of infliximab reduces the inflammatory activity as well as tissue TNF-α and MDA levels in chemical colitis in rats.Infliximab at a dose of 5 mg/kg BW achieves better histological results and produces higher reduction of the levels of TNF-α than at a dose of 10 mg/kg BW.Infliximab at a dose of 5 mg/kg BW produces

  2. Manual for procesorienteret musikterapi med personer med BPD

    DEFF Research Database (Denmark)

    Hannibal, Niels; Pedersen, Inge Nygaard; Bonde, Lars Ole

    2012-01-01

    Denne artikel introducerer et musikterapeutisk behandlingskoncept kaldet: Procesorienteret Musikterapi (PROM). PROM er et forsøg på at formulere en principiel ramme for musikterapi i psykiatrien, som dels tager udgangspunkt i 17 års klinisk erfaring, dels stiler mod at være ”best practice”. PROM ...... musikterapi for patienter med personlighedsforstyrrelser. Manualen indgår også som en del af et pilotprojekt, der har til formål at udvikle en protokol for et internationalt RCT projekt med samme målgruppe....

  3. Gruppemusikterapi med patienter med borderline-personlighedsforstyrrelse i dagbehandlingsregi

    DEFF Research Database (Denmark)

    Hannibal, Niels

    2008-01-01

    Denne artikel er første redegørelse for de erfaringer, som er gjort med gruppemusikterapi (GMT) for patienter med borderline-personlighedsforstyrrelse (BPF) i dagbehandlingsregi på Aalborg Psykiatriske Sygehus. Artiklen indeholder både konkrete anvisninger til aktiviteter og interventioner, ligesom...... den i et teoretisk perspektiv redegør for forskellige processer og reaktioner, der kan iagttages i behandlingen. Artiklen konkluderer, at GMT i sin nuværende form kan bidrage til udvikling af BPF-patienters evne til mentalisering og affektregulering, til opbygning af en gruppefølelse og fremme af...

  4. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation

    Institute of Scientific and Technical Information of China (English)

    Cathy Lu; Alistair Waugh; Robert J Bailey; Raeleen Cherry; Levinus A Dieleman; Leah Gramlich; Kata Matic

    2012-01-01

    AIM:To investigate genetic differences between Crohn's disease (CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index (CDAI)< 150] during follow-up visits based on physician global assessments.A CD relapse (loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity (CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients (n =6 who had a sustained long term remission after stopping infliximab,n =8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2 (NOD2)/caspase activation recruitment domain 15 (CARD15) polymorphisms (R702W,G908R and L1007fs) and the inflammatory bowel disease 5 (IBD5)polymorphisms (IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms (R702W,G908R and L1007fs) and the IBD5 polymorphisms (IGR2060a1 and IGR3081a1) in either group of patients; those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked

  5. Privat voldgift med offentligretlige delspørgsmål

    DEFF Research Database (Denmark)

    Werlauff, Erik

    2008-01-01

    Artiklen behandler de offentligretlige delspørgsmål, der kan opstå under en voldgiftssag, fx vedrørende el-, varme-, naturgas- og anden forsyningslovgivning, national eller fællesskabsretlig konkurrencelovgivning, forskrifter om statsforvaltningens godkendelse af vilkårene for udtræden af fællesk...

  6. Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study.

    Science.gov (United States)

    Alessandroni, L; Kohn, A; Cosintino, R; Marrollo, M; Papi, C; Monterubbianesi, R; Tersigni, R

    2011-12-01

    Perianal fistulas are frequent complications of Crohn's disease. Intravenous infliximab can control perianal disease and promote perianal fistula closure. Perifistular infliximab injections have been proposed for patients who are intolerant or unresponsive to intravenous therapy. The aim of this study was to assess the long-term efficacy of surgical treatment combined with local infliximab therapy. A prospective cohort study was designed. Twelve patients with Crohn's disease and high/complex transphincteric and intrasphincteric perianal fistulas refractory to other treatment were submitted to core-out fistulectomies, plus perifistular injections of infliximab (20-25 mg in 15-20 ml of 5% glucose) every 4-6 weeks. The main outcome measure was the clinical closure of all perianal fistulas. A 95% confidence interval was calculated for short- and long-term fistula closure rates. None of the procedures were associated with local or systemic adverse effects. Four patients did not complete treatment, two because of relapse of intestinal symptoms, which required intravenous infliximab. In one case, treatment with intravenous infliximab was complicated by a hypersensitivity reaction. Eight patients continued treatment until all perianal fistulas were closed and setons were removed (median: 5 sessions). Persistent closure was observed in seven (87.5%, 95% CI: 47.4-99.6) of the eight patients 12 months after completion of treatment and in five (62.5%; 95% CI: 24.5-91.5) of eight at the end of follow-up (range: 19-43 months, median: 35 months). The cohort we examined is small, but fistulectomy combined with repeated perifistular injections of infliximab appears to be safe and may help in fistula healing. However, in most patients, permanent closure of all fistulas is not achieved.

  7. Informationsledelse med mindset-map

    DEFF Research Database (Denmark)

    Brodersen, Lars

    Teorien og modellerne om informationsledelse med mindset-map bygger på Aalborg Universitets PBL-model, naturvidenskabelige principper, tekniske principper og humanistiske teorier. I kombination udgør disse grundlag et stærkt grundlag, som sikrer resultater. Informationsledelse handler om projektf......Teorien og modellerne om informationsledelse med mindset-map bygger på Aalborg Universitets PBL-model, naturvidenskabelige principper, tekniske principper og humanistiske teorier. I kombination udgør disse grundlag et stærkt grundlag, som sikrer resultater. Informationsledelse handler om...

  8. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

    Directory of Open Access Journals (Sweden)

    Abdalla A

    2017-03-01

    Full Text Available Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway, Ireland Purpose: To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory arthritis switched from reference product in our center. Patients and methods: In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval. Results: Around 34 patients with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12.9, mean disease duration 14.79 years (9.7, median duration on infliximab 57 months, and two-thirds on oral disease-modifying antirheumatic drugs. There was no difference in efficacy or safety in the first 6 months of therapy. By the end of 2015, the mean follow-up on biosimilar infliximab was 15.8 (standard deviation=6.3 months. Our results showed no significant difference in Health Assessment Questionnaire score, patient global assessment of disease activity, number of disease flares, or the medication dose between the originator and the biosimilar infliximab. However, reported pain and C-reactive protein values were significantly higher during the longer follow-up period (p=0.043, 0.001 respectively. There was no significant difference in the number of adverse events or infusion reactions during follow-up periods. Only five (14.7% patients discontinued the biosimilar infliximab. Conclusion: Our patients experienced similar efficacy and safety for managing their arthritis with the biosimilar infliximab as the reference product infliximab, but at a much lower cost. Keywords: biologic therapy, rheumatic diseases, biosimilar exchange, infliximab, adult

  9. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

    NARCIS (Netherlands)

    Bartelds, G.M.; Wijbrandts, C.A.; Nurmohamed, M.T.; Stapel, S.; Lems, W.F.; Aarden, L.; Dijkmans, B.A.C.; Tak, P.P.; Wolbink, G.J.

    2010-01-01

    OBJECTIVE: To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA). METHODS: This cohort study consisted of 235 patients with RA, all treated with adalimumab. At baseline 52 pati

  10. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Palarasah, Yaseelan; Bendtzen, Klaus

    2013-01-01

    BACKGROUND: Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs...

  11. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.

    NARCIS (Netherlands)

    Flendrie, M.; Creemers, M.C.W.; Welsing, P.M.J.; Riel, P.L.C.M. van

    2005-01-01

    OBJECTIVE: To investigate the influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in rheumatoid arthritis (RA) and to compare it to infliximab in combination with other disease-modifying anti-rheumatic drugs. METHODS: RA patients starting infliximab the

  12. Fotofilm om musikterapi med flygtninge

    DEFF Research Database (Denmark)

    Lindvang, Charlotte

    2016-01-01

    mennesker fra andre kulturer. Musikken er et universelt sprog og musik kan derfor være et mødested. Musikterapi i forbindelse med voksne traumatiserede flygtninge giver god mening, fordi musikken giver mulighed for at regulere den stress som sidder i krop og sind. Flygtningebørn kan have svært ved at udtale...

  13. Spilleregler i musikterapi med voksne

    DEFF Research Database (Denmark)

    Holck, Ulla

    2005-01-01

    Artiklen gennemgår udvalgt faglitteratur, der på et overordnet plan beskriver typer af spilleregler i musikterapi med (fortrinsvis) voksne klientgrupper. Udgangspunktet er Priestleys anvendelse af begrebet, og hendes inddeling af spilleregler i forhold til forskellige teknikker gennemgås, efterfu...

  14. Rundvisning med avatar Gunhild Soderstrom

    DEFF Research Database (Denmark)

    Grund, Cynthia M.

    2009-01-01

    Første optagelse tager seeren med på en rundvisning in-world, hvor Gunhild Soderstrom præsenterer Percipitopia, der bl.a. byder på en rekonstruktion af den irske filosof George Berkeleys hjem "Whitehall" på Rhode Island og The White Room of Disorientation, der illustrerer Berkeleys "Theory...

  15. Unges friluftsliv set med integrationsbriller

    DEFF Research Database (Denmark)

    Gentin, Sandra

    2010-01-01

    Det er almindelig kendt, at indvandrere ikke deltager i foreningsliv i samme omfang som etniske danskere. Det er der forsøgt rådet bod på ved at invitere unge med anden etnisk baggrund end dansk til at dyrke spejdersport i henholdsvis Varde og København NV. Tilgangen til at integrere de unge var...

  16. Interview med avatar Gunhild Soderstrom

    DEFF Research Database (Denmark)

    Grund, Cynthia M.; Christensen, Inger-Marie F.

    2009-01-01

    Interview med avatar Gunhild Soderstrom Bag avataren Gunhild Soderstrom gemmer sig lektor i filosofi Cynthia Grund fra SDU, som avataren Inga Miles alias Inger-Marie Christensen i anden optagelse har interviewet i Second Life. Det er blevet til en diskussion om læringspotentialet i virtuelle verd...

  17. Rundvisning med avatar Gunhild Soderstrom

    DEFF Research Database (Denmark)

    Grund, Cynthia M.

    2009-01-01

    Første optagelse tager seeren med på en rundvisning in-world, hvor Gunhild Soderstrom præsenterer Percipitopia, der bl.a. byder på en rekonstruktion af den irske filosof George Berkeleys hjem "Whitehall" på Rhode Island og The White Room of Disorientation, der illustrerer Berkeleys "Theory of vis...

  18. Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome

    Directory of Open Access Journals (Sweden)

    Elif Betül Türkoğlu

    2015-08-01

    Full Text Available Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases. Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who began treatment with systemic infliximab. Tear film break-up time (TBUT, anesthetized Schirmer’s 1 test, fluorescein staining test, and Ocular Surface Disease Index (OSDI scores were recorded before treatment and in the 3rd and 6th months of treatment. Results: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer’s values, TBUT, fluorescein staining, or OSDI scores (p=0.260, p=0.357, p=0.190 and p=0.07, respectively. In the 6th month of infliximab therapy, no significant changes were observed in TBUT, fluorescein staining, Schirmer’s value or OSDI scores (p=0.510, p=0.320, p=0.220 and p=0.344, respectively. Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141

  19. QUALITY OF LIFE IN CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS TREATED WITH INFLIXIMAB

    Directory of Open Access Journals (Sweden)

    R.V. Denisova

    2008-01-01

    Full Text Available Juvenile rheumatoid arthritis (JRA is chronic disease, leading to early incapacitating injury in patients. Treatment of JRA with new expensive biological agents allows obtaining long term remission of disease and improving its prognosis. Estimation of quality of life is one of the main effectiveness criteria of treatment. A quality of life in children who were 2–4 years old treated with infliximab was estimated. 43 patients with different types of JRA were examined. A quality of life was estimated with the help of questionnaire PEDSQL generic core scale, PEDSQL rheumatology module. Index of functional disability was estimated by childhood health assessment questionnaire (CHAQ. Significant increase of quality of life rates and decrease of index of functional disability was registered in 6 weeks of therapy with infliximab. The rates of quality of life in patients with JRA treated with infliximab were significantly equal to that in healthy children in the same age in 6, 12 and 24 months of treatment. Thus, treatment with infliximab significantly increases quality of life in children in 2–4 years old with JRA and their families, decreases negative influence of disease on child's living, improves physical activity and emotional state of patients, and allows improving contact between patients and healthy children in the same age.Key words: children, juvenile rheumatoid arthritis, quality of life, infliximab.

  20. Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.

    Science.gov (United States)

    Kim, Sang-Hyon; Son, Chang-Nam; Lee, Hyo-Jung; Cho, Ho-Chan; Jung, Sung-Won; Hur, Ji An; Baek, Won-Ki; Jung, Hye Ra; Hong, Ji Hee

    2015-05-01

    Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

  1. Crohn's disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue?

    Institute of Scientific and Technical Information of China (English)

    Itta M Minderhoud; Melvin Samsom; Bas Oldenburg

    2007-01-01

    AIM: To study the effect of infliximab on fatigue in relation to cytokine levels in Crohn's disease (CD) patients.METHODS: Fourteen CD patients were blinded for treatment and received placebo at baseline, and infliximab 2 wk later, with a follow-up of 4 wk. Blood samples were drawn on a regular basis, and questionnaires on fatigue,depression, quality of life, and clinical disease activity were completed at regular intervals.RESULTS: After placebo infusion, fatigue scores decreased within 3 d (3.5 points + 1.1, P ≤ 0.01), but returned to baseline values 14 d after this infusion.The drop of fatigue scores following infliximab infusion sustained until the end of the study (3.8 points ± 1.4, P ≤ 0.05). Quality of life was increased at the end of the study compared to baseline values (138.6 ± 9.4 vs179.4+ 6.7; P ≤ 0.005), whereas depression scores were decreased (20.4 ± 9.4 vs11.3 + 2.2; P ≤ 0.01). No correlation between the severity of fatigue and the level of cytokines was observed.CONCLUSION: The reduction of fatigue after infliximab infusion is subjective to a placebo effect. The effect of infliximab on fatigue, however, persists while the placebo effect disappears after a short period of time. A clear role of cytokines could not be substantiated.

  2. Infliximab en pacientes con espondilitis anquilosante activa: experiencia en el Hospital Nacional Edgardo Rebagliati Martins

    Directory of Open Access Journals (Sweden)

    Manuel Montero

    2007-06-01

    Full Text Available Infliximab es un medicamento efectivo en el tratamiento de pacientes con espondilitis anquilosante (EA activa. Sin embargo, debido a su alto costo, su uso indiscriminado es prohibitivo. Objetivo: Evaluar si un régimen de inducción con infliximab es efectivo en pacientes con EA activa. Diseño: Sólo expuestos. Lugar: Servicio de Reumatología del Hospital Nacional Edgardo Rebagliati. Participantes: Pacientes con espondilitis anquilosante activa refractaria. Intervenciones: infliximab a las 0, 2 y 6 semanas. Un paciente recibió dosis de 3 mg/kg y los restantes 5 mg/kg de infliximab. Todos los pacientes continuaron recibiendo sulfasalazina. Principales medidas de resultados: Se determinó la proporción de pacientes que alcanzaron mejoría de acuerdo a los criterios ASAS 20, ASAS 40 y BASDAI 50, en la última evaluación (mediana de 55 semanas. Resultados: En la última evaluación, cinco pacientes (71,4% presentaban respuesta ASAS 20 sostenida. Cuatro (57% y tres (43% de los pacientes alcanzaron BASDAI 50 y ASAS 40, respectivamente. Tres pacientes (43% recayeron en un tiempo promedio de 26,6 semanas. No se observó efectos adversos serios. Conclusiones: La infusión de tres dosis de infliximab es efectiva para controlar la actividad de la enfermedad de los pacientes con EA refractaria a AINEs y en algunos pacientes controla la enfermedad por periodos prolongados de tiempo.

  3. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.

    NARCIS (Netherlands)

    Ridder, L. de; Escher, J.C.; Bouquet, J.; Schweizer, J.J.; Rings, E.H.; Tolboom, J.J.M.; Houwen, R.H.J.; Norbruis, O.F.; Derkx, B.H.; Taminiau, J.A.

    2004-01-01

    OBJECTIVE: The purpose of this study was to describe the clinical experience with the anti-tumor necrosis factor chimeric monoclonal antibody, infliximab, in pediatric patients with Crohn disease in The Netherlands. DESIGN: Descriptive. METHODS: Clinical response and adverse effects of infliximab

  4. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands

    NARCIS (Netherlands)

    de Ridder, L.; Escher, J.C.; Bouquet, J.; Schweizer, J.J.; Rings, Edmond H. H.; Tolboom, J.J.M.; Houwen, R.H.J.; Norbruis, O.F.; Derkx, B.H.F.; Taminiau, J.A.J.M.

    Objective: The purpose of this study was to describe the clinical experience with the anti-tumor necrosis factor chimeric monoclonal antibody, infliximab, in pediatric patients with Crohn disease in The Netherlands. Design: Descriptive. Methods: Clinical response and adverse effects of infliximab

  5. Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience

    Directory of Open Access Journals (Sweden)

    S. Todesco

    2011-09-01

    Full Text Available Objective: We report the incidence and treatment of infusion reactions to infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor a, in a large cohort of patients with rheumatoid arthritis. Patients and methods: One hundred eighty six patients with rheumatoid arthritis treated with infliximab for a total of 216.6 patient years were retrospectively evaluated. Patients received 2160 infliximab infusions at the Division of Rheumatology at the University Hospital of Padua from May, 2000 to April, 2004. Specific treatment protocols for initial and subsequent acute infusion reactions were followed and the outcomes documented. Results: The overall incidence of infusion reactions to infliximab was 0.8% (19 out of 2160 of infusions, affecting 10.2% of patients (19 out of 186. Mild, moderate, or severe acute reactions occurred in 0.1% (3 of 2160, 0.6% (13 of 2160, and 0.04% (1 of 2160 of infliximab infusions, respectively. Delayed infusion reactions occurred in 0.09% (2 of 2160 of infusions. Use of specific treatment protocols resulted in rapid resolution of all acute reactions to infliximab. With a prophylaxis protocol, all patients who experienced an initial mild acute reaction were able to receive additional infusions. Conclusions: Using appropriate treatment protocols, infliximab infusion reactions were effectively treated and prevented in patients with mild acute reactions upon retreatment. In the case of moderate to severe infusion reactions, the risks and the benefits of the continuation of infliximab therapy need to be carefully considered.

  6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children

    DEFF Research Database (Denmark)

    Hyams, Jeffrey; Crandall, Wallace; Kugathasan, Subra

    2006-01-01

    BACKGROUND AND AIMS: The REACH study evaluated the safety and efficacy of infliximab in children with moderately to severely active Crohn's disease. METHODS: Patients (n = 112) with a Pediatric Crohn's Disease Activity Index (PCDAI) score >30 received infliximab 5 mg/kg at weeks 0, 2, and 6...

  7. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

    DEFF Research Database (Denmark)

    Katz, Lior; Gisbert, Javier P; Manoogian, Beth

    2012-01-01

    Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval-halving compared with dose...

  8. Infliximab treatment in a case of rheumatoid scleromalacia perforans.

    Science.gov (United States)

    Herrera-Esparza, R; Avalos-Díaz, E

    2009-01-01

    Ocular rheumatoid disease manifests as hyperemia of the conjunctiva and episclera, and in severe cases, episcleritis can result in nodular sclerotic and scleromalacia perforans. A clinical case of scleromalacia perforans in a 56-year-old woman with 20 years of seropositive rheumatoid arthritis of functional class IV is presented here. During that period, she received exclusively non-steroidal anti-inflammatory drugs (NSAIDs). She developed acute episcleritis of the left ocular globe, which rapidly progressed to scleromalacia perforans. Since the left eye became perforated, it was surgically enucleated, and the patient was maintained with steroidal therapy. Nevertheless, two months later she developed new-onset episcleritis of the right eye followed by scleromalacia. She was first evaluated by a rheumatologist and treated with 200 mg/dose of infliximab, which was administered monthly for the following four months. The biological treatment was accompanied by methotrexate and prednisone. With this therapy, the ocular lesion dramatically improved, and complete remission of rheumatoid arthritis and scleritis was archived four months later. In conclusion, tumour necrosis factor (TNF) blockers are effective therapeutic agents in ocular complications of rheumatoid arthritis.

  9. Med Kingo på dybt vand

    DEFF Research Database (Denmark)

    Arndal, Lars Stubbe

    2014-01-01

    Tag med digteren Thomas Kingo ud på dybt vand i selskab med lektor og mag.art. Lars Arndal, der kaster nye perspektiver på Kingos forlisdigt Hierte-Suk. Arndal kommer hermed også med et bud på, hvordan man som lærer kan invitere eleverne med på opdagelse i digtet...

  10. Metodekombination med kritisk analyse

    DEFF Research Database (Denmark)

    Bilfeldt, Annette

    2007-01-01

    "Metodekombination med kritisk teoretisk analyse" fremlægger en kombinationsmetode, der bygges op om en problemstilling med et normativt grundlag for studiet af køn og arbejdsliv. Med fokus på rationalitet og humaniseringsbarrierer i arbejdslivet lægges der med inspiration fra Marie Jahoda op til...

  11. Analysis list: Med [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available Med Cell line + dm3 http://dbarchive.biosciencedbc.jp/kyushu-u/dm3/target/Med.1.tsv... http://dbarchive.biosciencedbc.jp/kyushu-u/dm3/target/Med.5.tsv http://dbarchive.biosciencedbc.jp/kyushu-u/dm3/target/Med....10.tsv http://dbarchive.biosciencedbc.jp/kyushu-u/dm3/colo/Med.Cell_line.tsv http://dbarchive.biosciencedbc.jp/kyushu-u/dm3/colo/Cell_line.gml ...

  12. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?

    Science.gov (United States)

    Ben-Horin, Shomron; Heap, Graham A; Ahmad, Tariq; Kim, HoUng; Kwon, TaekSang; Chowers, Yehuda

    2015-01-01

    Biopharmaceuticals or 'biologics' have revolutionized the treatment of many diseases. However, some patients generate an immune response to such drugs, potentially limiting clinical efficacy and safety. Infliximab (Remicade(®)) is a monoclonal antibody used to treat several immune-mediated inflammatory disorders. A biosimilar of infliximab, CT-P13 (Remsima(®), Inflectra(®)), has recently been approved in Europe for all indications in which infliximab is approved. Approval of CT-P13 was based in part on extrapolation of clinical trial data from two indications (rheumatoid arthritis and ankylosing spondylitis) to all other indications, including inflammatory bowel disease. This review discusses the validity of extrapolating immunogenicity data across indications - a process adopted by the EMA as part of their biosimilar approval process - with a focus on CT-P13.

  13. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.

    Science.gov (United States)

    Stichweh, Dorothee S; Punaro, Marilynn; Pascual, Virginia

    2005-01-01

    Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF alpha), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

  14. Infliximab's influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model

    DEFF Research Database (Denmark)

    Frostberg, Erik; Ström, Petter; Gerke, Oke;

    2014-01-01

    and conclusions. The purpose of this study was to investigate whether a single dose infliximab has an adverse effect on the anastomotic healing process, observed as reduced anastomotic breaking strength and histopathologically verified lower grade of inflammatory response, in the small intestine of a rabbit....... METHODS: Thirty New Zealand rabbits (median weight 2.5 kg) were allocated to treatment with an intravenous bolus of either 10 mg/kg infliximab (n = 15) or placebo (n = 15). One week later all rabbits underwent two separate end-to-end anastomoses in the jejunum under general anesthesia. At postoperative...... day three, the anastomotic breaking strength was determined and histopathological changes were examined. RESULTS: The mean value of anastomotic breaking strength in the placebo group was 1.89 +/- 0.36 N and the corresponding value was 1.81 +/- 0.33 N in the infliximab treated rabbits...

  15. Profile of infliximab in the treatment of pediatric Crohn’s disease

    Directory of Open Access Journals (Sweden)

    Kierus J

    2015-06-01

    Full Text Available Jaroslaw Kierkus,1 Edyta Szymanska,2 Grzegorz Oracz,1 Anna Wiernicka,1 Maciej Dadalski1 1Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, 2Department of Pediatrics, Nutrition and Metabolic Disorders, The Children’s Memorial Health Institute, Warsaw, Poland Abstract: In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn’s disease, we review the profile of the agent in the treatment of this disease in a pediatric setting. Keywords: infliximab, Crohn’s disease, children, biologic therapy, anti-TNF-agents

  16. The use of infliximab in a patient with idiopathic granulomatous hepatitis

    Science.gov (United States)

    Kapoor, Sabrina Reenu; Snowden, Neil

    2009-01-01

    We report a therapeutic response to infliximab in a patient with idiopathic granulomatous hepatitis resistant to treatment with methotrexate and corticosteroids. A 41-year-old woman presented with a 12-month history of fever, night sweat, gross hepatomegaly and 13 kg weight loss. Infection and malignancy were carefully excluded and a liver biopsy showed changes consistent with idiopathic granulomatous hepatitis. The patient was treated with high dose steroids and methotrexate, but her clinical symptoms and biochemical and radiological signs did not settle. Introduction of infliximab led to rapid and sustained resolution of symptoms, hepatomegaly and liver function tests (LFTs) after 1 year of follow-up. To our knowledge this is the first successful use of infliximab in idiopathic granulomatous hepatitis. PMID:21686858

  17. Subfulminant hepatitis B after infliximab in Crohn's disease:Need for HBV-screening?

    Institute of Scientific and Technical Information of China (English)

    Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel

    2006-01-01

    Infections are a major adverse effect during the treatment with anti-TNF-α. While exclusion of any bacterial infection and screening for tuberculosis are mandatory before initiating a therapy with anti-TNFα-antibodies, there are no guidelines whether to screen for or how to deal with chronic viral infections such as hepatitis B. In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state. He recovered completely after lamivudine therapy was started, but this severe adverse event could have been prevented if screening for HBV and pre-emptive therapy with lamivudine would have been started prior to infliximab.We therefore strongly argue in favor of extended screening recommendations for infectious diseases including viral infections before considering a therapy with infliximab.

  18. Fang CO2 med Aminosyrer

    DEFF Research Database (Denmark)

    Lerche, Benedicte Mai

    2010-01-01

    Med såkaldte “carbon capture-teknikker” er det muligt at rense røgen fra kulfyrede kraftværker, således at den er næsten helt fri for drivhusgassen CO2. Kunsten er at gøre processen tilstrækkeligt billig. Et lovende fangstredskab i denne proces er aminosyrer.......Med såkaldte “carbon capture-teknikker” er det muligt at rense røgen fra kulfyrede kraftværker, således at den er næsten helt fri for drivhusgassen CO2. Kunsten er at gøre processen tilstrækkeligt billig. Et lovende fangstredskab i denne proces er aminosyrer....

  19. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study.

    Science.gov (United States)

    Fioravanti, Antonella; Fabbroni, Marta; Cerase, Alfonso; Galeazzi, Mauro

    2009-06-01

    Our pilot study aimed to investigate the efficacy and tolerability of intra-articular (i.a.) injections of infliximab as a therapy for erosive osteoarthritis of the hands. Ten women with bilateral involvement of the hands and typical erosive osteoarthritis radiographic findings were enrolled and followed for 12 months. All the patients were refractory to conventional drugs. Treatment consisted in monthly i.a. injections of 0.2 ml of infliximab (0.1 mg/ml) in each affected proximal and distal interphalangeal joint of the most involved hand, identified on the basis of clinical and radiological examinations. The other hand was treated with physiological saline (control). The patients did not know which hand was receiving infliximab. Clinical response was evaluated at enrollment, after 6 and 12 months. Posteroanterior radiographs of both hands were obtained at baseline and 12 months later. At 6 months all the patients experienced relief from spontaneous pain and pain on lateral pressure in the hand treated with infliximab and these findings became statistically significant after 1 year. No important modifications were recognized in the hand treated with physiological saline. The anatomical lesion progression system radiological score indicated a reduction, even if not statistically significant, in the hand treated with infliximab and a tendency to slow worsening in the hand treated with physiological saline at 12-month follow-up. No local or systemic adverse reactions were recorded. Our study shows the symptomatic effect and a possible disease modifying action of i.a. infliximab in erosive osteoarthritis of the hands.

  20. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study.

    Science.gov (United States)

    Biancone, Livia; Petruzziello, Carmelina; Orlando, Ambrogio; Kohn, Anna; Ardizzone, Sandro; Daperno, Marco; Angelucci, Erika; Castiglione, Fabiana; D'Incà, Renata; Zorzi, Francesca; Papi, Claudio; Meucci, Gianmichele; Riegler, Gabriele; Sica, Giuseppe; Rizzello, Fernando; Mocciaro, Filippo; Onali, Sara; Calabrese, Emma; Cottone, Mario; Pallone, Francesco

    2011-03-01

    The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD duration (±5 years). From 1999 to 2008 the frequency and characteristics of neoplasia were compared between CD-IFX and CD-C. In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months: 72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%) and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C: 9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated with infliximab use. The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables and followed up for a median of 6 years. Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

  1. Disseminated nocardiosis in a patient on infliximab and methylprednisolone for treatment-resistant Sweet's syndrome.

    Science.gov (United States)

    Drone, Elizabeth R; McCrory, Allison L; Lane, Natalie; Fiala, Katherine

    2014-07-01

    A 62-year-old white man with a 10-year history of treatment-refractory Sweet's syndrome was admitted to the hospital with the onset of purpuric lesions. Methylprednisolone and infliximab were administered. Our patient developed disseminated Nocardia infection and eventually succumbed. Opportunistic infections such as Nocardia have been associated with infliximab and other tumour necrosis factor (TNF)-α inhibitors. The astute clinician should be aware of the risk of rare opportunistic infections, particularly in patients on TNF-α inhibitors and systemic corticosteroids.

  2. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease

    Institute of Scientific and Technical Information of China (English)

    Vasilios Panteris; Anna Perdiou; Vasilios Tsirimpis; Demetrios Georgios Karamanolis

    2006-01-01

    Infliximab is a potent anti-TNF antibody, which is used with great success in Crohn's disease patients. Since its release in clinical practice, several adverse reactions have been observed. The interest in possible consequences of its administration is still high because of the recent introduction of the drug for the long-term maintenance therapy of refractory luminal and fistulizing Crohn's disease. We present a case of acute coronary syndrome (non-STEMI) in a patient with corticoid resistant Crohn's disease after his first dose of infliximab. By reviewing the scant articles that exist in the literature on this topic we made an effort to delineate the possible mechanisms of this phenomenon.

  3. Effectiveness of infliximab in the treatment of perianal fistulas in ulcerative colitis: report of two cases.

    Science.gov (United States)

    de la Piscina, Patricia Ramírez; Duca, Ileana; Estrada, Silvia; Spicakova, Katerina; Calderón, Rosario; Urtasun, Leire; Marra-López, Carlos; Salvador, Marta; Delgado, Elvira; Campos, Francisco García

    2013-01-01

    Ulcerative colitis is a chronic inflammatory bowel disease of unknown etiopathogenesis and increasing incidence in recent years. Perianal complications of ulcerative colitis are rare and seem to be associated with higher extent of inflammation and a more severe course of the disease. The cases of two male patients with severe corticoid-dependent ulcerative colitis of protracted clinical course who developed perianal fistulas and abscesses successfully treated with infliximab are reported. Treatment with infliximab was followed by perianal fistula closure with marked improvement in the quality of life over 2-year follow-up period.

  4. Fungal arthritis of the wrist caused by Candida parapsilosis during infliximab therapy for rheumatoid arthritis.

    Science.gov (United States)

    Miyamoto, Hideaki; Miura, Toshiki; Morita, Euan; Morizaki, Yutaka; Uehara, Kosuke; Ohe, Takashi; Tanaka, Sakae

    2012-11-01

    A 60-year-old woman with rheumatoid arthritis, who had been treated with infliximab, presented with uncontrollable wrist arthritis. Fungal arthritis caused by Candida parapsilosis was confirmed by examining her aspirated joint fluid. Her infliximab therapy was interrupted, and antifungal therapy with fluconazole was started. After the fungal infection had been ameliorated, surgical debridement and arthrodesis of the wrist joint were conducted, and her symptoms completely resolved. Although fungal arthritis is rare, it should be considered as a differential diagnosis of exacerbated monoarthritis in patients treated with biological agents.

  5. Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea.

    Science.gov (United States)

    Resorlu, Hatice; Kılıc, Sevilay; Isık, Selda; Gokmen, Ferhat

    2017-02-23

    The patient in this report was diagnosed simultaneously with primary biliary cirrhosis (PBC), spondyloarthritis, and generalized morphea and was started on infliximab therapy. In addition to an improvement in clinical symptoms with this therapy, an improvement was also observed in laboratory parameters such as cholestatic enzymes, C-reactive protein, and erythrocyte sedimentation rate. Infliximab was well tolerated in this 56-year-old patient. However, further studies must be performed in order to clarify the therapeutic role of TNF-α blockers in, PBC and generalized morphea.

  6. Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease

    Directory of Open Access Journals (Sweden)

    Remo Panaccione

    2004-01-01

    Full Text Available These guidelines are presented as a follow-up to the original Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn's disease, published in the Canadian Journal of Gastroenterology (1. The original guidelines represented publications between 1998 and 2000. The current guidelines have been updated to reflect knowledge gained from two pivotal randomized clinical trails, with the use of infliximab in the maintenance of inflammatory Crohn's disease in remission (2 and in the maintenance of fistulous Crohn's disease in remission (3.

  7. Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

    Directory of Open Access Journals (Sweden)

    Karla R. Castro

    2011-01-01

    Full Text Available Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA. Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8±49.7 versus 140.1±64.1 mg/dL, P=0.028 and VLDL-c (23.6±10.5 versus 28.4±13.7 mg/dL, P=0.019 levels. In contrast, there were no differences in the mean TC (P=0.28, LDL-c (P=0.42, and HDL-c (P=0.26 levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P>0.05. Positive correlations were found between VLDL-c and CRP (r=0.647, P=0.009 and between triglycerides and CRP (r=0.604, P=0.017 levels at 3M. ESR reduction was observed after 3M (P=0.04. Mean prednisone dose remained stable at beginning and at 3M (P=0.37. Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.

  8. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction

    Science.gov (United States)

    Heldmann, F; van den Bosch, F; Burmester, G; Gaston, H; van der Horst-Bruinsma, I E; Krause, A; Schmidt, R; Schneider, M; Sieper, J; Andermann, B; van Tubergen, A; Witt, M; Braun, J

    2016-01-01

    Objective To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8 years with specific focus on dosage and the duration of intervals between infliximab infusions. Methods EASIC included patients with AS who had received infliximab for 2 years as part of the ASSERT trial. After that period, rheumatologists were free to change the dose or the intervals of infliximab. Clinical data were status at baseline, end of ASSERT and for a total of 8 years of follow-up. Results Of the initially 71 patients with AS from EASIC, 55 patients (77.5%) had completed the 8th year of anti-tumour necrosis factor (TNF) treatment. Of those, 48 patients (87.3%) still continued on infliximab. The mean infusion interval increased slightly from 6 to 7.1±1.5 weeks, while 45.8% patients had increased the intervals up to a maximum of 12 weeks. The mean infliximab dose remained stable over time, with a minimum of 3.1 mg/kg and a maximum of 6.4 mg/kg. In patients receiving 85% patients still remained on the same treatment, without any major safety events. Furthermore, both the infusion intervals and also the mean infliximab dose were modestly reduced in ≥70% of the patients without the loss of clinical efficiency. PMID:27493791

  9. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.

    Science.gov (United States)

    Thorne, Kymberley; Alrubaiy, Laith; Akbari, Ashley; Samuel, David G; Morrison-Rees, Sian; Roberts, Stephen E

    2016-04-01

    This review aimed to compile all available published data on colectomy rates following treatment using infliximab or ciclosporin in adult ulcerative colitis patients and to analyse colectomy rates, timing to colectomy and postcolectomy mortality for each treatment. We systematically reviewed the literature after 1990 reporting colectomy rates in ulcerative colitis patients treated with infliximab or ciclosporin, excluding articles on paediatric patients, patients with indeterminate colitis or Crohn's disease and bowel surgery not related to ulcerative colitis. We presented weighted mean colectomy rates and mortality rates. Cox's regression was used to assess time to colectomy adjusting for colitis severity, patient age and sex. We tabulated 78 studies reporting on ciclosporin and/or infliximab and colectomy rates or postcolectomy mortality rates. Not all studies reported data in a standardized manner. Infliximab had a significantly lower colectomy rate than ciclosporin at 36 months when analysing all studies, studies directly comparing infliximab and ciclosporin and studies using severe colitis patients, but not at 3, 12 or 24 months. Severity and age were key indicators in the likelihood of undergoing colectomy after treatment. Postcolectomy mortality rates were less than 1.5% for both drugs. This review indicates that long-term colectomy rates following infliximab are significantly lower than ciclosporin in the longer term, and that postcolectomy mortality following infliximab and ciclosporin is very low. However, many key data items were missing from research articles, reducing our ability to establish with more confidence the actual impact of these two drugs on colectomy rates and postcolectomy mortality rates.

  10. Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis.

    Science.gov (United States)

    Kurata, Izumi; Tsuboi, Hiroto; Takahashi, Hidenori; Abe, Saori; Ebe, Hiroshi; Hagiwara, Shinya; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Matsumoto, Isao; Hoshi, Sujin; Oshika, Tetsuro; Sumida, Takayuki

    2015-01-01

    A 36-year-old man with a 16-year history of refractory Behçet's disease (BD)-associated uveitis and chronic renal failure requiring hemodialysis suffered from frequent ocular attacks despite treatment with systemic corticosteroids and cyclosporine A. Following infliximab administration, the patient's BD ocular attack score 24 and visual acuity improved. Although he developed mild acute gastroenteritis, he did not experience any other adverse events. In our review of the literature, we identified seven patients on hemodialysis with inflammatory disease successfully treated with infliximab. Infliximab may be effective and safe in cases of BD and other diseases, including in patients under hemodialysis.

  11. Børne- og ungdomspsykiatrisk indsats til unge med funktionelle somatiske symptomer. Sygdomsforståelse og empowerment efter familieterapeutisk intervention

    DEFF Research Database (Denmark)

    Hulgaard, Ditte Roth; Dehlholm-Lambertsen, Birgitte; Rask, Charlotte Ulrikka

    Formål og baggrund: Funktionelle somatiske symptomer (FSS) er almindelige hos børn og unge. FSS er ofte selvlimiterende, men for nogle udvikler symptomerne sig med konsekvenser som dårlig trivsel, skolefravær og stort forbrug af sundhedsydelser til følge. Funktionelle symptomer forstås i dag ud fra...... en biospsykosocial forklaringsmodel, hvor særligt familiære forhold vurderes at have betydning for FSS hos børn. Alligevel er der kun få studier der undersøger en egentlig familieterapeutisk tilgang i behandlingen af børn og unge med FSS. Ph.d. projektet vil undersøge, hvordan barnets og forældrenes...... velbeskrevet kvalitativ metode, der har rødder i en fænomenologisk og hermeneutisk tænkning. 10 – 12 deltagere udvælges blandt de børn, der er diagnosticeret med FSS på børneafdeling H3, Odense Universitetshospital og er henvist til videre behandling ved det funktionelle team i Børne- og ungdomspsykiatrien...

  12. Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

    Directory of Open Access Journals (Sweden)

    Chamaida ePlasencia

    2015-10-01

    Full Text Available BackgroundEvidence supporting treatment intensification in rheumatoid arthritis is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active rheumatoid arthritis (RA.MethodsThis study was a retrospective study of 42 RA patients who received increased infliximab following an insufficient response (DAS28 > 3.2. Serum concentrations of infliximab and antibodies to infliximab (ATI and DAS28 and EULAR clinical response parameters were recorded for one year. Analyses were performed in three patient groups that were defined by infliximab serum concentration prior to treatment enhancement: No detectable, Low (< 1.1 µg/mL or High (≥ 1.1 µg/mL drug levels. Results No circulating infliximab was detected in 20 patients (47.6 %, but 13 (30.9 % and 9 (21.4 % patients exhibited Low and High levels, respectively. ATI were only detected in patients with No detectable drug levels because the drug interferes with ELISA. DAS28 disease activity globally showed a modest improvement after dose escalation, but this improvement did not persist after 6 and 12 months. Infliximab serum levels increased significantly in the High group (p=0.016, but no increase was achieved in the Low and No detectable groups. The three study groups exhibited similar disease activity over time, and no improvement was observed in the non-responder EULAR rates. ConclusionsThese results suggest that the efficacy of an infliximab dose increase is limited, and the response is independent of the infliximab trough serum concentration that is achieved prior to escalation.

  13. Human melioidosis reported by ProMED

    Directory of Open Access Journals (Sweden)

    Katherinn Melissa Nasner-Posso

    2015-06-01

    Conclusions: Internet-based reporting systems such as ProMED are useful to gather information and synthesize knowledge on emerging infections. Although certain areas need to be improved, ProMED provided good information about melioidosis.

  14. LactMed: Drugs and Lactation Database

    Science.gov (United States)

    ... LactMed) SEARCH LACTMED BROWSE LACTMED ADVANCED SEARCH Search Search Term Records with Include Synonyms and CAS Numbers in ... For example: Remove Search Search LactMed Advanced Search Search Term Records with Include Synonyms and CAS Numbers in ...

  15. Noninfectious interstitial lung disease during infliximab therapy: case report and literature review.

    Science.gov (United States)

    Caccaro, Roberta; Savarino, Edoardo; D'Incà, Renata; Sturniolo, Giacomo Carlo

    2013-08-28

    Pulmonary abnormalities are not frequently encountered in patients with inflammatory bowel diseases. However, lung toxicity can be induced by conventional medications used to maintain remission, and similar evidence is also emerging for biologics. We present the case of a young woman affected by colonic Crohn's disease who was treated with oral mesalamine and became steroid-dependent and refractory to azathioprine and adalimumab. She was referred to our clinic with a severe relapse and was treated with infliximab, an anti-tumor necrosis factor α (TNF-α) antibody, to induce remission. After an initial benefit, with decreases in bowel movements, rectal bleeding and C-reactive protein levels, she experienced shortness of breath after the 5(th) infusion. Noninfectious interstitial lung disease was diagnosed. Both mesalamine and infliximab were discontinued, and steroids were introduced with slow but progressive improvement of symptoms, radiology and functional tests. This represents a rare case of interstitial lung disease associated with infliximab therapy and the effect of drug withdrawal on these lung alterations. Given the increasing use of anti-TNF-α therapies and the increasing reports of pulmonary abnormalities in patients with inflammatory bowel diseases, this case underlines the importance of a careful evaluation of respiratory symptoms in patients undergoing infliximab therapy.

  16. Suicide attempt in ulcerative colitis patient after 4months of infliximab therapy - A case report

    NARCIS (Netherlands)

    E.J. Eshuis; K.M.M.Y. Magnin; P.C.F. Stokkers; W.A. Bemelman; J. Bartelsman

    2010-01-01

    In the summary of product characteristics of infliximab (IFX), psychiatric side effects are reported to be rare, and in literature only limited data exist. This report presents a case of a patient with ulcerative colitis who developed a depression with psychotic symptoms during IFX therapy and made

  17. Infliximab Dependency in a National Cohort of Children with Crohn's Disease

    DEFF Research Database (Denmark)

    Wewer, Anne Vibeke; Riis, L; Vind, Ida;

    2006-01-01

    to 24 CD patients (9 male/15 female) aged median 15.4 (range 9.8-18.6) years with a median disease duration of 26 (range 0.7-93) months and a median number of infusions of 6 (range 2-11). Five milligrams of infliximab per kilogram infusions were given intravenously. Immediate response was as follows: 8...

  18. Transferability of antibody pairs from ELISA to fiber optic surface plasmon resonance for infliximab detection

    Science.gov (United States)

    Van Stappen, Thomas; Lu, Jiadi; Bloemen, Maarten; Geukens, Nick; Spasic, Dragana; Delport, Filip; Verbiest, Thierry; Lammertyn, Jeroen; Gils, Ann

    2015-03-01

    Tumor necrosis factor (TNF)-alpha is a pleiotropic cytokine up-regulated in inflammatory bowel disease, rheumatoid arthritis and psoriasis. The introduction of anti-TNF drugs such as infliximab has revolutionized the treatment of these diseases. Recently, therapeutic drug monitoring (TDM) of infliximab has been introduced in clinical decision making to increase cost-efficiency. Nowadays, TDM is performed using radio-immunoassays, homogeneous mobility shift assays or ELISA. Unfortunately, these assays do not allow for in situ treatment optimization, because of the required sample transportation to centralized laboratories and the subsequent assay execution time. In this perspective, we evaluated the potential of fiber optic-surface plasmon resonance (FO-SPR). To achieve this goal, a panel of 55 monoclonal anti-infliximab antibodies (MA-IFX) was developed and characterized in-house, leading to the identification of nine different clusters. Based on this high diversity, 22 antibody pairs were selected and tested for their reactivity towards IFX, using one MA-IFX as capture and one MA-IFX for detection, in a sandwich type ELISA and FO-SPR. This study showed that the reactivity towards IFX of each antibody pair in ELISA is highly similar to its reactivity on FO-SPR, indicating that antibody pairs are easily transferable between both platforms. Given the fact that FO-SPR shows the potential for miniaturization and fast assay time, it can be considered a highly promising platform for on-site infliximab monitoring.

  19. Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?

    DEFF Research Database (Denmark)

    Dan-Nielsen, Steffen; Wewer, Anne Vibeke; Paerregaard, Anders

    2014-01-01

    OBJECTIVES: The aim of the study was to evaluate clinical response, use of colectomy, and adverse events related to infliximab (IFX) treatment in acute and chronic active ulcerative colitis (UC) in children. METHODS: Children from 3 centers, who had received IFX for UC, were identified, and patie...

  20. Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate

    DEFF Research Database (Denmark)

    Ekenberg, C.; Friis-Møller, N.; Ulstrup, Thomas

    2016-01-01

    We present a case of a 56-year-old woman with Crohn's disease, treated with methotrexate and infliximab, who inadvertently received yellow fever vaccination (YFV) prior to a journey to Tanzania. She was not previously vaccinated against YF. YFV contains live-attenuated virus, and is contraindicated...

  1. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.

    NARCIS (Netherlands)

    Blom, M.; Kievit, W.; Kuper, H.H.; Jansen, T.L.Th.A.; Visser, H.; Broeder, A. den; Brus, H.L.; Laar, M.A. van de; Riel, P.L.C.M. van

    2010-01-01

    OBJECTIVE: To describe the frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in the treatment of rheumatoid arthritis (RA) in daily clinical practice. METHODS: All RA patients with a dose increase of tumor necrosis factor (TNF)-blocking therapy between January

  2. Infliximab inhibits DNA repair in ultraviolet B-irradiated premalignant keratinocytes

    DEFF Research Database (Denmark)

    Faurschou, A.; Gniadecki, R.; Wulf, Hans Chr.

    2008-01-01

    Anti-tumor necrosis factor-alpha (TNF alpha) approaches are increasingly used in the therapy of autoimmune diseases. One of the safety concerns is the potential enhancement of skin carcinogenesis. The aim of this study was to investigate if the TNF alpha neutralizing antibody, infliximab, directly...... dimers (CPD) in infliximab-treated cells was significantly increased at both 24 and 48 h after irradiation with 10 mJ/cm(2) UVB. As we have recently shown that protein kinase B/Akt is involved in the TNF alpha signalling pathway and promotes cell survival and skin carcinogenesis, we measured activatory...... phosphorylations of Akt (Ser-473 and Thr-308) and the signalling via related pathways Erk 1/2, p38 and p70-S6K. Infliximab inhibited Akt and its downstream targets p70-S6K and Erk 1/2, and stimulated p38 both in sham-irradiated and UVB-irradiated cells. In conclusion, despite the fact that infliximab blocks Akt...

  3. First study of infliximab treatment in patients with chronic obstructive pulmonary disease

    NARCIS (Netherlands)

    van der Vaart, H; Koeter, GH; Postma, DS; Kauffman, HF; ten Hacken, NHT

    2005-01-01

    Rationale: Tumor necrosis factor-alpha is believed to be important in the induction and maintenance of airway inflammation in chronic obstructive pulmonary disease. Objectives: We aimed to evaluate the effect of the anti-tumor necrosis factor-a drug infliximab in patients with chronic obstructive pu

  4. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease : A pilot study

    NARCIS (Netherlands)

    Dentener, Mieke A.; Creutzberg, Eva C.; Pennings, Herman-Jan; Rijkers, Ger T.; Mercken, Evi; Wouters, Emiel F. M.

    2008-01-01

    Background: Chronic obstructive pulmonary disease ( COPD) with cachexia is characterized by inflammation reflected by increased levels of tumor necrosis factor-alpha (TNF-alpha). Objectives: In this study, infliximab, an anti-TNF-alpha antibody, was evaluated for its effects on systemic ( plasma) an

  5. Recommendations for the long-term treatment of psoriasis with infliximab: A dermatology expert group consensus

    DEFF Research Database (Denmark)

    Reich, K.; Griffiths, C.; Barker, J.

    2008-01-01

    Background/Aims: Infliximab has been approved for the treatment of chronic plaque psoriasis for only a few years. As physicians gain confidence in initiating and maintaining this therapy, guidance on the management of patients beyond several months or years is needed. To date, there is little or ...

  6. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Svenson, M; Bendtzen, K;

    2011-01-01

    BACKGROUND: Infliximab (IFX) elicits acute severe infusion reactions in about 5% of patients with inflammatory bowel disease (IBD). AIM: To investigate the role of anti-IFX antibodies (Ab) and other risk factors. METHODS: The study included all IBD patients treated with IFX at a Danish university...

  7. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Al-Khalaf, Magid; Brynskov, Jørn;

    2012-01-01

    BACKGROUND: The aim of the study was to investigate variations in anti-infliximab (IFX) antibody (Ab) levels and clinical implications thereof in patients with inflammatory bowel disease (IBD). METHODS: A retrospective, explorative, single-center study of patients with IBD who developed anti-IFX Ab...

  8. MED-SUV Data policy

    Science.gov (United States)

    Sangianantoni, Agata; Puglisi, Giuseppe

    2014-05-01

    MED-SUV proposes the development and implementation of a digital infrastructure for data access and for volcanic risk management aimed at applying the rationale of Supersites GEO initiative to Campi Flegrei/Vesuvius and Mt. Etna. It's fully recognized the clear need of an open data policy in order to ensure that data will be properly and in an ethical manner managed and can be used and accessed from its community. In MED-SUV there is a multitude of different partners with varying scientific, technical, legal and economical interests and therefore data and data products produced will be wide-ranging so it's necessary to set principles and legal arrangements. Within Europe several Directives and Regulations have brought into force which provide the leading guidelines in terms of the principle of openness to knowledge and access to scientific information. So in creating a suite policy the EC Supersites (MarSite and FutureVolc, under the EPOS umbrella) projects need to strength their efforts in defining a common data management strategy. In this presentation we will show the leading principles of the data policy, as for instance Open Access, flexibility of approach in order to harmonize the different methods of data distribution among its partners, Creative Commons licensing, data preservation and unique identification through Persistent Identifiers.

  9. Pårørendes oplevelse af pleje og behandling af intensivpatienter

    DEFF Research Database (Denmark)

    Jensen, Hanne Irene

    fald gentages processen, evt. med færre testdeltagere. Derefter afprøves skemaet i en række europæiske lande. Status: Interviewundersøgelsen er i gang (indtil videre med inklusion af 6 pårørende). Sideløbende er udviklingsarbejdet med spørgeskemaet i gang. Der er pilottestet, og 2. udkast er udarbejdet...

  10. Stress i gymnasiet - Hvad der stresser gymnasielever og hvordan forebyggelse og behandling virker med ’Åben og Rolig for Unge’

    DEFF Research Database (Denmark)

    Nielsen, Anne Maj; Lagermann, Laila Colding

    Denne undersøgelse af stress hos gymnasieelever i Aalborg viser, hvordan stress giver sig udslag i gymnasiet, hvad der stresser eleverne, hvad der adskiller de stressramte elever fra andre elever, hvordan et stressreduktionskurset Åben og Rolig for Unge virker for de unge i gymnasiet, og hvad der...

  11. Mænd med rejsningsbesvær efter radikal prostatektomi bør behandles efter sædvanlige retningslinjer

    DEFF Research Database (Denmark)

    Fode, Mikkel; Hansen, Rikke Bølling; Maigaard, Thomas

    2015-01-01

    . The method is effective in animal models, but the results cannot be confirmed in humans. At this time, treatment regimens which actually create erections and allow for sexual intercourse following surgery should be prescribed. These include PDE5 inhibitors, vacuum erection devices, injection therapy...

  12. Kontrollmestringsteori og Becks kognitve teori. En sammenlignende undersøkelse av teoriene med henblikk på forståelse og behandling av depresjon

    OpenAIRE

    Brabrand, Kristin; Søvik, Ellen; Blomdal, Ane Jostedt

    2012-01-01

    Psychotherapy theories differ in how they understand and approach depression (Nordahl et al., 2012). In this paper we compare the control-mastery theory and Beck`s cognitive theory, with the aim to identify similarities and differences between the theories. In this comparison, similarities in conceptualization appeared. Both the control- mastery theory and Beck`s cognitive theory describe depression as developed on the basis of maladaptive cognitions (Beck, 1970; Weiss, 1993). At the same tim...

  13. Præhospital behandling af svært tilskadekomne patienter med fokus på damage control-kirurgi

    DEFF Research Database (Denmark)

    Sørensen, Anne Marie; Larsen, Claus Falck; Steinmetz, Jacob

    2011-01-01

    The majority of patients undergoing damage control surgery initially receive prehospital treatment. Bleeding causes 40% of trauma deaths, half of which happen in the prehospital setting. Future research and improved treatment before hospital admission should focus on control of the bleeding, avoi...

  14. Patienter med basalcellenævussyndrom bør tilbydes tidlig interdisciplinær opfølgning og behandling

    DEFF Research Database (Denmark)

    Bay, Christiane; Ousager, Lilian Bomme; Jelsig, Anne Marie

    2016-01-01

    Basal cell naevus syndrome (Gorlin-Goltz syndrome) is a rare, autosomal dominantly inherited condition with a wide range of developmental and multiple organ-related anomalies. Cardinal features include multiple basal cell carcinomas, jaw cysts, palmoplantar pits and calcification of the falx...

  15. OPUS: Randomiseret multicenterundersøgelse af integreret behandling sammenlignet med standardbehandling før første psykoseepisode--sekundaerpublikation

    DEFF Research Database (Denmark)

    Nordentoft, Merete; Petersen, Lone; Jeppesen, Pia;

    2006-01-01

    A total of 547 patients with first-episode psychosis were included in a randomised clinical trial comparing integrated treatment with standard treatment. The integrated treatment consisted of assertive community treatment with programmes for family involvement and social skills training. Patients...

  16. Rusmisbruk, angst og depresjon etter 10 år: En prospektiv undersøkelse av stoffmisbrukere med og uten LAR-behandling

    Directory of Open Access Journals (Sweden)

    Ravndal Edle

    2015-12-01

    Full Text Available Substance abuse, anxiety and depression after 10 years: A prospective study of drug users in and outside OMT treatment AIMS - The national Opiate Maintenance Treatment (OMT program in Norway started officially in 1998. The same year a treatment study was initiated, including the most used treatment measures for drug users in Norway. The main aim in the present study was to investigate the prevalence of live OMT patients in the total sample after 10 years, and to compare the outcome of primarily substance abuse, anxiety and depression among OMT patients versus non-OMT patients. DESIGN & METHODS - Four hundred and seven patients, in Oslo and the nearby regions, who started in 16 different in- and outpatients programs, were followed from intake to treatment and during ten years (1998-2009. Patients in the sample were interviewed after one, two, seven and ten years, and they were divided into three different treatment groups: inpatient residency for grown-ups, outpatient psychiatric youth teams and youths living in collectives. Data was collected through use of EuropASI and HSCL-25 at all follow-ups. RESULTS - After ten years 15 % were deceased. Of the 333 persons left, 73 % (n=248 were interviewed after ten years. Forty percent (n=99 were then in OMT. After ten years there were no gender differences regarding attendance to OMT, but the OMT-group was older (30 vs .28 yrs, p<0.05, and they used more benzodiazepines (p<0.000 and cannabis (p<0.01 than the others. The OMT-group reported to a larger extent more anxiety and depression throughout the total observation period than the non OMT participants. Use of heroin and criminality were significantly reduced in both groups. CONCLUSIONS - In spite of reduced use of heroin, the OMT patients seemed to have more difficulties in reducing the use of benzodiazepines and cannabis, whereas the anxiety and depression scores were high and stable through the total observation time.

  17. Mænd med rejsningsbesvær efter radikal prostatektomi bør behandles efter sædvanlige retningslinjer

    DEFF Research Database (Denmark)

    Fode, Mikkel; Hansen, Rikke Bølling; Maigaard, Thomas

    2014-01-01

    Penile rehabilitation programmes aim to improve long-term sexual function after nerve-sparing radical prostatectomy. Programmes aim to improve cavernous oxygenation to avoid structural damage in penile tissue. Especially, daily use of phosphodiesterase type 5 (PDE5) inhibitors has been studied. T......, urethral suppositories and penile implants....

  18. Mænd med rejsningsbesvær efter radikal prostatektomi bør behandles efter sædvanlige retningslinjer

    DEFF Research Database (Denmark)

    Fode, Mikkel; Hansen, Rikke Bølling; Maigaard, Thomas

    2015-01-01

    Penile rehabilitation programmes aim to improve long-term sexual function after nerve-sparing radical prostatectomy. Programmes aim to improve cavernous oxygenation to avoid structural damage in penile tissue. Especially, daily use of phosphodiesterase type 5 (PDE5) inhibitors has been studied. T......, urethral suppositories and penile implants....

  19. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

    DEFF Research Database (Denmark)

    Radstake, T R D J; Svenson, M; Eijsbouts, A M

    2008-01-01

    BACKGROUND: Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA). OBJECTIVE: To determine potential differences in clinical responses, soluble drug levels and antibody formation between patients with RA receiving......-infliximab/anti-adalimumab antibodies. RESULTS: 35 patients received infliximab, 34 received adalimumab. At 6 months, 15 (43%), 6 (17%) and 14 (40%) of the infliximab-treated patients fulfilled the EULAR criteria for good, moderate and non-responders, respectively, whereas the corresponding figures for adalimumab-treated patients were...

  20. Musikalsk leg med formgivning, timing og vitalitetsformer

    DEFF Research Database (Denmark)

    Holck, Ulla

    2015-01-01

    Ifølge de Udviklingsorienterede Social-Pragmatiske Interventionsformer til børn med Autisme Spektrum Forstyrrelse er en legende indfaldsvinkel, hvor man følger barnets lead, den mest effektive til at engagere yngre børn med autisme eller børn med svær autisme i et gensidigt samspil. Artiklen...

  1. Mini-Med School Planning Guide

    Science.gov (United States)

    National Institutes of Health, Office of Science Education, 2008

    2008-01-01

    Mini-Med Schools are public education programs now offered by more than 70 medical schools, universities, research institutions, and hospitals across the nation. There are even Mini-Med Schools in Ireland, Malta, and Canada! The program is typically a lecture series that meets once a week and provides "mini-med students" information on some of the…

  2. Langtidsforsøg med totrinsforgasseren "Viking"

    DEFF Research Database (Denmark)

    Henriksen, Ulrik Birk; Ahrenfeldt, Jesper; Bentzen, Jens Dall

    Projektets formål har været at få erfaringer med langtidsdrift, samt at løbende forbedre anlæggets komponenter i takt med de indvundne driftserfaringer. Status for Vikingforgasseren ved projektets afslutning er: • En række komponenter er løbende forbedret med henblik på driftssikkerhed, levetid, ...

  3. Hvad skal vi med et naturhistorisk museum?

    DEFF Research Database (Denmark)

    Kjærgaard, Peter C.

    2016-01-01

    I Danmark har vi nationale museer for kunsten, kulturen og naturen. Vi er i fuld gang med at lave et nyt, stort supermuseum for naturhistorien. Hvad skal vi egentlig med det? Efter et år på posten som direktør for Statens Naturhistoriske Museum gør Peter C. Kjærgaard status med en personlig...

  4. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.

    Science.gov (United States)

    Escudero-Vilaplana, Vicente; Ramírez-Herráiz, Esther; Alañón-Plaza, Estefanía; Trovato-López, Nicolás; García-Vicuña, Rosario; Carreño-Pérez, Luis; Morell-Baladrón, Alberto; Sanjurjo-Sáez, María

    2015-10-01

    Information on the use of ankylosing spondylitis (AS) therapies in clinical practice is a key factor in decision making, as more efficient treatments may involve substantial savings while maintaining the clinical benefits for the patient. To assess the mean annual doses and associated costs of the three main anti-tumour necrosis factor agents used in Spanish daily clinical practice in ankylosing spondylitis patients and to correlate these costs with disease activity. This retrospective, observational study included adult ankylosing spondylitis patients over a 4-year period that had been treated for at least 6 months with adalimumab, etanercept or infliximab at two University Hospitals in Spain. Disease activity was estimated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores at the start of anti-tumour necrosis factor (anti-TNF) therapy and in the last visit or whenever the drug was switched. Mean costs were estimated for a 52-week horizon from the delivered doses registered by pharmacy records. Outcomes were the doses and costs of anti TNFs administered to each patient, and the BASDAI score. A total of 119 patients (137 cases) were included (28 cases treated with adalimumab, 48 cases with etanercept and 61 with infliximab). Mean doses of adalimumab and etanercept were 92.8 and 88.8% of the initially prescribed doses, respectively, while the mean dose of infliximab administered was 102%. There were no statistical differences among treatments in terms of clinical effectiveness. Associated mean patient-year costs were significantly higher in the infliximab group (€14,235), compared to the other treatments [adalimumab €11,934; etanercept €10,516; (P ankylosing spondylitis patients, doses and associated costs of biological therapies can be reduced while controlling disease activity. Mean doses used in our clinical practice vary from the recommended doses and are significantly lower for adalimumab and etanercept than for infliximab. These

  5. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

    Directory of Open Access Journals (Sweden)

    Alejandro Pérez-Pitarch

    2015-03-01

    Full Text Available Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab. Aims: To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model. Methods: A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this population. Strategies 1 and 2 consisted on 5 mg/kg and 6 mg/kg doses, respectively, and 8 weeks inter-dose interval. Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix inter-dose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively. Strategies 5 and 6 used a fix dose of 5 mg/kg and individualized inter-dose intervals, adjusted to the same covariates, to achieve a target concentration, of 5 mg/L or 6 mg/L, respectively. Results: Strategies 2-6 reached trough levels statistically higher than strategy 1 (p < 0.05. Strategy 5 proved to be the best dosing strategy. It was associated with a higher proportion of responder patients than strategy 1 (62 % vs. 40 % without reaching higher peak concentrations. Conclusions: Optimization of maintenance treatment of colitis with infliximab by a pharmacokinetic approach could benefit infliximab-naive patients with ulcerative colitis.

  6. Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients

    Science.gov (United States)

    Lin, Zhiming; Liao, Zetao; Huang, Jianlin; Ai, Maixing; Pan, Yunfeng; Wu, Henglian; Lu, Jun; Cao, Shuangyan; Li, Li; Wei, Qiujing; Tang, Deshen; Wei, Yanlin; Li, Tianwang; Wu, Yuqiong; Xu, Manlong; Li, Qiuxia; Jin, Ou; Yu, Buyun; Gu, Jieruo

    2015-01-01

    Objectives. To evaluate the efficiency and the predictive factors of clinical response of infliximab in active nonradiographic axial spondyloarthritis patients. Methods. Active nonradiographic patients fulfilling ESSG criteria for SpA but not fulfilling modified New York criteria were included. All patients received infliximab treatment for 24 weeks. The primary endpoint was ASAS20 response at weeks 12 and 24. The abilities of baseline parameters and response at week 2 to predict ASAS20 response at weeks 12 and 24 were assessed using ROC curve and logistic regression analysis, respectively. Results. Of 70 axial SpA patients included, the proportions of patients achieving an ASAS20 response at weeks 2, 6, 12, and 24 were 85.7%, 88.6%, 87.1%, and 84.3%, respectively. Baseline MRI sacroiliitis score (AUC = 0.791; P = 0.005), CRP (AUC = 0.75; P = 0.017), and ASDAS (AUC = 0.778, P = 0.007) significantly predicted ASAS20 response at week 12. However, only ASDAS (AUC = 0.696, P = 0.040) significantly predicted ASAS20 response at week 24. Achievement of ASAS20 response after the first infliximab infusion was a significant predictor of subsequent ASAS20 response at weeks 12 and 24 (wald χ2 = 6.87, P = 0.009, and wald χ2 = 5.171, P = 0.023). Conclusions. Infliximab shows efficiency in active nonradiographic axial spondyloarthritis patients. ASDAS score and first-dose response could help predicting clinical efficacy of infliximab therapy in these patients. PMID:26273654

  7. The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis.

    Science.gov (United States)

    Kaufman, Ilana; Moscovici, Yolanda Braun; Abudi, Yair; Sofer, Denit; Mendelson, Ella; Balbir-Gurman, Alexandra; Caspi, Dan; Elkayam, Ori

    2010-01-01

    The duration of humoral immunity in patients treated with immunosuppressive drugs is poorly defined. The objective of the study was to investigate the effect of infliximab on the levels of antiviral antibodies against poliomyelitis, rubella and measles in rheumatoid arthritis (RA) patients. Fifty-two consecutive RA patients being treated with 3 mg/kg infliximab were prospectively studied. The antiviral antibody profiles for measles, rubella and three serotypes of poliomyelitis were tested on the day of the first infusion of infliximab and 6 months later. The study group comprised 36 women and 16 men (mean age 54 years, range 33-81) with a mean disease duration of 15 +/- 9 years. Forty-two (81%) patients were being treated with methotrexate and 22 (42%) were receiving prednisone. All patients had baseline protective levels of antibodies against measles and the three strains of polio, while 48 (92%) patients had protective antibodies against rubella. No significant change in the levels of antiviral antibodies was observed after 6 months of treatment with infliximab: from 3.67 at baseline to 3.87 IU/ml for measles, 169.50-197.0 IU/ml for rubella. No change was noticed for the geometric mean concentrations of antibodies against strains of poliomyelitis: 366-478 IU/ml for the Mahoney polio strain, 906-845 IU/ml for the MEF strain and 175-196 IU/ml for the Sauket strain. Patients with longstanding RA conserve long-term immunity to common viruses despite the use of immunosuppressive drugs. Levels of antiviral antibodies against measles, rubella and polio remain stable under treatment with infliximab.

  8. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.

    Science.gov (United States)

    Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; Péntek, Márta

    2014-05-01

    The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries. This paper presents the estimated budget impact of the introduction of biosimilar infliximab in RA over a 3-year time period in six selected countries, namely Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. A prevalence-based model was constructed for budget impact analysis. Two scenarios were compared to the reference scenario (RSc) where no biosimilar infliximab is available: biosimilar scenario 1 (BSc1), where interchanging the originator infliximab with biosimilar infliximab is disallowed, and only patients who start new biological therapy are allowed to use biosimilar infliximab; as well as biosimilar scenario 2 (BSc2), where interchanging the originator infliximab with biosimilar infliximab is allowed, and 80% of patients treated with originator infliximab are interchanged to biosimilar infliximab. Compared to the RSc, the net savings are estimated to be €15.3 or €20.8 M in BSc1 and BSc2, respectively, over the 3 years. If budget savings were spent on reimbursement of additional biosimilar infliximab treatment, approximately 1,200 or 1,800 more patients could be treated in the six countries within 3 years in the two biosimilar scenarios, respectively. The actual saving is most sensitive to the assumption of the acquisition cost of the biosimilar drug and to the initial number of patients treated with biological therapy. The study focused on one indication (RA) and demonstrated that the introduction of biosimilar infliximab can lead to substantial budget savings in health care budgets. Further savings are expected for other indications where biosimilar medicines are implemented.

  9. Stormfuld vandretur med nymodens teknik

    DEFF Research Database (Denmark)

    Nielsen, Niels Christian

    2008-01-01

    Lørdag den 1. marts 2008 havde en af vores samarbejdspartnere, Miljøforeningen på Fanø havde inviteret til vandretur ad Hjertestien ved Nordby. Vi benyttede lejligheden til at afprøve GPS-udstyr, der var anskaffet til ToLearn projektet, mhp. introduktion af nye steds-baserede teknologier og medie...... i turisme og kulturformidling. Forsøget lykkedes, da de indhentede geografiske data var af tilstrækkelig præcision, og da det med brug af frit tilgængeligt software lod sig gøre at lave grafisk tilfredsstillende illustrationer til brug i den lokale presse. Udgivelsesdato: 13/3 2008...

  10. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

    DEFF Research Database (Denmark)

    Carlsen, K M; Riis, L; Madsen, O R

    2009-01-01

    We present a case of toxic hepatitis related to infliximab treatment in a 38-year-old woman with rheumatoid arthritis (RA). The patient had previously been treated with different disease-modifying drugs (DMARDs) alone or in combination but had never revealed signs of liver dysfunction. Due to high...... disease activity, treatment with infliximab (3 mg/kg i.v.) was initiated in combination with methotrexate (MTX) (25 mg/week) and folic acid (5 mg/week). The patient stopped MTX and folic acid on her own initiative after 3 weeks due to improvement of joint symptoms. After seven infusions, progressive...... elevations of the transaminases up to five times the upper normal limit were noted and treatment with infliximab was terminated. Serological tests for viral and autoimmune hepatitis and for ANA and anti-dsDNA were all negative. Specific infliximab antibodies could not be detected. Ultrasound of the liver...

  11. The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production

    Science.gov (United States)

    Kanojia, Gaurav; Have, Rimko ten; Bakker, Arjen; Wagner, Koen; Frijlink, Henderik W.; Kersten, Gideon F. A.; Amorij, Jean-Pierre

    2016-01-01

    In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn’s disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients. The drying processes did not affect Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF binding) were retained. Accelerated stability studies (1 month at 60°C) showed that the TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations showed some chemical modification of the IgG in the dextran-sucrose formulation, probably due to Maillard reaction products. This study indicates that, with the appropriate formulation, both spray-drying and freeze-drying may be useful for (bulk) powder production of Infliximab. PMID:27706175

  12. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

    DEFF Research Database (Denmark)

    Bendtzen, Klaus; Geborek, Pierre; Svenson, Morten

    2006-01-01

    Infliximab, an anti-tumor necrosis factor alpha (anti-TNFalpha) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be beneficial...

  13. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel.

    Science.gov (United States)

    Shrestha, Rabin K; Stoller, James K; Honari, Golara; Procop, Gary W; Gordon, Steven M

    2004-06-01

    The use of humanized antibody against tumor necrosis factor alpha (TNF-alpha) may increase the risk of various opportunistic infections, including tuberculosis and fungal infections. We report a case of cryptococcal pneumonia in a patient who was taking infliximab for rheumatoid arthritis. A temporally related exposure history raised the possibility that our patient acquired the infection from his pet cockatiel. It seems prudent to advise patients receiving infliximab to avoid exposure to pet avian excreta.

  14. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.

    Science.gov (United States)

    Cárdenas, M; de la Fuente, S; Font, P; Castro-Villegas, M C; Romero-Gómez, M; Ruiz-Vílchez, D; Calvo-Gutiérez, J; Escudero-Contreras, A; Casado, M A; Del Prado, J R; Collantes-Estévez, E

    2016-02-01

    Biological drugs have proven efficacy and effectiveness in treatment of rheumatoid arthritis (RA), although none has been shown to be superior. Few studies have evaluated the cost-effectiveness of biological drugs in real-life clinical conditions. The objective of this study was to compare the cost-effectiveness of infliximab, etanercept and adalimumab in achieving clinical remission (DAS28 infliximab, etanercept or adalimumab in the Reina Sofia Hospital (Cordoba, Spain) between January 1, 2007, and December 31, 2012. Effectiveness was measured as the percentage of patients who achieved clinical remission after 2 years. The cost analysis considered the use of direct health resources (perspective of the healthcare system). Cost-effectiveness was calculated by dividing the total mean cost of each treatment by the percentage of patients who achieved remission. One hundred and thirty patients were included: 55 with infliximab, 44 with adalimumab and 31 with etanercept. After 2 years, 45.2 % of patients with adalimumab achieved clinical remission, versus 29.1 % with infliximab (p = 0.133) and 22.7 % with etanercept (p = 0.040), with no differences between etanercept and infliximab (p = 0.475). The average total cost at 2 years was €29,858, €25,329 and €23,309 for adalimumab, infliximab and etanercept, respectively, while the mean cost (95 %CI) to achieve remission was €66,057 (48,038–84,076), €87,040 (78,496–95,584) and €102,683 (94,559–110,807), respectively. Adalimumab was more efficient than etanercept (p infliximab (p = 0.026), with no differences between etanercept and infliximab (p = 0.086). Adalimumab was the most cost-effective treatment in achieving clinical remission in real-life clinical conditions in RA patients during the study period.

  15. Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment.

    Science.gov (United States)

    Takeuchi, Masaru; Karasawa, Yoko; Harimoto, Kohzou; Tanaka, Atsushi; Shibata, Masaki; Sato, Tomohito; Caspi, Rachel R; Ito, Masataka

    2017-02-01

    To examine antigen-stimulated cytokine production by Behçet disease patients (BD) before and after infliximab infusion. PBMCs were obtained before and after infliximab infusion in BD patients with or without recurrent uveitis during at least 1 year of infliximab therapy, and from healthy subjects. PBMCs were cultured with IRBP, and Th-related cytokines in cultures were measured. Levels of IL-4, IL-6, IL-10 IL-17A, IL-17F, IL-31, IFN-γ, and TNFα were higher in BD before infliximab infusion than in healthy subjects, and these levels were the highest in BD with recurrent uveitis. After infliximab infusion, these cytokine levels were reduced to a greater extent in BD without recurrent uveitis than in BD with recurrence. Th-related cytokines produced by IRBP-stimulated PBMCs were elevated in BD, and infliximab infusion suppressed these cytokines to a greater extent in BD without recurrent uveitis than in those with recurrence.

  16. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients*

    Science.gov (United States)

    Antonio, João Roberto; Sanmiguel, Jessica; Cagnon, Giovana Viotto; Augusto, Marília Silveira Faeda; de Godoy, Moacir Fernandes; Pozetti, Eurides Maria Oliveira

    2016-01-01

    Background Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature. Objective To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis). Method Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment. Results 168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events. Conclusion Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions. PMID:27438197

  17. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

    Directory of Open Access Journals (Sweden)

    Rafael Denadai

    2012-06-01

    Full Text Available CONTEXT: Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD patients. OBJECTIVE: To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach. METHODS: A systematic literature review was performed utilizing Medline, Embase, SciELO and Lilacs databases. Published studies were identified, reviewed and the data were extracted. RESULTS: Thirty-four studies (69 IBD patients met inclusion criteria for review. There was inconsistency in reporting of some clinical and therapeutic aspects. Most patients included had Crohn's disease (89.86%, was female (47.83%, had an average age of 27.11 years, and no reported history of psoriasis (84.05%. The patients developed primarily plaque-type psoriasis (40.58%. There was complete remission of psoriatic lesions in 86.96% of IBD patients, existing differences in the therapeutic approaches; cessation of infliximab therapy led to resolution in 47.83% of cases and 43.48% of patients were able to continue infliximab therapy. CONCLUSION: As increasing numbers of IBD patients with psoriasis induced or exacerbated by infliximab, physicians should be aware of its clinical manifestations so that appropriate diagnosis and treatment are properly established. The decision whether to continue or discontinue infliximab should be individualized.

  18. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.

    Science.gov (United States)

    Cañete, Juan D; Pablos, José L; Sanmartí, Raimon; Mallofré, Carmen; Marsal, Sara; Maymó, Joan; Gratacós, Jordi; Mezquita, Jovita; Mezquita, Cristobal; Cid, Maria C

    2004-05-01

    Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to analyze the effects of infliximab on angiogenesis in the synovial membrane of patients with PsA who responded to this therapy. The study group comprised 9 patients with PsA who were selected for the presence of active polyarthritis (including knee synovitis) despite methotrexate therapy. Clinical and biologic evaluations were performed at each visit. Arthroscopy and synovial biopsies were performed at week 0, before infliximab therapy was initiated, and at week 8, after administration of 3 intravenous infusions of infliximab (5 mg/kg). We used immunohistochemistry to identify changes in infiltrating cells and in the angiogenesis modulators alphavbeta3 integrin, vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang-2), flt-1 (VEGF receptor 1 [VEGFR-1]), kinase insert domain receptor [KDR]/flk-1 (VEGFR-2), and stromal cell-derived factor 1 (SDF-1). Neovascularization was assessed by automated histomorphometry of CD31+ vessels and by measuring alphavbeta3 expression. Rapid and significant clinical and biological improvement were observed after treatment in all patients. In the synovium, infliximab therapy induced a significant reduction in macrophages, the CD31+ vascular area, alphavbeta3+ neovessels/Ulex europaeus agglutinin+ vessels, VEGF and its receptor KDR/flk-1 (VEGFR-2), and SDF-1+ vessels. Expression of flt-1 (VEGFR-1), and SDF-1 in lining cells showed a nonsignificant reduction, whereas expression of Ang-2 increased. In 3 patients, reverse transcription-polymerase chain reaction confirmed the changes in some of these markers at the messenger RNA level. These results show consistent changes in several factors involved in angiogenesis regulation, in parallel with the clinical response to

  19. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

    OpenAIRE

    Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; Péntek, Márta

    2014-01-01

    The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries. This paper presents the estimated budget impact of the introduction of biosimilar infliximab in RA over a 3-year time period in six selected countries, namely Bulgaria, the Czech Republic, Hungary...

  20. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.

    Science.gov (United States)

    Dillman, Jonathan R; Dehkordy, Soudabeh Fazeli; Smith, Ethan A; DiPietro, Michael A; Sanchez, Ramon; DeMatos-Maillard, Vera; Adler, Jeremy; Zhang, Bin; Trout, Andrew T

    2017-07-01

    Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab. We included 28 pediatric patients treated with infliximab for newly diagnosed ileal Crohn disease who underwent bowel sonography prior to medical therapy and at approximately 2 weeks, 1 month, 3 months and 6 months after treatment initiation; these patients also had laboratory testing at baseline, 1 month and 6 months. We used linear mixed models to compare mean results between visits and evaluate whether ultrasound measurements changed over time. We used Spearman rank correlation to assess bivariate relationships. Mean subject age was 15.3±2.2 years; 11 subjects were girls (39%). We observed decreases in mean length of disease involvement (12.0±5.4 vs. 9.1±5.3 cm, P=0.02), maximum bowel wall thickness (5.6±1.8 vs. 4.7±1.7 mm, P=0.02), bowel wall color Doppler signal (1.7±0.9 vs. 1.2±0.8, P=0.002) and mesenteric color Doppler signal (1.1±0.9 vs. 0.6±0.6, P=0.005) at approximately 2 weeks following the initiation of infliximab compared to baseline. All laboratory inflammatory markers decreased at 1 month (P-valuesdisease involvement (P=0.0002) and bowel wall color Doppler signal (PCrohn's disease activity index score. The ultrasound appearance of the bowel changes as early as 2 weeks after the initiation of infliximab therapy. There is strong correlation between bowel wall color Doppler signal and fecal calprotectin.

  1. Uso de infliximab en pacientes de un centro reumatológico Use of infliximab in patients of a rheumatologic center

    Directory of Open Access Journals (Sweden)

    Ingrid Strusberg

    2005-03-01

    Full Text Available El objetivo de este estudio fue obtener información postmarketing sobre el uso de infliximab en un centro reumatológico de atención ambulatoria. Se realizó un análisis retrospectivo y prospectivo de las historias clínicas de pacientes con diagnóstico de artritis reumatoidea ( n=37 , artritis psoriásica ( n=5 , enfermedad mixta del tejido conectivo ( n=1 y espondilitis anquilosante ( n=2 que recibieron infliximab (3 mg / kg desde agosto de 2000 a junio de 2003. El análisis descriptivo se realizó con porcentajes, media o mediana y desviación estándar o intervalo intercuartilo . La prueba de Wilcoxon se utilizó para el análisis apareado de dosis de antiinflamatorios no esteroideos y metotrexato , anterior y posterior a la administración de infliximab. Se consideraron significativos valores de p £ 0.05. Se incluyeron 45 pacientes a los que se les administraron un total de 207 infusiones. En 2 pacientes el infliximab se discontinuó debido a lumbalgia severa durante la infusión y en otros 2 por anafilaxia intrainfusional. Otras reacciones adversas ocurridas durante las infusiones fueron moderadas y respondieron adecuadamente al tratamiento estándar. Se presentó un caso de artritis séptica de rodilla por estafilococos. Un caso de artritis reumatoidea con insuficiencia renal compensada recibió infliximab en dosis de 1.9 mg / kg cada 30 días, sin cambios en la función renal. Al momento, ningún paciente ha desarrollado tuberculosis activa. Debido a la mejoría clínica, se redujo la dosis de corticoides en 14/39 (35.9% pacientes, de antiinflamatorios no esteroideos en 15/43 (34.8% y de metotrexato en 12/34 (35.3%. En esta serie de casos se muestra el perfil de seguridad de infliximab, la posibilidad de reducir la dosis de drogas concomitantes, así como algunos enfoques individuales sobre situaciones para las cuales no disponemos de guías basadas en la evidencia médica, y en las que los reumatólogos debemos tomar decisiones seg

  2. Mødet med det fremmede

    DEFF Research Database (Denmark)

    Ernlund, Mette Skovgaard

    Bogen tager læseren med på en spændende rejse igennem Danmark, Norge, Belgien og Frankrig, hvor studerende i international mobilitet ivrigt fortæller om deres liv og oplevelser med at være i en fremmed kultur. Formålet med de kvalitative undersøgelser, der ligger bag bogens tilblivelse, har såled...

  3. Casestudie - En ung pige med debuterende skizofreni

    OpenAIRE

    Britta Frederiksen

    2005-01-01

    Artiklen beskriver et individuelt musikterapiforløb med en ung skizofren pige. Der fokuseres på at beskrive den musikalske interaktion som udtryk for patientens udvikling i forløbet. For at strukturere og overskueliggøre beskrivelsen af det musikalske materiale anvendes bl.a. Mercedes Pavlicevics Musikalske Interaktion Ratings (MIR) med 9 niveauer til at beskriveinteraktionen mellem patient og terapeut i musikalske kliniske improvisationer. Suppleret med patient kommentarer og terapeutens not...

  4. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Brynskov, Jørn; Thomsen, Ole Ø

    2015-01-01

    BACKGROUND: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. AIM: This study investigated long-term economic outcomes......-protocol patients (n = 55), costs at the week 20 follow-up visit were even lower (49 %) in the algorithm group: $8,742 versus $17,236; p = 0.002. Figures were similar for patients having completed the 12-week trial as per protocol (50 % reduction in costs) (n = 45). Among patients continuing the allocated study...

  5. Danske børn med sprogforstyrrelser

    DEFF Research Database (Denmark)

    Sundahl Olsen, Lone

    2013-01-01

    , italiensk, svensk og hebræisk osv. Det specifikke udfald af SLI afviger dog fra sprog til sprog, og der er på nuværende tidspunkt ikke udført systematisk forskning, der dokumenterer det specifikke udfald af SLI for danske børn. De primære mål med denne ph.d.-afhandling var at undersøge:  Grammatiske...... aldersmatchede og yngre børn med typisk sprogudvikling. Studie III viste, at sproglige vanskeligheder var signifikant associeret med dårlig arbejdshukommelse for børnene med SLI, men ikke for børnene med typisk sprogudvikling. Børnene med SLI havde dog alderssvarende hukommelsesmæssige færdigheder, når der var...... hos børn med SLI end den, der kendertegner børn, der følger en typisk sprogudvikling. Studiet indikerer dog, at børn med SLI ikke har generelle hukommelsesmæssige vanskeligheder, men at der formodentlig eksisterer en uoverensstemmelse mellem krav og ressourcer, hvor børnene med typisk sprogudvikling...

  6. Tandlægers erfaringer med at foreslå og få gennemført behandling med kroner og broer i privat praksis [Experiences of Danish dentists in private practice in motivating treatment with crowns and bridges

    DEFF Research Database (Denmark)

    Isidor, F.; Moore, R.

    2003-01-01

    English:What subjective experiences have Danish dentists in private practice to propose and implement treatment with crowns and bridges? A mailed questionnaire were completed and returned by 216 private practice dentists for a random sample from Aarhus. Of these, 22% thought...... and bridges, or lack of success in getting treatment completed hung mostly with practice type and location. Almost 76% of the dentists felt that it should be possible to learn how to motivate patients for the expensive treatments (eg bridges). More than 90% of the dentists felt the need for a better insurance...

  7. Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab

    Directory of Open Access Journals (Sweden)

    Fernando A. Díaz-Couselo

    2011-01-01

    Full Text Available Acremonium spp. are filamentous, cosmopolitan fungi commonly isolated from plant debris and soil. They are infrequent pathogens in humans. Acremonium fungemia has been reported in neutropenic patients associated with central venous catheters and in nonneutropenic patients receiving long-term total parenteral nutrition. TNF-α blockade is associated with fungal infections, but no Acremonium spp. infection had been reported up to the present. In this paper, we present a patient with ulcerative colitis who developed Acremonium kiliense fungemia associated with infliximab therapy while receiving total parenteral nutrition. The patient was successfully treated with voriconazole. Acremonium sp. infection must be suspected as another cause of fungal infection in patients under treatment with infliximab.

  8. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: A case report.

    Science.gov (United States)

    Rüddel, J; Schleenvoigt, B T; Schüler, E; Schmidt, C; Pletz, M W; Stallmach, A

    2016-09-01

    We report the case of a 59-year-old patient who accidentally underwent live vaccination against yellow fever during continuous treatment with the TNF-α-antibody (AB) infliximab for ulcerative colitis. The clinical course showed fever of short duration and elevation of liver enzymes without further clinical complications. Yellow fever viremia was not detectable and protective antibodies were developed. A primary vaccination against yellow fever under infliximab has not been reported in the literature before, although vaccination is an important topic in IBD. Live vaccinations, like Stamaril(®) against yellow fever, are contraindicated during TNF-α-AB treatment. Treatment regimens containing TNF-α-AB are of growing importance, not only in gastroenterology, but also in rheumatology and dermatology. We discuss this topic by presenting our case and reviewing the current literature.

  9. Complement activation in plasma before and after infliximab treatment in Crohn disease

    DEFF Research Database (Denmark)

    Zimmermann-Nielsen, E; Agnholt, J; Thorlacius-Ussing, O

    2003-01-01

    BACKGROUND: Crohn disease is characterized by up-regulated intestinal inflammation mainly caused by increased tumour necrosis factor alpha (TNF-alpha) levels. However, the complement system (C) may also have a role in maintaining inflammation. METHODS: Plasma from 26 patients with Crohn disease...... complicated by fistulizing ano-rectal disease was collected before and after three Infliximab infusions (5 mg kg(-1)). RESULTS: Before treatment, the C3-activation capacities (C3-AC) in plasma from patients with Crohn disease were comparable with values obtained from healthy controls. The classical C pathway......-mediated C3-AC, mannan-binding lectin C4-AC, leucocyte count, C-reactive protein concentration and Crohn Disease Activity Index decreased significantly 8 weeks after the first infusion of Infliximab (P

  10. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.

    Science.gov (United States)

    Williet, Nicolas; Paul, Stephane; Peyrin-Biroulet, Laurent; Roblin, Xavier

    2016-04-01

    Local or national policy, patients' preferences, safety and/or economic concerns, or reimbursement issues may dictate stopping drug in inflammatory bowel diseases (IBD) patients. Sustained deep remission is an important predictor of a better outcome after anti-tumor necrosis (TNF) factor therapy discontinuation, including infliximab (IFX) in IBD patients, but this is not sufficient to prevent future relapse in these patients. In IBD patients under combotherapy, trough level of infliximab (TRI) could be helpful to choose stopping one of the two drugs. In patients on IFX monotherapy, TRI could help to decide reduction of drug dosing, particularly in IBD patients with supratherapeutic trough levels. Incidental findings of undetectable TRI in patients with deep remission may identify a subset of patients who may be considered for IFX cessation. Controlled trials further assessing this issue are eagerly awaited. Pending these trials, clear international recommendations for discontinuing anti-TNF therapy are needed.

  11. [Utility of infliximab therapy in severe enterorrhagia associated with Crohn's disease. Report of three cases].

    Science.gov (United States)

    Alcalde Vargas, Alfonso; Justiniano, José Manuel Herrera; Carnerero, Eduardo Leo; Salado, Claudio Trigo; Domingo, Ignacio Gutiérrez; Galán, José Luis Márquez

    2011-01-01

    Severe lower gastrointestinal (GI) bleeding is an infrequent complication in Crohn's disease. We report the cases of three patients with Crohn's disease, localized in distinct areas, who developed severe enterorrhagia requiring multiple transfusions. All three patients responded favorably to infliximab administration, which resolved the life-threatening hemorrhages and avoided emergency surgical resection, which had seemed inevitable. Based on this clinical experience and a review of the literature comparing infliximab with other pharmacological options, we believe that this drug should be the treatment of choice in patients with Crohn's disease who develop severe lower gastrointestinal bleeding. This strategy can, in some cases, avoid surgery if the bleeding stops due to rapid healing of the deep mucosal lesions causing the hemorrhagic episode.

  12. Diarrhoea in a patient with metastatic melanoma:Ipilimumab ileocolitis treated with infliximab

    Institute of Scientific and Technical Information of China (English)

    Rob; ME; Slangen; Alfonsus; JM; van; den; Eertwegh; Adriaan; A; van; Bodegraven; Nanne; KH; de; Boer

    2013-01-01

    Administration of ipilimumab,a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody,leads to enhancement of the anti-tumor T-cell respons and as a result shows a significant survival benefit in metastatic melanoma patients.Therefore patients are currently receiving this promising therapy as a secondline strategy.Unfortunately,by activation of the T-cell immune reponse,ipilimumab therapy may lead to an unwanted induction of different autoimmune phenomena.Diarrhoea and colitis occur in up to one third of patients.Here we present a case of ipilimumab induced ileocolitis which was successfully treated with infliximab,an anti-tumor necrosis factor monoclonal antibody,after corticosteroid therapy failure.Although formal trials are lacking,recently publicated series suggest that infusional therapy of infliximab is effective in ipilimumab induced ileocolitis.

  13. Effect of infliximab on small bowel stenoses in patients with Crohn's disease

    Institute of Scientific and Technical Information of China (English)

    Nadia Pallotta; Fausto Barberani; Naima Abdulkadir Hassan; Danila Guagnozzi; Giuseppina Vincoli; Enrico Corazziari

    2008-01-01

    AIM: To assess prospectively small bowel stenoses in Crohn's disease (CD) patients treated with infliximab using Small Intestine Contrast Ultrasonography (SICUS).METHODS: Twenty patients (M 12, age, 42.7 ± 11.8 years), 15 of whom showed obstructive symptoms indicating the presence of small bowel stenosis, and 5 without stenosis, were treated with infliximab (5 mg/kg at wk 0, 2, 6 and 5 mg/kg every 8 wk thereafter) for steroid refractoriness, fistulizing disease, or to avoid high-risk surgery. SICUS was performed at the induction phase and at regular time intervals during the follow-up period of 34.7 ± 16.1 mo (range 7-58). Small bowel stenoses were detected by SICUS, endoscopy and MRI.RESULTS: In no case was progression of stenoses or the appearance of new ones seen. Of the 15 patients with stenosis, 5 stopped treatment after the induction phase (2 for no response, 3 for drug intolerance, one of whom showed complete regression of one stenosis). Among the remaining 10 patients, a complete regression of 8 stenoses (1 stenosis in 5 patients and 3 stenoses in one patient) was observed after 6-22 infliximab infusions.CONCLUSION: In patients with CD treated with infliximab we observed: (a) No progression of small bowel stenosis and no appearance of new ones, (b) Complete regression of 1/22 stenosis after the induction phase and of 8/15 (53.3%) stenosis after 6-22 infusions during maintenance therapy.

  14. Infliximab for the Treatment of Crohn'S Disease: Review and Indications for Clinical Use in Canada

    Directory of Open Access Journals (Sweden)

    Remo Panaccione

    2001-01-01

    Full Text Available Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract. It may affect any portion of the gastrointestinal tract from the mouth to the anus. Symptoms typically include cramping abdominal pain, diarrhea (which may be bloody and nausea. As the severity of the illness worsens, patients may experience constant abdominal pain, vomiting, weight loss and fever. From the perspective of the patient, disease symptoms significantly impair quality of life, and interfere with their work environment and activities of daily living. Unfortunately, there is no cure for Crohn's disease. Patients experience a chronic, relapsing course characterized by recurrent flares of their disease. Conventional medical treatment of Crohn's disease includes the use of non-specific anti-inflammatory drugs (5-aminosalicylic acid agents, prednisone, budesonide, immunosuppressives (6-mercaptopurine, azathioprine, methotrexate and antibiotics. A variable onset of action, incomplete response rates and a significant risk of adverse effects characterize current therapies. Although surgery is frequently used to treat complications or medically refractory disease, postoperative recurrence is a common problem. Infliximab, a murine chimeric monoclonal antibody directed toward tumour necrosis factor-alpha, is a highly effective treatment of active Crohn's disease. In randomized, placebo-controlled clinical trials, 33% of patients treated with infliximab 5 mg/kg achieved remission (Crohn's Disease Activity Index score less than 150, compared with only 4% of those receiving placebo (P<0.001. Additionally, infliximab is the only drug therapy shown to be effective for the treatment of fistulizing Crohn's disease. In studies done to date, infliximab appears to be well tolerated and has a favourable side effect profile.

  15. Crohn's Disease Associated with Sweet's Syndrome and Sjögren's Syndrome Treated with Infliximab

    Directory of Open Access Journals (Sweden)

    Erina N. Foster

    2005-01-01

    Full Text Available The association of Crohn's disease (CD and Sweet's syndrome is rare and the presence of Sjögren's syndrome in Crohn's disease is even rarer, with only three reports found in the literature. We describe two cases of Crohn's disease associated with Sweet's syndrome, one of which is the first case of CD and Sweet's concomitantly associated with Sjögren's syndrome. Both cases responded rapidly to Infliximab therapy with complete resolution of the skin lesions.

  16. EFFECTIVENESS AND SAFETY OF INFLIXIMAB IN PATIENTS WITH EARLY AND LATE JUVENILE RHEUMATOID ARTHRITIS

    Directory of Open Access Journals (Sweden)

    Е.I. Alexeeva

    2010-01-01

    Full Text Available The article presents results of a study of effectiveness and safety of infliximab — monoclonal antibodies to the tumor necrotizing factor (TNF in treatment of 100 patients11 months — 17 years old with early and late articular types of juvenile rheumatoid arthritis. The duration of treatment was 3 months — 2 years. Infliximap was delivered intravenously by scheme: infusion on 0, 2nd, 6th weeks and then every 8th week. The single dose of infliximab in patients with early rheumatoid arthritis was 6.7 (5.5; 9.0 mg/kg, with late type — 6.0 (5.0; 7.0 mg/kg of body weight. 102 weeks of treatment with anti-TNF-agent provided development of clinical remission, decrease and normalization of laboratory tests of disease’s activity, total restoration of joint’s function, increase of quality of life (on 97% in patients with early type, and 72% 0 in ones with late type. The drug was abolished in 39 (39% of patients, 23% — due to the development of secondary inefficiency, and 11% — due to the development of unfavorable effects.Key words: children, early and late rheumatoid arthritis, treatment, infliximab.(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(3:30-42

  17. The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis.

    Science.gov (United States)

    Ersözlü-Bozkırlı, E D; Keşkek, S O; Bozkırlı, E; Yücel, A E

    2015-01-01

    Ankylosing spondylitis is a chronic inflammatory disease which physically, psychologically, and socially affects the patient's life. Previous studies have reported a correlation between ankylosing spondylitis and depression. In this study we investigated the effect of infliximab on depression in ankylosing spondylitis patients. A total of 29 patients with ankylosing spondylitis were enrolled in this prospective study. Infliximab was administered intravenously at a dose of 5 mg/kg at baseline, weeks 2 and 6. The measurements of morning stiffness, modified Schober's test, chest expansion, erythrocyte sedimentation rate, C-reactive protein, Bath ankylosing spondylitis disease activity index, Bath ankylosing spondylitis functional index and Beck depression inventory scores were compared with baseline and 12th week. The modified Schober's test and chest expansion increased, the morning stiffness duration, erythrocyte sedimentation rate and C-reactive protein levels decreased after infliximab treatment (p ankylosing spondylitis disease activity index, Bath ankylosing spondylitis functional index and Beck depression invantory scores of patients after 12 weeks (p ankylosing spondylitis..

  18. Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress.

    Science.gov (United States)

    Benhamou, Ygal; Miranda, Sébastien; Armengol, Guillaume; Harouki, Najah; Drouot, Laurent; Zahr, Noel; Thuillez, Christian; Boyer, Olivier; Levesque, Hervé; Joannides, Robinson; Richard, Vincent

    2015-08-01

    Antiphospholipid syndrome (APS), induces endothelial dysfunction, oxidative stress and systemic inflammation that may be mediated by TNFα. Thus, we investigated the possible protective effect of the anti-TNFα antibody infliximab (5μg/g) on endothelial function in a mouse APS model (induced by injection of purified human anti-β2GP1-IgG). Seven days after anti-β2GPI-IgG injection, we observed an increase in plasma sVCAM-1 and sE-selectin levels and in aortic mRNA expression of VCAM-1 and E-selectin. This was associated with a decreased endothelium-dependent relaxation of isolated mesenteric arteries to acetylcholine, together with decreased mesenteric eNOS mRNA expression and increased eNOS uncoupling, accompanied by increased iNOS and gp91phox mRNA and increased left ventricular GSH/GSSH ratio. Infliximab significantly improved the NO-mediated relaxing responses to acetylcholine, and induced a decrease in iNOS and gp91phox mRNA expression. The õpro-adhesive and pro-coagulant phenotypes induced by the anti-β2GP1-IgG were also reversed. This study provides the first evidence that TNFα antagonism improves endothelial dysfunction in APS and suggests that endothelial dysfunction is mediated by TNFα and oxidative stress. Therefore, infliximab may be of special relevance in clinical practice.

  19. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.

    Science.gov (United States)

    Hernández-Flórez, Diana; Valor, Lara; de la Torre, Inmaculada; Nieto, Juan Carlos; Martínez-Estupiñán, Lina; González, Carlos; López-Longo, Francisco Javier; Monteagudo, Indalecio; Garrido, Jesús; Naredo, Esperanza; Carreño, Luis

    2015-06-01

    There are various immunosorbent assays which can be used to determine infliximab (IFX) levels. Results vary between assays complicating reliability in everyday clinical practice. The aim of this study was to determine whether quantitative or qualitative assay data prove more accurate in the assessment of infliximab levels in AS patients. We analyzed 40 serum samples, taken prior to infusion, from AS patients who had been undergoing IFX therapy as a first-line of biological treatment for more than a year. IFX levels and IFX-anti-drug antibodies (ADA) were measured using two different ELISA assays [Promonitor IFX R1 and R2 (version 1), Promonitor IFX and anti-IFX (version 2) (Progenika Biopharma, Spain)] strictly following the manufacturer's guidelines. Cohen's unweighted kappa and the intraclass correlation coefficient determined qualitative and quantitative agreement for serum levels in version 1 and version 2. Bland-Altman plots were drawn to compare both assays. The comparison of data measuring IFX levels for version 1 and version 2 resulted in questionable quantitative agreement (ICC 0.659; 95% CI 0.317-0.830) and moderate qualitative agreement (κ 0.607; 95% CI 0.387-0.879) owing to systematically higher values in version 2 than version 1. Version 2 consistently detected higher levels of infliximab, particularly when analyzed in a quantitative context. Further research is needed to synchronize cutoff levels between essays and diseases so therapeutic drug ranges can be established.

  20. Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas

    Science.gov (United States)

    Wu, Xiao-Li; Tao, Li-Ping; Wu, Jian-Sheng; Chen, Xiang-Rong

    2016-01-01

    Aim. This study was performed to evaluate the additional enteral nutrition (EN) in the efficacy of infliximab (IFX) compared with the conventional therapy in managing Crohn's disease (CD) complicated with intestinal fistulas. Methods. A total of 42 CD with intestinal fistulas were randomly divided into infliximab treatment group (n = 20) and conventional therapy group (n = 22). We evaluated the laboratory indexes, Crohn's disease activity index (CDAI), Crohn's disease simplified endoscopic score (SES-CD), and healing of fistula in the two groups before treatment, at 14 weeks, and at 30 weeks, respectively. Results. In the IFX treatment group, the CDAI score, the SES-CD, erythrocyte sedimentation rate, and C-reactive protein levels were significantly decreased during treatment compared with those before treatment. The body mass index and albumin levels were increased in both groups. Moreover, in the IFX treatment group, fistula healing was found in 8 at the 14th week and 18 at the 30th week, respectively, which was greater than that in the conventional therapy group. Conclusion. Our study suggested that infliximab combined with EN is an effective treatment for CD patients complicated with intestinal fistulas.

  1. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].

    Science.gov (United States)

    Vinagre, Filipe; Santos, Maria José; Silva, J Canas da

    2007-01-01

    The aim of this study was to access the maintenance of therapeutic response in patients with ankylosing spondylitis (AS) receiving infliximab, after prolongation of the interval between infusions. In AS patients with sustained therapeutic response to infliximab administered every six weeks, a prolongation of the interval between infusions was proposed. The therapeutic response was evaluated using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), pain, stiffness, patient's global evaluation and acute phase reactants (ESR and CPR). Twenty patients participated in the study. Sixteen were male, with a mean age of 40.3 +- 10.9 years and mean disease duration of 12 +- 9.4 years. The initial BASDAI was 59.5 +- 22.8 and initial BASFI 50.7 +- 27. The interval between infusions was lengthened to 8 +- 1 weeks (minimum 7; maximum 10) and this change occurred between 12 and 142 weeks (median 21) of treatment. The mean followup after changing the therapeutic regimen was 86 +- 45 weeks. Sixty-five percent (13/20) of the patients maintained an adequate response. Two thirds of AS patients with sustained therapeutic response to infliximab administrated every six weeks maintained an adequate response with prolongation of interval between infusions. Therefore the increase of the interval between infusions seems to be an adequate option in selected patients.

  2. Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab in psoriasis

    Directory of Open Access Journals (Sweden)

    Sridhar J

    2006-01-01

    Full Text Available Background: Insights into the pathogenesis of psoriasis have provided opportunities to target key steps in the disease process. Tumor necrosis factor-alpha (TNF-a being crucial to the pathogenesis of psoriasis, monoclonal antibodies against this cytokine have proved useful in its treatment. Aim: To study the efficacy of chimeric monoclonal antibody to TNF-a (infliximab in Indian patients with recalcitrant psoriasis vulgaris. Materials and Methods: Three patients with recalcitrant psoriasis vulgaris were studied. Baseline haemogram, biochemical parameters, chest radiograph and Mantoux skin test were performed. A loading dose regimen of 5 mg/kg infliximab was administered at weeks 0, 2 and 6. PASI assessment, adverse drug event monitoring and laboratory assessments were carried out at 2-week intervals until week 10. Patients were followed up until week 22 for relapse. Results: Infliximab was well tolerated. The mean PASI was 25.4 at presentation and declined to 5.5 at 10 weeks. PASI 75 was attained at a mean of 9.6 weeks. Relapse occurred at a mean of 18.6 weeks after the first infusion. Conclusions: This study on Indian patients brings out the importance of cytokine-based therapies in psoriasis. Indigenous production could make these therapies a viable therapeutic option for psoriasis patients in the near future.

  3. Hva er det med Irma?

    Directory of Open Access Journals (Sweden)

    Anne Beate Reinertsen

    2016-10-01

    Full Text Available Abstract: This article is about formative quality assessment in a posthuman or newmaterial perspective; embodied knowledges.  Theory and method are written together in immanence to envision complexity.  The aim and scope of the article is to follow the flow of events Irma produces opening up for affirmative poetical critique praxis. Quality is forwarded as an intensity and force in a moment only.  The moment is therefore the only structure of the text, as moving quality. The intention and inner logic of the text is therefore designed to work against fixed definitions and conceptualizations of what quality and quality assessment is.  This way I hope to show what posthuman and newmaterial approaches can contribute with to build cultures of innovation in which quality is assessed and produces again and again. They put differences to work and open up for creating moments of educational justice. Sammendrag: Artikkelen handler om kvalitetsvurdering i et nymaterielt perspektiv: Kroppslig kunnskap og viten. Teori og metode skrives sammen i immanent samtidighet for å gi et bilde på kompleksitet. Både hensikt og mål med artikkelen er å følge den flyten som Irma som hendelse eller event produserer, for å åpne opp potensialitet for en bekreftende eller affirmativ poetiserende kritikkpraksis og en ny forståelse av- og vurdering for kvalitet. Kvalitet skrives fram som en hendelse, intensitet eller kraft i et øyeblikk. Øyeblikket er derfor tekstens eneste og bærende struktur, som kvalitet i bevegelse. Tekstens indre logikk har slik til hensikt å motvirke forsøk på å skape definerte, faste eller bestemte oppfatninger av hva kvalitet er og hvordan kvalitet kan vurderes. På denne måten håper jeg å vise hva nymaterielle perspektiver kan gjøre for å bygge kulturer for innovasjon hvor kvalitet vurderes og produseres igjen og igjen. De setter forskjellighet i bevegelse og åpner opp for å skape rettferdige utdanningsøyeblikk.

  4. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis

    Institute of Scientific and Technical Information of China (English)

    Robert P Willert; Ian Craig Lawrance

    2008-01-01

    AIM: To determine if infliximab can prevent or delay surgery in refractory ulcerative colitis (UC).METHODS: UC patients who failed to have their disease controlled with conventional therapies and were to undergo colectomy if infliximab failed to induce a clinical improvement were reviewed.Patients were primarily treated with a single 5 mg/kg infliximab dose.The Colitis Activity Index (CAI) was used to determine response and remission.Data of 8 wk response and colectomy rates at 6 mo and 12 mo were collected.RESULTS: Fifteen patients were included, 7 with UC unresponsive or intolerant to IV hydrocortisone, and 8 with active disease despite oral steroids (all but one with therapeutic dosage and duration of immunomodulation).All the Ⅳ hydrocortisone-resistant/intolerant patients had been on azathioprine/6-MP < 8 wk.At 8 wk, infliximab induced a response in 86.7% (13/15) with 40% in remission (6/15).Within 6 mo of treatment 26.7% (4/15)had undergone colectomy and surgery was avoided in 46.6% (7/15) at 12 mo.The colectomy rate at 12 mo in those on immunomodulatory therapy < 8 wk at time of infliximab was 12.5% (1/8) compared with 100%(7/7) in patients who were on long-term maintenance immunomodulators (P < 0.02).CONCLUSION: Infliximab prevented colectomy due to active disease in immunomodulatory-naive, refractory UC patients comparable to the use of Cyclosporine.In patients, however, on effective dosage and duration of immunomodulation at time of infliximab therapy colectomy was not avoided.

  5. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial)

    Science.gov (United States)

    Eshuis, Emma J; Bemelman, Willem A; van Bodegraven, Ad A; Sprangers, Mirjam AG; Bossuyt, Patrick MM; de Wit, AW Marc van Milligen; Crolla, Rogier MPH; Cahen, Djuna L; Oostenbrug, Liekele E; Sosef, Meindert N; Voorburg, Annet MCJ; Davids, Paul HP; van der Woude, C Janneke; Lange, Johan; Mallant, Rosalie C; Boom, Maarten J; Lieverse, Rob J; van der Zaag, Edwin S; Houben, Martin HMG; Vecht, Juda; Pierik, Robert EGJM; van Ditzhuijsen, Theo JM; Prins, Hubert A; Marsman, Willem A; Stockmann, Henricus B; Brink, Menno A; Consten, Esther CJ; van der Werf, Sjoerd DJ; Marinelli, Andreas WKS; Jansen, Jeroen M; Gerhards, Michael F; Bolwerk, Clemens JM; Stassen, Laurents PS; Spanier, BW Marcel; Bilgen, Ernst Jan Spillenaar; van Berkel, Anne-Marie; Cense, Huib A; van Heukelem, Henk A; van de Laar, Arnold; Slot, Warner Bruins; Eijsbouts, Quirijn A; van Ooteghem, Nancy AM; van Wagensveld, Bart; van den Brande, Jan MH; van Geloven, Anna AW; Bruin, Karien F; Maring, John K; Oldenburg, Bas; van Hillegersberg, Richard; de Jong, Dirk J; Bleichrodt, Robert; van der Peet, Donald L; Dekkers, Pascal EP; Goei, T Hauwy; Stokkers, Pieter CF

    2008-01-01

    Background With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction. The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs. Methods/design The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007. Discussion The LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the

  6. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial

    Directory of Open Access Journals (Sweden)

    van Heukelem Henk A

    2008-08-01

    Full Text Available Abstract Background With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction. The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs. Methods/design The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007. Discussion The LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab

  7. The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes.

    Science.gov (United States)

    Park, Eun Jung; Song, Ki-Hwan; Baik, Seung Hyuk; Park, Jae Jun; Kang, Jeonghyun; Lee, Kang Young; Goo, Ja Il; Kim, Nam Kyu

    2017-08-26

    Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease. From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Patients were categorized into two groups as simple fistula (n = 20) and complex fistula group (n = 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6 weeks after surgical treatments. Then every eight weeks, the responders continued to receive 5 mg/kg infliximab for maintenance therapy. Complete response of induction therapy was 72.3%, and partial response was 27.7%. After maintenance therapy, complete response was 97.9% and partial response was 2.1%. There was no patient without a response to infliximab in this study. The median time to the first fistula closure was 6.00 ± 8.00 weeks. Infliximab was used on average 2.13 ± 0.71 times until the first fistula closure. The rate of recurrence was 8.5% and adverse events were 4.2%. In comparison with clinical manifestations between simple and complex fistula groups, there was no significant difference except for the coexistence of perianal abscess. Combined surgical and infliximab therapy was efficacious to treat fistulizing perianal Crohn's disease with rapid treatment response and favorable clinical outcomes. It is expected that this top-down strategy with combining surgeries can overcome previous limitations in treating perianal Crohn's disease. Copyright © 2017. Published by Elsevier Taiwan.

  8. Tratamento com infliximabe da doença de Behçet ativa Therapy with infliximab in active Behçet's disease

    Directory of Open Access Journals (Sweden)

    Alexandre Wagner Silva de Souza

    2005-04-01

    Full Text Available Os autores descrevem o caso de uma paciente de 41 anos de idade com diagnóstico de doença de Behçet, diagnosticada em abril de 2000. A paciente apresentava envolvimento mucocutâneo, articular e neurológico persistentes, apesar do tratamento com colchicina, corticosteróides e metotrexato, durante os três anos que se seguiram ao diagnóstico. Em abril de 2003, a paciente mantinha-se com a doença ativa, necessitando de altas doses de corticosteróides e de metotrexato. Optou-se, então, pela administração do infliximab, 3mg/kg por via endovenosa. Uma semana depois, havia ocorrido regressão completa das manifestações da doença de Behçet nesta paciente.The authors describe the case of a 41 years old woman with the diagnosis of Behçet's syndrome since April 2000, when she presented mucocutaneous, articular and ocular manifestations. The disease remained active despite of the treatment with colchicine, corticosteroid and methotrexate, during the three years following diagnosis. In April 2003, the patient still needed high doses of corticosteroid and methotrexate. Nevertheless, the disease remained active. Treatment with infliximab was then started with intravenous 3 mg/Kg and, one week later, all the manifestations of this patient were in complete remission.

  9. CanMEDS 2015: nog betere dokters?

    NARCIS (Netherlands)

    Borleffs, J C C; Mourits, M J E; Scheele, F

    2016-01-01

    Recently, the CanMEDS model, which forms the basis for competency-based learning in both undergraduate and postgraduate training, has been renewed by the introduction of CanMEDS 2015. The most prominent change is the emphasis on leadership skills, which is also reflected by the name change for the

  10. Automation med pneumatiske servodrev - status og fremtid

    DEFF Research Database (Denmark)

    Sørensen, Paul Haase

    1996-01-01

    Der er råd for problemer med ulineariteter. Med de nyeste metoder kan der lineære driftsområde udvides. Men pneumatikkomponenter skal være af høj kvalitet, når positionering skal være nøjagtig....

  11. At udvikle med børn

    DEFF Research Database (Denmark)

    Rasmussen, Jørgen; Sørensen, Tina Holm

    2012-01-01

    bl.a. gennem længerevarende processer og partnerskab med skoler og institutioner. Ligeledes inddrager artiklen erfaringer fra et tværfagligt projektet, ”Digi Form” og beskriver de udfordringer og potentialer der er identificeret gennem dette forløb. Artiklen afsluttes med en refleksion over hvorfor...

  12. Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease Retratamiento y tratamiento de mantenimiento con infliximab en la enfermedad de Crohn fistulizante

    Directory of Open Access Journals (Sweden)

    L. Rodrigo

    2004-08-01

    Full Text Available Objectives: infliximab has clearly demonstrated its efficacy in the short-term treatment of fistulizing Crohn' disease. We present here the results of retreatment and long-term maintenance therapy. Patients and methods: eighty one consecutive patients with active fistulizing Crohn' disease, in whom previous treatments had failed, were treated with infliximab. All patients received as the initial treatment of 5 mg/kg i.v. infusions (weeks 0, 2, and 6. Those patients who failed to respond after the initial cycle (group 1, n= 25, or those who relapsed after having responded (group 2, n=13, received retreatment with three similar doses (weeks 0,2, and 6. Those who responded to retreatment were included in a long-term maintenance programme (n=44, with repeated doses (5 mg/kg i.v. infusions every eight weeks for 1-2 years. Results: in the initial treatment 56% of the patients responded partially; this response being complete in 44%. In the retreatment, 28% of group 1 (non-responders presented a complete response, compared to 77% in group 2 (relapsers (pObjetivos: el infliximab ha demostrado su eficacia en el tratamiento a corto plazo de la enfermedad de Crohn (EC fistulosa. En este trabajo presentamos los resultados del retratamiento y del tratamiento de mantenimiento a largo plazo. Pacientes y métodos: se trataron con infliximab un total de 81 pacientes consecutivos con EC fistulosa activa, en los cuales, habían fallado tratamientos previos. Todos los pacientes recibieron como tratamiento inicial infusiones a dosis de 5 mg/kg i.v. en las semanas 0, 2 y 6. Aquellos pacientes que no respondieron después del ciclo inicial (grupo 1, n=25, o los que recayeron después de haber respondido (grupo 2, n=13, recibieron retratamiento con 3 dosis similares (semanas 0, 2 y 6. Aquellos que respondieron a la terapia de retratamiento fueron incluidos en un programa de mantenimiento a largo plazo (n=44, con dosis repetidas (infusiones con 5 mg/kg i.v. cada 8

  13. Relevansen af nyere psykodynamisk teori for det klinisk musikterapeutiske arbejde med psykiatriske patienter med personlighedsforstyrrelser

    DEFF Research Database (Denmark)

    Hannibal, Niels

    2007-01-01

    Denne artikel beskriver et rationale for anvendelse af musik i en psykoterapeutisk kontekst. Det eksplicitte og implicitte forandringsniveau i psykoterapi med patienter med borderline-personlighedsforstyrrelse (BPF) diskuteres herpå med henvisning til to forskellige syn på terapeutisk forandring...

  14. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind,placebo-controlled multicenter trial

    Institute of Scientific and Technical Information of China (English)

    YANG Hai-zhen; LIU Xiao-ming; TU Cai-xia; JI Su-zhen; SHEN Yang; ZHU Xue-jun; WANG Ke; JIN Hong-zhong; GAO Tian-wen; XIAO Sheng-xiang; XU Jin-hua; WANG Bao-xi; ZHANG Fu-ren; LI Chun-yang

    2012-01-01

    Background Tumor necrosis factor-α is a key mediator in the pathogenesis of psoriasis.Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-a.The purpose of this study was to validate the efficacy and safety of 5 mg/kg infiiximab therapy in Chinese patients with moderate to severe plaque psoriasis.Methods In this multicenter,double-blind,placebo-controlled trial,129 patients with moderate-to-severe psoriasis were randomized to the induction therapy (weeks 0,2 and 6) with infliximab 5 mg/kg (n=84) or placebo (n=45),followed with infliximab 5 mg/kg scheduled at week 14 and week 22 in the infliximab group,and infliximab 5 mg/kg scheduled at weeks 10,12 and 16 in the placebo group,The primary end point was the proportion of patients who achieved at least 75%improvement in Psoriasis Area and Severity Index (PASI 75 response rate) from baseline at week 10.Results At week 10,B1.0% of patients treated with infliximab (5 mg/kg) achieved a 75% or greater improvement compared with 2.2% of patients treated with placebo (P <0.001).A significant improvement in PASI,Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI),was seen from week 6 through week 14 in the infliximab group compared with the placebo group.Through week 22,PASI,PGA,DLQI were well maintained.The incidence of adverse events for the infliximab treatment group was slightly higher in comparison to the placebo treatment group during the first 10 weeks without statistical significance.However,there were 3 cases of tuberculosis that developed during the 26 weeks treatment with infliximal.Conclusions Infliximab treatment was effective as induction and maintenance treatments for Chinese patients with moderate to severe plaque psoriasis.Most drug-induced adverse events were mild to moderate,and well tolerated.Screening for tuberculosis is essential and prophylactic treatment should be given if necessary.

  15. CARD15 gene overexpression reduces effect of etanercept, infliximab, and adalimumab on cytokine secretion from PMA activated U937 cells.

    Science.gov (United States)

    Teimourian, Shahram; Masoudzadeh, Nooshin

    2015-09-05

    Crohn's disease (CD), a subcategory of inflammatory bowel disease, is an immune-related disorder characterized by inflammation of the gastrointestinal mucosa, which can take place in any region along the alimentary tract. The most important gene involved in the etiology of CD is NOD2/CARD15 located on chromosome 16. It has been shown that CARD15 is overexpressed in monocytes of CD patients. The common treatment for the disease is anti-TNF-alpha drugs, the most hopeful of which are probably infliximab and etanercept. Infliximab rapidly reduces signs and symptoms of active Crohn's disease. In contrast, etanercept shows no such effect. In the present study, we evaluated the effects of the CARD15 gene overexpression in monocytic cell line U937 in the production of anti-inflammatory cytokine, IL-10, and proinflammatory cytokine, Il-1 beta, produced after incubation with infliximab, adalimumab, and etanercept separately. Our results show that infliximab and adalimumab significantly decreased IL-10 and IL-1beta secretion levels. However, etanercept inhibition of secretion was less compared with infliximab or adalimumab. In all three cases, suppression of cytokine production is reduced by CARD15 overexpression.

  16. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    AIM: To evaluate the safety and efficacy of a longterm therapy with infliximab in Crohn's disease (CD) and ulcerative colitis (UC) patients retrospectively.METHODS: The medical charts of 50 patients (40 CD and 10 UC), who received after a loading dose of 3 infliximab infusions scheduled re-treatments every 8 wk as a maintenance protocol, were reviewed.RESULTS: Median (range) duration of treatment was 27 (4-64) mo in CD patients and 24.5 (6-46) mo in UC patients. Overall, 32 (80%) CD and 9 (90%) UC patients showed a sustained clinical response or remission throughout the maintenance period. Three CD patients shortened the interval between infusions. Eight (20%) CD patients and 1 UC patient underwent surgery for flare up of disease. Nine out of 29 CD and 4 out of 9 UC patients, who discontinued infliximab scheduled treatment, are still relapse-free after a median of 16 (5-30) and 6.5 (4-16) mo following the last infusion,respectively. Ten CD patients (25%) and 1 UC patient required concomitant steroid therapy during maintenance period, compared to 30 (75%) and 9 (90%) patients at enrolment. Of the 50 patients, 16 (32%) experienced at least 1 adverse event and 3 patients (6%) were diagnosed with cancer during maintenance treatment.CONCLUSION: Scheduled infliximab strategy is effective in maintaining long-term clinical remission both in CD and UC and determines a marked steroid sparing effect.Long-lasting remission was observed following infliximab withdrawal.

  17. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality

    DEFF Research Database (Denmark)

    Caspersen, Sarah; Elkjaer, Margarita; Riis, Lene

    2008-01-01

    BACKGROUND & AIMS: Data on safety and long-term follow-up evaluation of population-based cohorts of inflammatory bowel disease (IBD) patients treated with infliximab are sparse. The aim of this article is to describe the use of infliximab in a national Danish population-based IBD cohort during 19...

  18. Tratamento da doença de Crohn com infliximabe: primeira opção? Treatment of Crohn's disease with infliximab: first choice?

    Directory of Open Access Journals (Sweden)

    Anna Paula Rocha Malheiros

    2009-06-01

    Full Text Available RACIONAL: A doença de Crohn é uma inflamação crônica do trato gastrointestinal ainda de difícil tratamento. Há busca permanente de novos agentes que possam colaborar com a melhoria dos resultados. O infliximabe é um anticorpo monoclonal quimérico anti-fator de necrose tumoral alfa e está indicado na doença de Crohn refratária e fistulizante. OBJETIVO: Observar os resultados do tratamento da doença de Crohn com o anti-fator de necrose tumoral alfa. MÉTODOS: Estudo prospectivo de 60 doentes com doença de Crohn no período de seis anos. Foram considerados como critérios de exclusão: infecção atual ou nos últimos três meses; diagnóstico de tuberculose; quadro clínico e/ou radiológico de oclusão intestinal parcial ou total; gravidez ou amamentação. Todos os doentes foram previamente submetidos à radiografia do tórax, leucograma e intradermo reação para tuberculose. Foram tratados com infliximabe na dose de 5mg/kg de peso, aplicado por via endovenosa a intervalos de dois meses. Os doentes foram divididos em três grupos de acordo com o tempo de doença, isto é, grupo 1 aqueles com até cinco anos de diagnóstico, grupo 2 com seis até 10 anos e grupo 3 com mais de 10 anos de diagnóstico. Os resultados foram considerados subjetivamente através de protocolo após cada aplicação como: melhor, pior ou inalterado em relação ao estado geral do doente, sintomas intestinais e doença perianal. RESULTADOS: No tratamento inicial 76% dos pacientes responderam ao anticorpo. Observou-se que após a primeira dose da medicação, os com mais de 10 anos de doença e submetidos à operação abdominal tiveram resultado satisfatório semelhantemente aqueles doentes com menos de cinco anos de doença e não operados (62,5% e 80% respectivamente dos doentes que melhoraram, sendo este resultado estatisticamente significativo. CONCLUSÃO: O tratamento com infliximabe mostrou-se eficaz e tolerável no manejo dos sintomas dos pacientes

  19. PVC med DEHP - funktionelt men farligt

    OpenAIRE

    2009-01-01

    Nærværende projekt beskæftiger sig med problematikkerne ved Polyvinylchlorid (PVC) artikler med [Di-2-ethyl-hexyl]phthalat (DEHP) til patientbehandling i hospitalssektoren. En lovgivning omkring substitution af materialet PVC har spillet fallit, hvorfor fokus rettes mod udbyder og efterspørgere, der som aktører, kan presse på en substitution af PVC artikler med DEHP. Feltets aktører eksemplificeres ved plastproducenten Coloplast A/S, Glostrup Hospital samt Region Hovedstadens indkøbscentral, ...

  20. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

    Science.gov (United States)

    Afonso, Joana; Lopes, Susana; Gonçalves, Raquel; Caldeira, Paulo; Lago, Paula; Tavares de Sousa, Helena; Ramos, Jaime; Gonçalves, Ana Rita; Ministro, Paula; Rosa, Isadora; Vieira, Ana Isabel; Coelho, Rosa; Tavares, Patrícia; Soares, João; Sousa, Ana Lúcia; Carvalho, Diana; Sousa, Paula; da Silva, João Pereira; Meira, Tânia; Silva Ferreira, Filipa; Dias, Cláudia Camila; Chowers, Yehuda; Ben-Horin, Shomron; Magro, Fernando

    2016-01-01

    Background: There is scant information on the accuracy of different assays used to measure anti-infliximab antibodies (ADAs), especially in the presence of detectable infliximab (IFX). We thus aimed to evaluate and compare three different assays for the detection of IFX and ADAs and to clarify the impact of the presence of circulating IFX on the accuracy of the ADA assays. Methods: Blood samples from 79 ulcerative colitis (UC) patients treated with infliximab were assessed for IFX levels and ADAs using three different assays: an in-house assay and two commercial kits, Immundiagnostik and Theradiag. Sera samples with ADAs and undetectable levels of IFX were spiked with exogenous IFX and analyzed for ADAs. Results: The three assays showed 81–96% agreement for the measured IFX level. However, the in-house assay and Immundiagnostik assays detected ADAs in 34 out of 79 samples, whereas Theradiag only detected ADAs in 24 samples. Samples negative for ADAs with Theradiag, but ADA-positive in both the in-house and Immundiagnostik assays, were positive for IFX or IgG4 ADAs. In spiking experiments, a low concentration of exogenous IFX (5 µg/ml) hampered ADA detection with Theradiag in sera samples with ADA levels of between 3 and 10 µg/ml. In the Immundiagnostik assay detection interference was only observed at concentrations of exogenous IFX higher than 30 µg/ml. However, in samples with high levels of ADAs (>25 µg/ml) interference was only observed at IFX concentrations higher than 100 µg/ml in all three assays. Binary (IFX/ADA) stratification of the results showed that IFX+/ADA- and IFX-/ADAs+ were less influenced by the assay results than the double-positive (IFX+/ADAs+) and double-negative (IFX-/ADAs-) combination. Conclusions: All three methodologies are equally suitable for measuring IFX levels. However, erroneous therapeutic decisions may occur when patients show double-negative (IFX-/ADAs-) or double-positive (IFX+/ADAs+) status, since agreement between

  1. [CanMEDS 2015: better doctors?].

    Science.gov (United States)

    Borleffs, J C C; Mourits, M J E; Scheele, F

    2016-01-01

    Recently, the CanMEDS model, which forms the basis for competency-based learning in both undergraduate and postgraduate training, has been renewed by the introduction of CanMEDS 2015. The most prominent change is the emphasis on leadership skills, which is also reflected by the name change for the role of 'manager' to 'leader'. The addition of milestones provides clearly defined targets for learning and assessment, which facilitates the monitoring of the progression in competence. Furthermore, CanMEDS 2015 strongly focusses on the overall coherence of the separate competencies. CanMEDS, designed as a model that helps to train young doctors to become good doctors, also helps us - the trainers - to become better doctors ourselves.

  2. New Cholesterol Fighting Meds Target Key Gene

    Science.gov (United States)

    ... https://medlineplus.gov/news/fullstory_165942.html New Cholesterol Fighting Meds Target Key Gene Two trials show ... New gene-based therapies appear to significantly decrease cholesterol levels in people, and could even cut down ...

  3. Can Your Heartburn Meds Shorten Your Life?

    Science.gov (United States)

    ... gov/news/fullstory_167005.html Can Your Heartburn Meds Shorten Your Life? Study found association between prolonged ... of Medicine, in St. Louis. "There was a relationship between duration of use and risk of death," ...

  4. Serial intralesional injections of infliximab in small bowel Crohn’s strictures are feasible and might lower inflammation

    DEFF Research Database (Denmark)

    Hendel, Jakob; Karstensen, John Gásdal; Vilmann, Peter

    2014-01-01

    BACKGROUND: Crohn's disease can cause strictures throughout the gastrointestinal tract. Endoscopic balloon dilatation is a well-established treatment, but recurrence is seen in up to three out of four cases. Infliximab is playing an increasingly important role in the modern systemic treatment...... is feasible. OBJECTIVE: We wanted to assess whether serial intralesional injection of infliximab in small bowel strictures is feasible and reduces local inflammation. METHODS: We included six patients with Crohn's disease and inflammatory small bowel strictures. They were treated with endoscopic serial...... balloon dilatation. Subsequent to each dilatation, 40 mg infliximab was injected submucosally. A modified simplified endoscopic score for Crohn's disease was used for the involved area before the initial treatment and at the final follow-up after six months. Complications and development of symptoms were...

  5. Elefanter med krøllede snabler?

    DEFF Research Database (Denmark)

    Daugaard, Line Møller; Kristensen, Kitte Søndergaard

    2012-01-01

    Thushanti på tre år producerer ubestemmelige røde tegn i børnehaven. Måske er det kruseduller? Måske leger hun med den røde farve? Eller kunne det være tamilske skrifttegn? Artiklen sætter fokus på skriftsprogspraksisser og sprogideologiske processer i børnehaven. Med afsæt i analyse af empirisk ...

  6. Dimensioner i arbejdet med egne sagtekster

    DEFF Research Database (Denmark)

    Hermann, Jesper

    1990-01-01

    Sprogpsykologi, skrivning: "For at skrive er det ikke nødvendigt med hverken geni eller personlighed, for der er objektive regler der gælder for alle og altid" "Brev til en lærerinde" 1971, 13  ......Sprogpsykologi, skrivning: "For at skrive er det ikke nødvendigt med hverken geni eller personlighed, for der er objektive regler der gælder for alle og altid" "Brev til en lærerinde" 1971, 13  ...

  7. Effektelektronik - teknologi med energibesparelser og forbedret performance

    DEFF Research Database (Denmark)

    Blaabjerg, Frede

    2004-01-01

    Lige siden transistoren blev opfundet, har det altid været ønskeligt at kunne anvende en sådan til at styre store strømme/spændinger i elektriske systemer. Det er teknologisk også sket, først med tyristorer til styring af store effekter, men siden hen også med den bipolare transistor MOSFET, samt...

  8. Lydpuder med musik til psykiatriske patienter

    DEFF Research Database (Denmark)

    Bonde, Lars Ole

    2009-01-01

    Kort gennemgang af musikmedicinske og musikterapeutiske målsætninger og arbejdsmåder i psykiatrien i Danmark. Omtale af forsøg med musiklytning via "lyttepude" til psykiatriske patienter.......Kort gennemgang af musikmedicinske og musikterapeutiske målsætninger og arbejdsmåder i psykiatrien i Danmark. Omtale af forsøg med musiklytning via "lyttepude" til psykiatriske patienter....

  9. Ud med Freud, Marx og Lacan

    DEFF Research Database (Denmark)

    Clasen, Mathias

    2009-01-01

    Det er på høje tid, at humanister løsriver sig fra deres forældede teorier. Freud, Marx og Lacan skal erstattes med evolutionspsykologi, biologi og kognitionsvidenskab.......Det er på høje tid, at humanister løsriver sig fra deres forældede teorier. Freud, Marx og Lacan skal erstattes med evolutionspsykologi, biologi og kognitionsvidenskab....

  10. Hvad skal vi med Trump-satire?

    DEFF Research Database (Denmark)

    Møller, Mette

    2017-01-01

    Trump-satire er et stort hit, og særligt en lang række satiriske videohilsner til Trump fra lande verden over får folk til at trække på smilebåndet. Men hvorfor er det så sjovt at gøre grin med Trump, og hvad kan vi bruge den politiske humor til? Link: http://videnskab.dk/kultur-samfund/hvad-skal-vi-med-trump-satire...

  11. Ud med Freud, Marx og Lacan

    DEFF Research Database (Denmark)

    Clasen, Mathias

    2009-01-01

    Det er på høje tid, at humanister løsriver sig fra deres forældede teorier. Freud, Marx og Lacan skal erstattes med evolutionspsykologi, biologi og kognitionsvidenskab.......Det er på høje tid, at humanister løsriver sig fra deres forældede teorier. Freud, Marx og Lacan skal erstattes med evolutionspsykologi, biologi og kognitionsvidenskab....

  12. Sociale indsatser til mennesker med ADHD

    DEFF Research Database (Denmark)

    Bengtsson, Steen; Alim, Winnie; Holmskov, Henriette

    Igennem de seneste år har flere og flere fået stillet diagnosen ADHD, som er en adfærdsmæssig forstyrrelse. Mennesker med ADHD har meget forskelligt støttebehov, og rapportens formål er at skabe overblik over de eksisterende sociale indsatser og tilbud til børn, unge og voksne med ADHD. Langt de...... ansvar for sociale end for terapeutiske tilbud i forhold til gruppen med ADHD. Mange voksne med ADHD beskriver, at det kræver mange ressourcer at få den fornødne støtte fra kommunen, mens forældre til børn med ADHD oplever det som nemmere at få adgang til de rette støttetilbud. Men begge grupper møder...... mange udfordringer som fx manglende koordinering og hyppige sagsbehandlerskift. Rapporten er udarbejdet i tilknytning til Servicestyrelsens projekt ’Ny og forstærket indsats til børn, unge og voksne med ADHD’ og er finansieret af Socialministeriet....

  13. Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

    DEFF Research Database (Denmark)

    Frederiksen, Madeline Therese; Ainsworth, Mark Andrew; Brynskov, Jørn

    2014-01-01

    BACKGROUND: A notable proportion of patients with inflammatory bowel disease (IBD) are switched from infliximab (IFX) to adalimumab (ADL). We investigated if immunogenicity of IFX influenced immunogenicity and clinical outcomes of later ADL therapy. METHODS: Single-center cohort study including all...... patients with IBD assessed for antibodies (Abs) against IFX or ADL. RESULTS: Anti-IFX Abs were evaluated in 187 patients treated with IFX as first line anti-TNF agent. Approximately, half (49%) were positive. Detected anti-IFX Abs had functional capacity as judged by a median IFX concentration below limit...... to develop de novo anti-ADL Abs, which may result in therapeutic failure. Assessment of ADL immunogenicity in anti-IFX Ab-positive switchers is required to ensure optimal interventions at inadequate treatment responses and to avoid inappropriate ADL intensification regimens....

  14. Disseminated nocardiosis in a patient on infliximab and methylprednisolone for treatment-resistant Sweet′s syndrome

    Directory of Open Access Journals (Sweden)

    Elizabeth R Drone

    2014-01-01

    Full Text Available A 62-year-old white man with a 10-year history of treatment-refractory Sweet′s syndrome was admitted to the hospital with the onset of purpuric lesions. Methylprednisolone and infliximab were administered. Our patient developed disseminated Nocardia infection and eventually succumbed. Opportunistic infections such as Nocardia have been associated with infliximab and other tumour necrosis factor (TNF-α inhibitors. The astute clinician should be aware of the risk of rare opportunistic infections, particularly in patients on TNF-α inhibitors and systemic corticosteroids.

  15. PubMedAlertMe--standalone Windows-based PubMed SDI software application.

    Science.gov (United States)

    Ma'ayan, Avi

    2008-05-01

    PubMedAlertMe is a Windows-based software system for automatically receiving e-mail alert messages about recent publications listed on PubMed. The e-mail messages contain links to newly available abstracts listed on PubMed describing publications that were selectively returned from a specified list of queries. Links are also provided to directly export citations to EndNote, and links are provided to directly forward articles to colleagues. The program is standalone. Thus, it does not require a remote mail server or user registration. PubMedAlertMe is free software, and can be downloaded from: http://amp.pharm.mssm.edu/PubMedAlertMe/PubMedAlertMe_setup.zip.

  16. PubMedAlertMe - Standalone Windows-based PubMed SDI Software Application

    Science.gov (United States)

    Ma’ayan, Avi

    2008-01-01

    PubMedAlertMe is a Windows-based software system for automatically receiving e-mail alert messages about recent publications listed on PubMed. The e-mail messages contain links to newly available abstracts listed on PubMed describing publications that were selectively returned from a specified list of queries. Links are also provided to directly export citations to EndNote, and links are provided to directly forward articles to colleagues. The program is standalone. Thus, it does not require a remote mail server or user registration. PubMedAlertMe is free software, and can be downloaded from: http://amp.pharm.mssm.edu/PubMedAlertMe/PubMedAlertMe_setup.zip PMID:18402930

  17. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis.

    Science.gov (United States)

    Hooper, Davyd R; Tarnopolsky, Mark A; Baker, Steven K

    2008-10-01

    We report 2 cases of Lewis-Sumner syndrome (LSS) diagnosed in patients suffering from rheumatoid arthritis undergoing treatment with the antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody infliximab. While experiencing clinical improvement in their arthritic symptoms, both patients experienced sensory deficits and weakness in multiple nerve distributions. They had electrodiagnostic evidence of motor conduction block and subsequent improvement with intravenous immunoglobulin (IVIg). We describe the details of the cases and review the literature on immune-mediated neuropathies associated with anti-TNF-alpha therapy.

  18. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission

    DEFF Research Database (Denmark)

    Steenholdt, Casper; Molazahi, Akbar; Ainsworth, Mark Andrew

    2012-01-01

    Abstract Objective. To investigate duration of remission, including risk factors for relapse and response to retreatment with infliximab (IFX), in patients with Crohn's disease (CD) and ulcerative colitis (UC) who had discontinued IFX while in clinical remission. Methods. Observational, single......%) experienced complete clinical remission when retreated with IFX after relapse. Conclusion. While the short-term prognosis seems favorable, the majority of patients who discontinue IFX while in remission relapse over time. The response to retreatment with IFX at relapse seems favorable in this subpopulation....

  19. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.

    Science.gov (United States)

    Swale, V J; Saha, M; Kapur, N; Hoffbrand, A V; Rustin, M H A

    2005-03-01

    A 63-year-old man with chronic lymphocytic leukaemia developed pyoderma gangrenosum following minor trauma to the leg. He required intensive inpatient management with a multitude of treatments including larval therapy, surgical debridement, ciclosporin, methotrexate, thalidomide, pulsed intravenous methylprednisolone and high-dose intravenous immunoglobulin, clofazamine and high dose oral corticosteroids, none of which were helpful. Treatment complications included steroid-induced diabetes, Cushing's syndrome and perforated peptic ulcer. The pyoderma remained refractory to treatment and continued to extend until he received intravenous infliximab 5 mg/kg at weeks 0, 2 and 6.

  20. USE OF INFLIXIMAB IN THE CASE OF INFLAMMATORY BOWEL DISEASE IN CHILDREN

    Directory of Open Access Journals (Sweden)

    N.E. Shchigoleva

    2010-01-01

    Full Text Available The Article is focused on the pressing issue, i.e. the therapy of inflammatory bowel diseases. It reviews in detail the aspects of using monoclonal antibodies to the tumor necrosis factor in the case of Crohn’s disease and unspecific ulcerative colitis. The article describes the results of the authors’ observations and provides data obtained by foreign researchers.Key words: ulcerative colitis, Crohn’s disease, treatment, Infliximab, antibodies to the tumor necrosis factor, children. (Pediatric Pharmacology. – 2010; 7(1:55-61

  1. Episcleritis Related to Drug-Induced Lupus Erythematosus following Infliximab Therapy: A Case Report

    Directory of Open Access Journals (Sweden)

    Irini P. Chatziralli

    2011-01-01

    Full Text Available Drug-induced lupus erythematosus is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. Herein, we describe a patient with distinct clinical manifestations of anti-TNF-associated DILE related to infliximab therapy. The patient exhibited clinical and laboratory findings of lupus-like illnesses as well as ocular disorders, such as episcleritis. The main message is that the symptoms of DILE should not be overlooked, although sometimes other systematic conditions may underlie them. As a result, it is very important for the clinicians to evaluate the symptoms of DILE and manage appropriately these cases.

  2. Cambios psicológicos en pacientes con espondiloartritis axial tratados con infliximab

    OpenAIRE

    Morlà Novell, Rosa M.

    2015-01-01

    Es conocido que los pacientes con enfermedades reumáticas presentan alteraciones psicológicas relacionadas con su enfermedad articular crónica. Algunos estudios reportan el beneficio de las terapias biológicas en las espondiloartritis (EsP), pero son pocos los datos acerca del impacto de los fármacos biológicos en los síntomas psicológicos. El objetivo del estudio fue el de analizar la influencia del tratamiento con un fármaco biológico anti-TNFα, infliximab (IFX), en los síntomas de ansiedad...

  3. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.

    Science.gov (United States)

    Dold, Sylvia; Justiniano, Maria E; Marquez, Javier; Espinoza, Luis R

    2007-07-01

    The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of initial treatment in the majority of cases of PM/DM. The treatment of refractory disease can be challenging despite the utilization of the medications currently available. We report two patients with refractory DM who were treated with infliximab. We describe their presentation, clinical course, treatment, and outcomes.

  4. Treatment of fistulating pouchitis with tumour necrosis factor-alpha-inhibitor (infliximab)

    DEFF Research Database (Denmark)

    Semb, S.; Nordgaard-Lassen, I.

    2008-01-01

    The surgical first choice treatment for patients with ulcerative colitis (UC) involves total proctocolectomy with ileal pouch-anal anastomosis (IPAA). Postoperative development of pouch-related fistula is a rare complication, but it is associated with significant morbidity, a high recurrence rate...... and is a major cause of pouch failure. We report the use of infliximab, a monoclonal antibody to tumour necrosis factor-alpha, in three patients who developed pouch-related fistula after undergoing IPAA surgery for UC Udgivelsesdato: 2008/12/8...

  5. The MED-SUV Multidisciplinary Interoperability Infrastructure

    Science.gov (United States)

    Mazzetti, Paolo; D'Auria, Luca; Reitano, Danilo; Papeschi, Fabrizio; Roncella, Roberto; Puglisi, Giuseppe; Nativi, Stefano

    2016-04-01

    In accordance with the international Supersite initiative concept, the MED-SUV (MEDiterranean SUpersite Volcanoes) European project (http://med-suv.eu/) aims to enable long-term monitoring experiment in two relevant geologically active regions of Europe prone to natural hazards: Mt. Vesuvio/Campi Flegrei and Mt. Etna. This objective requires the integration of existing components, such as monitoring systems and data bases and novel sensors for the measurements of volcanic parameters. Moreover, MED-SUV is also a direct contribution to the Global Earth Observation System of Systems (GEOSS) as one the volcano Supersites recognized by the Group on Earth Observation (GEO). To achieve its goal, MED-SUV set up an advanced e-infrastructure allowing the discovery of and access to heterogeneous data for multidisciplinary applications, and the integration with external systems like GEOSS. The MED-SUV overall infrastructure is conceived as a three layer architecture with the lower layer (Data level) including the identified relevant data sources, the mid-tier (Supersite level) including components for mediation and harmonization , and the upper tier (Global level) composed of the systems that MED-SUV must serve, such as GEOSS and possibly other global/community systems. The Data level is mostly composed of existing data sources, such as space agencies satellite data archives, the UNAVCO system, the INGV-Rome data service. They share data according to different specifications for metadata, data and service interfaces, and cannot be changed. Thus, the only relevant MED-SUV activity at this level was the creation of a MED-SUV local repository based on Web Accessible Folder (WAF) technology, deployed in the INGV site in Catania, and hosting in-situ data and products collected and generated during the project. The Supersite level is at the core of the MED-SUV architecture, since it must mediate between the disparate data sources in the layer below, and provide a harmonized view to

  6. Hverdagslivet som uformel omsorgsudøver med en partner med Parkinsons sygdom, – en interviewundersøgelse af kvinders erfaringer med omsorg og livskvalitet

    DEFF Research Database (Denmark)

    Hounsgaard, Lise; Pedersen, B.; Wagner, L.

    2012-01-01

    Formål: At undersøge de levede erfaringer for kvindelige partnere til hjemmeboende patienter med Parkinsons sygdom. Baggrund: Det er kendt, at hverdagslivet med en partner med Parkinsons sygdom indebærer radikale omvæltninger i familien, især for den kvindelige partner. Metode: En fænomenologisk......-hermeneutisk metode blev anvendt. I 2008 gennemførtes interview med kvindelige partnere (N = 10) til hjemmeboende patienter med Parkinsons sygdom. Den franske filosof Ricoeurs teori om fortolkning blev anvendt i analysen af data. Konklusion: Undersøgelsen viste, at livet sammen med en partner med Parkinsons sygdom...

  7. A marvel of precision: MedAustron

    CERN Multimedia

    Anaïs Schaeffer

    2013-01-01

    MedAustron, which is currently being built in Austria, will be one of the most advanced centres for ion beam therapy and research in Europe. It is based on the same design as the Italian National Centre for Oncological Hadrontherapy (CNAO), which in turn is based on the CERN-led Proton Ion Medical Machine Study (PIMMS). MedAustron should welcome its first patient at the end of 2015.   Layout of the MedAustron accelerator complex.  With three ion-sources, a linac, a synchrotron and four irradiation rooms (see picture), MedAustron is a huge accelerator complex. Among other equipment, it comprises 300 magnets of 30 different types, all designed at CERN but produced at different sites: “We are working with five main suppliers from Europe and Russia,” explains Thomas Zickler, leader of the MedAustron magnet group. “All the magnets come to CERN to undergo a series of strict acceptance tests.” From the interfaces, to the electrical insulation, the co...

  8. Casestudie - En ung pige med debuterende skizofreni

    Directory of Open Access Journals (Sweden)

    Britta Frederiksen

    2005-02-01

    Full Text Available Artiklen beskriver et individuelt musikterapiforløb med en ung skizofren pige. Der fokuseres på at beskrive den musikalske interaktion som udtryk for patientens udvikling i forløbet. For at strukturere og overskueliggøre beskrivelsen af det musikalske materiale anvendes bl.a. Mercedes Pavlicevics Musikalske Interaktion Ratings (MIR med 9 niveauer til at beskriveinteraktionen mellem patient og terapeut i musikalske kliniske improvisationer. Suppleret med patient kommentarer og terapeutens noter beskrives, hvordan der i musikterapien skabes et rum for patienten hvor hendes kreative ressourcer og egne initiativer kan komme til udtryk, og hjælpe hende til at være i samspil frem for at isolere sig. Som beskrevet i forrige kapitel er det følgende en beskrivelse af et musikterapiforløb med en ung pige med debuterende skizofreni. Musikterapien forløb over et halvt år under hendes indlæggelse på et psykiatrisk sygehus.

  9. Paclitaxels farmakogenomik hos patienter med kræft i æggestokken

    DEFF Research Database (Denmark)

    Bergmann, Troels Korshøj; Mirza, Mansoor Raza; Andersen, Charlotte Brasch;

    Formål og baggrund: Paclitaxel (Taxol®) er et kemoterapeutikum der bruges til behandling af bl.a æggestokkræft. Paclitaxel doseres individuelt (175mg/m2) men alligevel er der klinisk betydende variation i forekomsten af bivirkninger (neurotoksicitet, kvalme/opkast, knoglemarvspåvirkning m...

  10. Predicting clicks of PubMed articles.

    Science.gov (United States)

    Mao, Yuqing; Lu, Zhiyong

    2013-01-01

    Predicting the popularity or access usage of an article has the potential to improve the quality of PubMed searches. We can model the click trend of each article as its access changes over time by mining the PubMed query logs, which contain the previous access history for all articles. In this article, we examine the access patterns produced by PubMed users in two years (July 2009 to July 2011). We explore the time series of accesses for each article in the query logs, model the trends with regression approaches, and subsequently use the models for prediction. We show that the click trends of PubMed articles are best fitted with a log-normal regression model. This model allows the number of accesses an article receives and the time since it first becomes available in PubMed to be related via quadratic and logistic functions, with the model parameters to be estimated via maximum likelihood. Our experiments predicting the number of accesses for an article based on its past usage demonstrate that the mean absolute error and mean absolute percentage error of our model are 4.0% and 8.1% lower than the power-law regression model, respectively. The log-normal distribution is also shown to perform significantly better than a previous prediction method based on a human memory theory in cognitive science. This work warrants further investigation on the utility of such a log-normal regression approach towards improving information access in PubMed.

  11. Improvement with Infliximab of a Disseminated Sarcoidosis in a Patient with Crohn’s Disease

    Directory of Open Access Journals (Sweden)

    Nader Chebib

    2014-01-01

    Full Text Available Sarcoidosis and Crohn’s disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs and are seldom associated. While anti-TNFα is a recognized treatment of Crohn’s disease, its usage is discussed in sarcoidosis. A 42-year-old man presented with an 11-year-long history of Crohn’s disease; upon discovery of an abnormal chest CT scan the diagnosis of multivisceral sarcoidosis was made and, later, a treatment with an anti-TNFα agent, infliximab, was started, because of worsening Crohn’s disease recurrences. CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions. Pathologies obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn’s disease and sarcoidosis leading to the diagnosis of both diseases. We report a rare case of steroid resistant Crohn’s disease associated with multivisceral sarcoidosis, treated successfully by an anti-TNFα agent, infliximab.

  12. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

    DEFF Research Database (Denmark)

    Julsgaard, Mette; Christensen, Lisbet A; Gibson, Peter R

    2016-01-01

    these correlated with drug concentrations in mothers at birth and risk of infection during the first year of life.  Methods  We performed a prospective study of 80 pregnant women with inflammatory bowel diseases at tertiary hospitals in Denmark, Australia, and New Zealand from March 2012 through November 2014: 36......) and in mothers at time of birth (adalimumab, r = -0.80; infliximab, r = -0.80; P mother drug concentration at birth was 1.21 for adalimumab (95% confidence interval [CI], 0.94–1.49) and 1.97 for infliximab (95% CI, 1.50–2.43). The mean time to drug clearance...... risk for infection was 2.7 in infants whose mothers received the combination of an anti-TNF agent and thiopurine, compared with anti-TNF monotherapy (95% CI, 1.09–6.78; P =.02).  Conclusions  In a prospective study of infants born to mothers who received anti-TNF agents during pregnancy, we detected...

  13. Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer

    Science.gov (United States)

    Liu, Fen; Ai, Feiyan; Tian, Li; Liu, Shaojun; Zhao, Lian; Wang, Xiaoyan

    2016-01-01

    Colon cancer (CC) is among the most common malignant diseases with a dismal survival. Tumor necrosis factor-alpha (TNF-α) has been identified as a therapeutic target in various cancers, and anti-TNF-α treatment has shown promising effects in different cancer models. However, if TNF-α can be targeted in CC, the therapeutic values of anti-TNF-α treatment in CC remain unknown. Our study indicated that TNF-α is highly expressed in CC cell lines and patient tumor samples. High expression of TNF-α is an independent adverse prognosticator of CC. Targeting the TNF-α by its antibody infliximab induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and enhanced apoptosis leading to cell death. The combination of infliximab with 5-fluorouracil showed better responses in vitro and in vivo than 5-fluorouracil alone. In conclusion, this study identified TNF-α as a target of CC and anti-TNF-α treatment synergized with chemotherapy leading to a better outcome in preclinical models. PMID:27757041

  14. Efeitos adversos durante a infusão de infliximabe em crianças e adolescentes: estudo multicêntrico Adverse reactions during infliximab infusion in children and adolescents: multicenter study

    Directory of Open Access Journals (Sweden)

    Cássia Maria Passarelli Lupoli Barbosa

    2008-10-01

    Full Text Available OBJETIVO: Avaliar a freqüência e a gravidade dos efeitos adversos durante a infusão de infliximabe. MATERIAL E MÉTODOS: Avaliação retrospectiva de prontuários de 58 pacientes acompanhados em cinco serviços de reumatologia pediátrica. Todos apresentavam doença refratária ou eram intolerantes ao uso de uma ou mais drogas modificadoras de doença e receberam uma ou mais infusões de infliximabe. A análise estatística foi descritiva, levando-se em conta a freqüência e o tipo dos efeitos adversos, assim como sua relação com o número de infusões, a dose de infliximabe e a indicação. RESULTADOS: A média da idade na época da introdução do infliximabe foi de 12 anos e 9 meses e a média do tempo de evolução da doença foi de 7 anos e 7 meses. A principal indicação da medicação foi artrite idiopática juvenil (43. Dos 58 pacientes avaliados, 25 (43,1% apresentaram efeitos adversos durante a infusão e em 17 (29,3%, a medicação teve de ser suspensa. As reações que ocorreram foram: dispnéia (dez, náuseas e vômitos (oito, rash cutâneo (sete, choque anafilático (seis, rubor facial (cinco, angioedema (quatro, dor torácica (quatro, urticária e hipertensão, entre outras. A reação anafilática foi mais freqüente entre a quarta e a sexta infusão. CONCLUSÃO: A freqüência e a gravidade dos efeitos adversos ao infliximabe devem ser levadas em conta, não apenas por ocasião da sua indicação, mas principalmente por ocasião da escolha do local para a sua aplicação, que deve contar com estrutura para atendimento de urgência.OBJECTIVE: To evaluate the frequency and the severity of the adverse reactions during the infusion of infliximab. METHODS: We performed a retrospective chart review of 58 patients, followed up at 5 paediatric rheumatology centers. All patients presented refractory disease or were intolerant to one or more disease modifying drugs and received one or more infliximab infusions. The data analysis

  15. I krig med livrem og livvagt

    DEFF Research Database (Denmark)

    Agger, Gunhild

    2010-01-01

    En amerikansk tilgang til moralsk autoritet og en amerikansk genrehåndtering præger tv-serien Livvagterne. Danmarks krigsdeltagelse er forudsætningen for, at Livvagterne tør rejse de store spørgsmål om omkostningerne for frihed og demokrati. Det er al ære værd at ville være nationens samvittighed....... Men det er et problem, at svarene er ladet med patos. Og at skurkene er skildret så skematisk og endimensionelt, at ingen seer næppe bliver udfordret eller kommer i tvivl. Det er krigsspil med livrem på....

  16. Forandringslæring med autismediagnoser?

    DEFF Research Database (Denmark)

    Gustafson, Kari Ingrid; Mørck, Line Lerche

    2013-01-01

    Rasmus’ ændringer i læring, selvforståelse og tilhørsforhold perspektiveres med andre ASF-diagnostiseredes læring udforsket bl.a. gennem gruppeinterviews i regi af Asperger-foreningen. Artiklen byder således på et alternativ i form af at forstå forandringslæring som overskridende læring, med langt større...... hvor fx Asperger-foreningen, lærere og skolebørns- og unges-fællesskaber, samt forældrene er vigtige aktører i overskridelsen af marginalisering....

  17. En demokratisk skole med udfordringer for alle

    DEFF Research Database (Denmark)

    Bogen formidler viden om det pædagogiske udviklingsarbejde der foregik på Kroggårdsskolen ved Odense i 1960'erne med bl.a. orienteringsundervisning, lejrskoler og skoledemokrati, og udviklingsarbejdet relateres til den sociale, kulturelle og politiske historie.......Bogen formidler viden om det pædagogiske udviklingsarbejde der foregik på Kroggårdsskolen ved Odense i 1960'erne med bl.a. orienteringsundervisning, lejrskoler og skoledemokrati, og udviklingsarbejdet relateres til den sociale, kulturelle og politiske historie....

  18. Ti år med formidlingspligt

    DEFF Research Database (Denmark)

    Meyer, Gitte

    2014-01-01

    Jubilæet blev markeret ved et symposium - men hvor var journalisterne, og hvor var forskerne? For få uger siden lagde TV 2 hus til et symposium om videnskab, formidling, journalistik og spin. Danske Videnskabsjournalister og Akademiet for de Tekniske Videnskaber tog med arrangementet et behjertet...... initiativ. De ville gøre status efter ti år med lovfæstet formidlingspligt på universiteterne. Samtidig lagde de op til et kritisk blik på universitetsverdenens kommunikationsafdelinger...

  19. Finding Fluid Form: en arkitektur med vaner

    DEFF Research Database (Denmark)

    Ramsgaard Thomsen, Mette

    2007-01-01

    I efteråret 2006 afholdt CITA en række kurser i parametrisk design, realiseret gennem et gæsteprofessorat med Mark Goulthorpe fra MIT og tegnestuen d'ECOI. CITA inviterede desuden Roly Hudson fra University of Bath til at undervise i Generative Components. Parallelt med dette underviste Gehry...... Technologies i Digital Projects. CITA planlægger p.t. en række kurser, som skal undersøge den digitale formgivningsproces i forhold til produktionsprocessen....

  20. Forandringslæring med autismediagnoser?

    DEFF Research Database (Denmark)

    Gustafson, Kari Ingrid; Mørck, Line Lerche

    2013-01-01

    Rasmus’ ændringer i læring, selvforståelse og tilhørsforhold perspektiveres med andre ASF-diagnostiseredes læring udforsket bl.a. gennem gruppeinterviews i regi af Asperger-foreningen. Artiklen byder således på et alternativ i form af at forstå forandringslæring som overskridende læring, med langt større...... hvor fx Asperger-foreningen, lærere og skolebørns- og unges-fællesskaber, samt forældrene er vigtige aktører i overskridelsen af marginalisering....